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CD30 is only expressed on a few activated B and T cells. Until now, the small amount
of these cells limited the ways of investigations. Several B cell lymphomas, like Hodgkin
lymphomas and diffuse large B cell lymphomas, express the CD30 receptor and are often
associated with herpesviral infections. However so far, the contribution of CD30 signaling
and herpesviral infections to lymphomagenesis remained largely unknown.
In order to address the physiological and patho-physiological function of CD30 in B cells, a
transgenic mouse line expressing conditionally a constitutively active CD30 (LMP1/CD30)
was generated by my predecessor Petra Fiedler. She could show that the activation of
LMP1/CD30 in all B cells by CD19cre resulted in the expansion of the B1 cell and plasma
cell population in the spleen and in the peritoneal cavity. I analyzed this phenotype fur-
ther and could show that the expanded B1 cells are intermixed with plasmablasts and
plasma cells. My data provided evidence that the expansion of B1 cells and plasmablasts
occurs during T cell independent immune responses. Moreover, B2 cells, with a chronic
CD30 signaling, differentiated towards this B1-like population upon CD40 stimulation in
vitro. Analysis of the signaling pathways which may be responsible for this phenotype,
revealed increased pSTAT3 and pSTAT6 levels, and a stronger nuclear translocation of
p65 and Interferon regulatory factor 4 (Irf4) upon CD40 stimulation in vitro. These
data suggest that the expanded B1-like cell population in LMP1/CD30 mice is generated
upon activation of B1 and B2 cells. Together with Petra Fiedler, I could show that aged
LMP1/CD30 mice develop pre-germinal center B cell lymphomas with a plasmablastic
phenotype. These results proofed for the first time that deregulated CD30 signaling has
an oncogenic potential in B cells.
Most of CD30+ B cell lymphomas derive from germinal center or post-germinal center B
cells. Since LMP1/CD30 mice displayed a block in the germinal center reaction, these
mice were insufficient to study the function of deregulated CD30 signaling in germinal
center B cells. To induce a deregulated CD30 signaling in germinal center B cells, we
crossed the LMP1/CD30 mouse strain with a Cγ1-cre mouse strain. Immunization of
these mice resulted in elevated numbers of IRF4+ plasmablasts and plasma cells, indi-
cating that constitutive CD30 signaling also drives plasma cell differentiation in GC B
cells. Next, we studied whether the deregulated CD30-expression in germinal center cells
results in lymphoma development and whether herpesviral infections further increases
lymphomagenesis. Since EBV does not infect murine B cells, we used instead the murine
herpesvirus MHV-68. To detect the infected cells, a reporter virus expressing NGFR was
constructed (MHV-68-NGFR). The infection with MHV-68-NGFR induced a germinal
center reaction with germinal center B cells positive for NGFR and was therefore suited
to study the cooperative effect of deregulated CD30 signaling and herpesviral infections in
germinal center B cells. A significantly higher incidence of lymphomas was developed in
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the infected LMP1/CD30//Cγ1-cre mice in comparison to the immunized mice, suggest-
ing a synergistic effect of a γ-herpesviral infection and chronic CD30 signaling in germinal
center B cells regarding lymphomagenesis. The lymphomas of both groups displayed a
B1-like or plasmablasts phenotype. IRF4 was upregulated in all lymphomas whereas PR
domain zinc finger protein 1 (Blimp-1) was rather downregulated. These data indicated
that lymphomas arise from plasma cell progenitors which have not upregulated BLIMP-1
yet.
Since most of the EBV+ CD30+ lymphomas express the EBV protein LMP1, I evalu-
ated in the third part of the thesis, whether a LMP1-expressing MHV-68 virus further
enhances lymphomagenesis in LMP1/CD30-mice. Up to this end, LMP1 was inserted
in the MHV-68 genome. Two viruses were generated, MHV-68-LMP1wt and as control,
MHV-68-LMP1mut which leads to the expression of LMP1 with a truncated signaling
domain. Strikingly, the MHV-68-LMP1wt but not the MHV-68-LMP1mut infected cells
were eliminated upon infection of wildtype mice. We could demonstrate that the elimi-
nation of the infected cells was partly but not exclusively evoked by T cells and NK cells.
Although, this MHV-68 LMP1 virus was not suited to study its impact on B cell lym-
phomagenesis, it is an interesting tool to investigate why LMP1 signaling induces such a
strong immune response in context with a MHV-68 infection.
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2 Zusammenfassung
CD30 wird nur von wenigen aktivierten B und T Zellen exprimiert. Die geringe An-
zahl dieser Zellen erschwerte bisher die Funktionsanalyse von CD30. Des Weiteren wird
CD30 von verschiedene B Zell Lymphomen, wie dem Hodgkin Lymphom und dem diffusen
großzelligen B Zelllymphom, stark exprimiert. Dabei treten diese Lymphome häufig mit
γ-herpesviralen Infektionen auf. Bisher war nicht bekannt, ob und welchen Einfluss das
CD30 Signal und die herpesvirale Infektion auf die Lymphomentstehung haben.
Um die physiologische und pathophysiologische Funktionsweise von CD30 aufklären zu
können, wurde zunächst das transgene Mausmodel entwickelt, welches zu einem kon-
ditionalen, konstitutiv-aktiven CD30 Signal (LMP1/CD30) führt. Dieses Mausmodell
wurde von meiner Vorgängerin Petra Fiedler generiert. Sie konnte zeigen, dass die Ak-
tivierung von LMP1/CD30 in allen B Zellen durch die Kreuzung mit CD19cre zu einer Ex-
pansion von B1 Zellen und der Plasmazellpopulation in der Milz und im Peritoneum führt.
Ich analysierte diesen Phänotyp weiter und konnte zeigen, dass die expandierte Popula-
tion sowohl aus B1 Zellen, Plasmablasten aber auch Plasmazellen bestand. Meine Daten
bewiesen, dass die Expansion dieser Zellen durch eine T Zell unabhängige Immunantwort
hervorgerufen wird. Weiterhin zeigten die B2 Zellen dieser Mäuse eine verstärkte Dif-
ferenzierung zu dieser B1-zellähnlichen Population nach CD40 Stimulation. Die Analyse
der Signalwege, welche für den Phänotyp verantwortlich sein könnten, wiesen eine erhöhte
Phosphorylierung von STAT3 und STAT6, sowie verstärkte nukleäre Translokation von
p65 und IRF4 nach CD40 Stimulation in vitro auf. Diesen Daten weisen darauf hin,
dass die expandierte B1-ähnliche Population in LMP1/CD30 Mäusen durch Aktivierung
von B1 und B2 Zellen generiert wird. Zusammen mit Petra Fiedler konnte ich zeigen,
dass gealterte LMP1/CD30 Mäuse Prä-Keimzentrums-B-Zelllymphome mit einem Plas-
mablasten Phänotyp entwickeln. Diese Ergebnisse zeigten zum ersten Mal, dass dereg-
uliertes CD30 Signal ein onkogenes Potential in B Zellen hat. Jedoch handelt es sich
bei den meisten CD30+ B-Zelllymphomen um Keimzentrums-oder Post-Keimzentrums-
B Zellen. Da LMP1/CD30 Mäuse keine Keimzentrumsreaktion nach Immunisierung
zeigen, waren sie zur Funktionsanalyse von dereguliertem CD30 Signal in Keimzentrum
B Zellen ungeeignet. Aus diesem Grund kreuzten wir LMP1/CD30 Mäuse mit Cγ1-cre
Mäusen, um dereguliertes CD30 Signal in Keimzentrums-B-Zellen zu induzieren. Die Im-
munisierung dieser Mäuse führte zu einer erhöhten Anzahl von IRF+ Plasmablasten und
Plasmazellen. Das weist darauf hin, dass konstitutives CD30 Signal die Plasmazelldif-
ferenzierung auch in Keimzentrums-B-Zellen treibt. Nachfolgend analysierten wir, ob die
Expression von LMP1/CD30 in Keimzentrums-B-Zellen zur Lymphomentstehung führt
und, ob eine zusätzliche herpesvirale Infektion diese weiter ansteigen lässt. Da EBV
keine murinen B Zellen infiziert, verwendeten wir stattdessen MHV-68, einen murinen
γ-Herpesvirus. Dieser wurde als NGFR exprimierender Reportervirus kloniert. Da die In-
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fektion mit dem Reportervirus zu NGFR exprimierenden Keimzentrums-B-Zellen führte,
stellte er sich als geeignet zur Bearbeitung der Fragestellung heraus. Die virusinfizierten
LMP1/CD30//Cγ1-cre Mäuse entwickelten signifikant mehr Lymphome als die immu-
nisierten. Dies implizierte einen eindeutigen synergistischen Effekt zwischen Virusinfek-
tion und dereguliertem CD30 Signal in Keimzentrums-B-Zellen hinsichtlich der Lympho-
mentstehung. Die Lymphome zeigten einen B1 Zell/Plasmablasten-ähnlichen Phänotyp.
IRF4 war in allen Lymphomen hochreguliert, wohingegen BLIMP-1 eher runterreguliert
war. Dies weist daraufhin, dass die Lymphome aus Plasmazellvorläufern entstehen, welche
BLIMP-1 bisher nicht hochreguliert haben.
Da die meisten EBV+, CD30+ Lymphome das EBV Protein LMP1 exprimieren, bes-
timmte ich im dritten Teil der Arbeit, ob ein LMP1 exprimierender MHV-68 zur ge-
steigerten Lymphomentstehung in LMP1/CD30 Mäusen führt. Dafür wurde LMP1 in
zwei Varianten in das MHV-68 Genom integriert. Zum einen MHV-68-LMP1wt und als
Kontrolle, MHV-68-LMP1mut, welcher zur Expression von LMP1 mit trunkierten Sig-
naldomänen führt. Nach der Infektion von Wildtyp Mäusen wurden MHV-68-LMP1wt
infizierte Zellen, jedoch nicht die MHV-68-LMP1mut infizierten Zellen, eliminiert. Wir
konnten zeigen, dass T Zellen und NK Zellen teilweise, aber nicht ausschließlich, für diesen
Vorgang verantwortlich sind. Obwohl MHV-68-LMP1wt nicht geeignet ist, um seinen Ein-
fluss auf die B Zell Lymphomentwicklung zu untersuchen, ist es ein gutes Hilfsmittel, um
herauszufinden, aus welchem Grund das LMP1 Signal ein solche starke Immunantwort
während einer MHV-68 Infektion hervorruft.
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3 Introduction
Every year, 20 new cases of lymphomas per 100.000 people occur in the western world
[Küppers, 2005]. Despite similar amounts of B and T cells in the human body, most of
the lymphomas derive from B cells. In order to generate a broad repertoire of diverse anti-
bodies, B cells undergo several differentiation processes which makes them vulnerable for
malignant transformation [Murphy et al., 2012]. There are more than 15 different types
of B cell lymphomas distinguished by the World Health Organization [Küppers, 2005].
These lymphomas originate from B cells at various differentiation stages where they are
somehow ”frozen”. Besides the physiological mechanisms which are exploited by malig-
nant transformation, also γ-herpesviral infections seem to be involved in these processes.
Some of the B cell lymphomas contain to a high extent Epstein Barr Virus (EBV) and
Kaposi´s sarcoma-associated herpesvirus (KSHV) which are implicated in the pathogen-
esis of these lymphomas [Küppers, 2005].
3.1 B cells
3.1.1 Development
Both, B and T lymphocytes originate from the same progenitor cell, the common lym-
phoid progenitor which arises by differentiation from the pluripotent hematopoietic stem
cell (HSC). The common cell progenitor is situated in the bone marrow (BM) but only
B cells derive from this side whereas T cells mature in the thymus. But unlike T cells,
B cells also undergo further maturation in this site. The micro-environment provided by
the BM is crucial for this differentiation process of B cells. Mainly, stromal cells con-
tribute through direct cell contact over adhesion molecules and ligands and by secreting
chemokines and cytokines which induce proliferation and differentiation of the B cell pro-
genitors [Tsuneto et al., 2014]. The common lymphoid progenitor gives rise to the early
pro-B cell. This is the first stage of B cell commitment which differentiates afterwards
through the following phases called late pro-B cell, large pre-, small pre-, and immature B
cell. During this process, the B cells start to rearrange and to express their immunoglob-
ulin genes. The light chain and the heavy chain are encoded in different gene segments.
The light chains are assembled from V and the J segments, the heavy chain includes an
additional D segment. From all segments, several copies are present but only one is chosen
during resemble of the final chains. First, the heavy chain undergoes VDJ recombination
and afterwards the pre-B cell receptor is formed, followed by the VJ recombination of
the light chain. After successful recombination of the heavy and light chain, membrane
bound IgM is expressed on the immature B cells [Murphy et al., 2012].
The specificity of the B cell receptor (BCR) is characterized by a high diversity. The first
set of the diverse repertoire is generated during the V(D)J recombination in the B cell de-
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velopment. Rag1 and Rag2 are recombination-activating enzymes and build the enzyme
complex V(D)J-recombinase which is essential for the V(D)J-recombination. During the
recombination process, for every gene segment one copy is randomly chosen which results
in the great diversity of the BCR. Additionally, the enzyme terminal deoxynucleotidyl
transferase introduces random nucleotides to the single strand DNA ends which occur
after hairpin cleavage. This ends up with a B cell repertoire which recognizes 5x1013
antigens in human. The immature B cell leaves the BM and migrates towards the spleen.
There, it undergoes three transitional stages (T1-T3) and differentiates either towards
marginal zone B cells (MZB) or follicular B cells (FoB). The strength of the BCR signal-
ing, canonical NF-κB signaling downstream of B cell activating factor (BAFF) receptor,
and an active Notch signaling are crucial players in mediating the cell fate decision into
one of the two phenotypes in the periphery [Pillai and Cariappa, 2009].
Besides MZB and FoB which are called B2 cells, B1 cells belong to the B cell popula-
tions. The model of the ”layered immune system hypothesis” suggests B1 and B2 cells as
two different emerging lineages [Herzenberg and Herzenberg, 1989]. B1 cells are proposed
to emerge earlier during the embryonal development of the murine embryo in the yolk
sack and the fetal liver. After birth, B2 cells are generated in the BM. After migrating
to the spleen, B1 cells also undergo the three transitional stages which differ in terms of
regulation from the B2 cell transitional cells [Montecino-Rodriguez and Dorshkind, 2011].
In the pleural and peritoneal cavities, the B1 cell gains either the B1a or the B1b cell
phenotype [Montecino-Rodriguez and Dorshkind, 2012]. The development of B1a cells
depends on CD19 signaling. In contrast, an overexpression of CD19 leads to impaired
B1b cell development [Haas et al., 2005]. Further, the survival and proliferation of B1
cells which were generated from the transitional stage rely upon strong BCR and canoni-
cal NFκB signaling. But, B1 cells are independent from BAFF and alternative NFκB
signaling. These signaling pathways are necessary for the development of MZB and
FoB [Montecino-Rodriguez and Dorshkind, 2012]. A few weeks after birth, the devel-
opment of B1 cells is abandoned and the population is maintained mainly by self-renewal
[Baumgarth, 2016].
3.1.2 The role of B1 cells
The B1 cells play a main role in this thesis. For this reason, this chapter explains
the function of B1 cells in more detail. Besides the developmental differences, B1 and
B2 also vary in tissue distribution and receptivity, and response towards antigens and
mitogens [Baumgarth, 2016]. Unlike B2 cells, B1 cells undergo self-renewal in the pe-
riphery and are probably replaced by cells from the adult BM to a very limited ex-
tent [Kreslavsky et al., 2018]. The expression of CD5 divides the B1 cell population in
CD5+ B1a and CD5low B1b cells. CD5 is a membrane glycoprotein which is also ex-
pressed on T cells. Its role on B1 cells is to prevent uncontrolled self-reactivity and
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to inhibit BCR signaling [Dalloul, 2009]. B1 cells produce natural antibodies which
are generated independent of the presence of an exogenous antigen. By regulating B
cell development and selection as well as clearing of self-antigens, they prevent auto-
reactivity [Savage et al., 2017]. Further, they avert as primary response towards bac-
terial and viral infections like Streptococcus pneumoniae and Salmonella thyphi as well
as the influenza virus [Baumgarth, 2016]. The natural antibodies which are secreted by
the B1 cells are mainly of IgM and, to a lesser extent of, class-switched isotype, IgG3.
The differentiation towards natural IgG3 antibody secreting cells (ASC) has been shown
to be BLIMP-1 independent in some cases [Savage et al., 2017]. The highest frequen-
cies of B1 cells are found in the peritoneal cavity (PerC), other major niches are the
spleen and the BM [Hayakawa et al., 1986, Baumgarth, 2016]. The functions of the B1
cells differ depending on the site they reside. In the spleen, B1 cells mostly show ef-
fector functions through IgM and cytokine secretion, however, B1 cells from the PerC
seem to provide a natural memory compartment and migrate upon innate signals like
IL5, IL10, and type-I Interferon (IFN) into the spleen in order to differentiate to ASC
[Baumgarth, 2016]. Nevertheless, adoptive transfer of adult-derived PerC B1 cells into
newborn mice leads to colonization of all known niches like the spleen, BM and other
body cavities [Lalor et al., 1989, Choi et al., 2012, Förster and Rajewsky, 1987]. Addi-
tional data reveal a dependency of tissue location for the gene expression profile of isolated
B1 cells [Stoermann et al., 2007]. Further, B1 cells of the PerC are characterized by β-2
integrin CD11b expression and a continuous circulation. CD11b gets lost after arrival of
B1 cells into the secondary lymphoid organs but is necessary for the effective homing in
the lymph node (LN) and the spleen [Waffarn et al., 2015]. Peritoneal B1 cells can also
differentiate towards intestinal IgA ASC. The Peyer´s patches (PP) and mesenteric LN
with constitutively active GC reaction are the source of these plasma cells (PC). The
differentiation of intestinal IgA ASC can be proceeded in a T cell independent (TI) or
T cell dependent (TD) manner [Bunker et al., 2015]. Isolated lymphoid follicles which
belong also to the gut-associated mucosa mainly support the TI differentiation of IgA
ASC [LORENZ and NEWBERRY, 2004, Bunker and Bendelac, 2018]. Up to 40% of the
secreted serum IgA originates from B1 cells [Mora and von Andrian, 2008].
3.1.3 Immune response
B1 and B2 cells differ not only in their development but also in the repertoire of anti-
gens they respond to. B1 cells react mainly towards TI antigen whereas B2 cells re-
spond upon TD antigen encounter. An exception are the MZB which belong to the
B2 cells but work also as a first line defense against penetrating pathogens like the B1
cells [Balázs et al., 2002]. The TI antigens are further divided into class 1 and 2 anti-
gens. Lipopolysaccharide (LPS) and bacterial DNA belong to the TI1-antigens and cause
polyclonal activation which induces, regardless of the B cell specificity, proliferation and
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differentiation through signaling over the Toll like receptor (TLR) [Murphy et al., 2012].
Penetrating capsulated pathogens belong to the TI2-antigens. If the highly repetitive
structures, like found in bacterial capsular polysaccharides, crosslink a critical number
of BCRs, mature B cells can differentiate to IgM secreting plasmablasts (PB). This
happens without the help of T cells and therefore represents a rapid response against
capsulated bacteria. However, dendritic cells, which provide membrane bound signaling
molecules and release BAFF, support proliferation and class switch towards IgG3. BAFF
is a cytokine which belongs to the tumor necrosis factor (TNF)-family and interacts with
transmembrane activator and CAML interactor (TACI) and the BAFF receptor on B
cells. Only mature B cells can be activated by TI2 antigens, whereas TI1 antigens can
also activate immature B cells. The encounter with a TI1 antigen does not lead to the
development of memory cells [Murphy et al., 2012].
Another class of antigens are TD antigens. These antigens which evoke a germinal cen-
ter (GC) reaction are mainly recognized by FoB [MacLennan, 1994]. In order to obtain
signals from T cells, B cells need to present the antigen in a specific manner. Upon anti-
gen recognition by the BCR, the BCR-antigen complex is internalized. The antigen gets
processed into antigenic peptides and is loaded onto a major histocompatibility complex
(MHC)-class II molecule. The MHC-class II-peptide complex is transferred onto the B
cell surface and interacts with the T cells [Yuseff et al., 2013]. The encounter with an
antigen induces the upregulation of C-C chemokine receptor 7 (CCR7) in B cells and
C-X-C chemokine receptor type 5 (CXCR5) in T cells. Due to the secreted chemokines
CXCL13 and CCL21, the cells migrate towards the border of the T and B cell zone.
At this site, they start excessive proliferation and form a GC. The GC is divided into
two zones called the dark zone (DZ) and the light zone (LZ). In the DZ, the B cells
are named centroblasts. These cells express C-X-C chemokine receptor type 4 (CXCR4)
which keeps them into this densely packed site where they undergo several rounds of
proliferation. Targeted mutations in the immunoglobulin V regions are introduced by
the enzyme activation induced cytidine deaminase (AID) [Muramatsu et al., 2000]. This
process is called somatic hypermutation (SHM) [Murphy et al., 2012]. The downregu-
lation of CXCR4 and the upregulation of CXCR5 leads them into the LZ. Here, the
follicular dendritic cells (FDC) and the T follicular helper cells control the affinity of
the BCR. If the B cell is able to bind the antigen, it achieves signals from the FDC
and the T follicular helper cells which leads partly to the migration back into the DZ
[Victora and Nussenzweig, 2012]. There it goes through further rounds of proliferation
and SHM known as the cyclic reentry model. The avidity and affinity of the antigen
binding of the B cells is controlled by T cells. B cells with successful mutated BCR receive
survival and proliferation signals which induce the differentiation towards either PC or
memory B cells. Besides SHM, GC B cells also undergo class switch recombination. This
is mediated by the cytokine release and CD40 interaction of mainly CD4+ T helper cells.
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The change of the isotype of the heavy chain changes the effector function of the released
antibody and increases its versatility. After escape from the GC, PC migrate to different
body cavities also depending on their isotype [Murphy et al., 2012, Kräutler et al., 2017].
Memory B cells persist as recirculating cells in the organism and are positioned nearby
antigen drainage, for example the splenic marginal zone, the mucosal epithelium of the
tonsil and the BM [Tangye and Tarlinton, 2009]. Memory B cells are long lived cells, with
surface immunoglobulin expression, no antibody secretion, and a very slow proliferation
rate. In contrast, the life span of PC depends on the side they are residing, they only
express intracellular immunoglobulin and secrete high amounts of antibodies. Short-lived
PC are located in the extra follicular sides like the spleen or the medullary chords of
the LN. Long-lived PC are situated in the BM and the gut-associated lymphoid tissues
[Brynjolfsson et al., 2018]. Upon secondary immune response, memory B cells can effi-
ciently present low amounts of antigen towards T cells and either differentiate rapidly
into PC or re-enter with other B cells the GC reaction [Victora and Nussenzweig, 2012].
Also, they produce high amounts of specific antibodies. The mechanisms which control
the differentiation to either one of the phenotypes upon GC reaction still need to be in-
vestigated [Kräutler et al., 2017].
But the regulation network of the different transcription factors (TF) is broadly estab-
lished. B-cell lymphoma 6 protein (Bcl6) is highly expressed during the GC reaction and
acts as transcriptional repressor. Thereby, it prevents terminal B cell differentiation by
repressing TFs like BLIMP-1. Additionally, it leads to proliferation of GC B cells and
facilitates tolerance of high rates of SHM [Cattoretti et al., 2006]. BACH2 induces the
expression of Aicda which is necessary for class switch recombination and SHM. Paired
box protein 5 (Pax5) represses Xbp1 and has an essential role in preserving the GC pheno-
type [Nera et al., 2006]. Also, IRF4 is expressed in low levels which also induces Bcl6 and
Aicda expression. If GC B cells are committed to the PC phenotype, high levels of IRF4
are expressed which leads to expression of BLIMP-1 and repression of BCL6. BLIMP-1
in turn also represses Bcl6 and Pax5 [Nutt et al., 2015]. This allows the expression of
XBP1, another master regulator of PC differentiation [De Silva et al., 2016]. Memory B
cells remain positive for BACH2 and PAX5 expression [Nutt et al., 2015].
3.2 B cell lymphoma
In order to provide this wide range of diverse specific antibodies, the BCR undergoes dif-
ferent processes during development and upon antigen encounter as described in chapter
3.1.1 and 3.1.3. These cascades used to establish antibody diversification in B cells make
them vulnerable for malignant transformation. Therefore, it is not surprising that 95%
of lymphomas originate from B cells and only 5% from T cells [Campo et al., 2011].
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3.2.1 Cellular origin of B cell lymphomas
The subtypes of lymphomas originate from distinct stages of the B cell differentiation
process. They were characterized depending on the presence or absence of mutations in
the immunoglobulin variable region and by gene expression profiles. The splenic folli-
cle consists of different regions characterized by the composition of specific cell types.
The marginal zone surrounds the B cell follicle and is dominated by the MZB. Extra
nodal mucosa-associated lymphoid tissue (MALT) lymphomas and nodal marginal-zone
B-cell lymphomas originate probably from the marginal zone and consist of FoB and
MZB with unmutated variable V region genes. Therefore, it is assumed that these lym-
phomas derive from naive B cells which are in the differentiation process towards MZB.
The mantle zone borders the GC and contains naive B cells expressing the surface marker
CD5. The mantle cell lymphomas probably originate from this cell type but 20-30%
of the lymphoma cells contain mutated V regions hinting to cells which passed the GC
[Shaffer et al., 2012]. Also, chronic lymphocytic leukemia arises from CD5+ B cells which
are characterized by either unmutated or mutated variable heavy chain mutations. There-
fore, they evolve either from SHM unexperienced cells or from cells which underwent
the GC reaction, respectively [Kipps et al., 2017]. Follicular lymphoma (FL), classical
Hodgkin lymphoma (cHL), Burkitt Lymphoma (BL) and the GC B cell-like subtype of
the diffuse large B cell lymphoma (DLBCL) derive from GC B cells [Küppers, 2005]. Post-
germinal center PB are the origin of the activated B-cell like (ABC) subtype of DLBCL
[Matsumoto et al., 1996, Shaffer et al., 2000]. In most cases, post-transplant lymphomas
which often derive in patients with an organ transplant, are composed of antigen-selected,
GC B cells. The cells of the primary effusion lymphoma (PEL) reveal distinct cellular
origins and can either come from naive, GC, or post-germinal center B cells which is also
influenced by the presence or absence of an EBV infection [Hamoudi et al., 2004].
3.2.2 Transforming events
The transforming events during B cell maturation and differentiation processes can cause
oncogenic mutations. The engagement of one of the Ig loci and a proto-oncogene are
found in many types of B cell lymphomas. Due to the translocation, the proto-oncogene
is positioned under the control of the active Ig locus. Now, the expression of the proto-
oncogene is deregulated and constitutive active. These events can occur during V(D)J
recombination in the early B cell development in the BM but mostly during the GC reac-
tion while SHM process or class-switch recombination take place [Küppers, 2005]. There
are three different kinds of breakpoints in the Ig locus. The first is adjacent to the Ig
heavy chain J-region or next to the joining region of the Ig heavy chain D-region and
J-region. This can be found in the FL which is associated with a Bcl2-IgH transloca-
3 INTRODUCTION 11
tion. Other translocations are by-products of SHM because they are present within or
nearby of somatically mutated rearranged V(D)J- genes. During class switch recombi-
nation, DNA breaks are introduced in the IgH constant switch regions. These break-
points characterize the third type of translocations. Examples for IgH translocations are
BCL2 found in the FL, MYC in the BL and cyclin D1 in the mantle cell lymphoma
[Chesi, 1996, Johnson et al., 2009, Gostissa et al., 2009]. During SHM, mutations are in-
troduced in the immunoglobulin variable regions of the BCR through substitution, dele-
tion, or insertions of single base pairs. In lymphomas, aberrant SHM leads to mutations
in genes in addition to the V genes. For example, the DLBCL displays mutations in proto-
oncogenes like PIM1, MYC, RhoH/TTF, and PAX5 [Pasqualucci et al., 2001]. The char-
acteristic mutation pattern in these genes is similar to SHM in the V-gene region. However,
normal GC B cells do not display mutations in these loci [Pasqualucci et al., 2001].
One of the most common targets influenced by translocation, amplification, and muta-
tion occurring in the lymphomas are genes encoding for TFs. BCL6, IRF4 and BLIMP-1
which are important TFs during the GC reaction belong to the main targets in this pro-
cess. Therefore, the following section explains several mutations in these TFs leading to
lymphoma development (see: 3.1.3). The master regulator of the GC reaction, BCL6 is
often deregulated in B cell lymphomas. For example, in DLBCL and FL, the promoter re-
gion of BCL6 is replaced by constitutive active heterologous regulatory regions leading to
an impaired downregulation of BCL6 in these lymphomas [Ye et al., 1993]. This in turn
leads to a block in PC differentiation, increased proliferation, and a block of the DNA
repair mechanisms [Shaffer et al., 2000, Phan et al., 2005]. Multiple myeloma and ABC
DLBCL reveal a high expression of IRF4 [Alizadeh et al., 2000]. The active NFκB path-
way in these lymphomas mediates directly the expression of IRF4 which plays a key role in
PC differentiation by transactivating PRDM1 and repressing BCL6 [Saito et al., 2007].
The difference between multiple myeloma and the ABC DLBCL is the differentiation
stage of the lymphoma cells. The cells of multiple myeloma have a PC phenotype dis-
playing the full gene expression profile of mature PC, the cells of the ABC DLBCL have a
plasmablastic phenotype caused by the inactivation of PRDM1 [Pasqualucci et al., 2006].
In order to avoid cell death, lymphoid malignancies are often characterized by a con-
stitutively active NFκB signaling. NFκB signaling promotes survival in different kinds
of cell types and gets transiently activated via receptors like BCR, CD40, CD30, and di-
verse TLRs. Among others, ABC DLBCL, cHL, gastric MALT lymphoma, and multiple
myeloma are associated with constitutively active NFκB signaling. The IκB kinase (IKK)
complex consisting of α, β, γ (NEMO) subunits is applied in the classical pathway and
requires phosphorylation of IKKβ and ubiquitination of IKKγ. Upon activation, IKKβ
phosphorylates IκBα which leads to its ubiquitination and degradation. IκBα is an in-
hibitor of the heterodimers p50/p65 and p50/cRel, preventing them to shuttle into the
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nucleus. Due to degradation of IκBα, the heterodimers migrate into the nucleus and
activate the transcription of target genes. In contrast, the alternative pathway relies on
the IKK complex consisting of two IKKα subunits which get activated by the kinase NIK.
The activated IKKα complex phosphorylates p100 causing proteolytic processing into the
NFκB subunit p52. This subunit migrates together with RelB towards the nucleus, ac-
tivating transcription by binding to the DNA [Shaffer et al., 2012]. The stabilization of
NIK is the main cause for constitutive active NFκB pathway in multiple myeloma. This
is either achieved through mutations causing loss of function in TRAF3 or with gain-
of-function-mutations inducing overexpression of NIK, CD40, or LTβR. Chronic BCR
signaling which is induced through gain-of-function-mutations in CD79A/B result in con-
stitutively active NFκB signaling in ABC DLBCL. Additionally, inactivation of A20 which
is a negative regulator of the NFκB pathway contribute to the steady active NFκB path-
way in this B cell lymphoma [Nagel et al., 2014].
3.2.3 CD30+ B cell lymphoma
CD30 is highly expressed in Hodgkin lymphoma (HL) and anaplastic large cell lym-
phoma (ALCL) but also found on cells of the PEL and DLBCL, especially in EBV
positive cases. The HL is subdivided into the cHL which amounts to 95% of all cases
and the nodular lymphocyte predominant form (NLPHL). The hallmark of the cHL are
the Hodgkin and Reed/Sternberg cells (HRS). HRS cells derive from GC B cells, have
downregulated the most B cell specific genes, and display clonally rearranged and so-
matically mutated Ig heavy- and light-chain genes. The HRS cells are surrounded by
various different cell types. The most frequent ones are the T cells. Different kind of
T cells are attracted through chemokine release of the HRS cells and are arranged in a
rosette like structure around these cells. Genetic lesions in HRS cells lead to constitu-
tively active NFκB, JAK/STAT, and PI3K/Akt pathways [Küppers, 2012]. CD30 is also
expressed on non HL like the DLBCL. These subsets reveal partly EBV infection. EBV+
DLBCL show more frequently a CD30 expression than EBV− cases. EBV+, CD30+ DL-
BCL cases are often accompanied with advanced age. The pathological analysis of the
EBV+ DLBCL of the elderly displays strong polymorphisms and varies from large B-cell
like, Hodgkin lymphoma-like, and polymorphic lymphoproliferative disorder-like. The B
cells display an activated B cell phenotype. The surrounding cells are mostly composed
of small lymphocytes and PC. Further, this lymphoma displays an involvement of the
canonical and alternative NFκB pathways, concomitantly or independent of one another
[Ramachandiran et al., 2015]. Thereby, the EBV infection seems to have an additional
impact in activating these pathways [Montes-Moreno et al., 2012]. CD30+ DLBCL cases
seem to have a preferable outcome than CD30 negative cases. However, the combination
of CD30 expression and EBV infection resulted in significantly poorer clinical survival
and outcome in comparison to CD30+, EBV− and CD30−, EBV+ cases [Hu et al., 2013]
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3.3 CD30
Lymphomas which are positive for CD30 expression reveal this CD30 expression in almost
all lymphoma cells [Montes-Moreno et al., 2015]. Under physiological conditions, the ex-
pression of CD30 is restricted to a few activated T and B cells [Dürkop et al., 1997].
Despite the high incidence of CD30+ lymphomas, the role of CD30 in B cells is still
not fully understood. It is a member of the TNF-receptor superfamily and character-
ized as a marker for different kinds of B cell lymphomas [Younes and Aggarwall, 2003,
Klein et al., 2003, Bhatt et al., 2013]. Further, the use of CD30 as prognostic value to
determine the clinical outcome of the lymphoma is still unclear. But in DLBCL, it could
be shown that CD30+ cases are characterized by more B symptoms, and stronger BM
involvement than the CD30− cases [Hao et al., 2015]. The CD30 protein undergoes differ-
ent maturation stages during biosynthesis. The precursor protein with a size of 84 kDa is
processed by high mannose N-linked glycosylation to a 90 kDa precursor. This precursor
migrates in the endoplasmic reticulum and the Golgi complex and gets further processed
through addition of sialic acids, O-linked glycosylation and the conversion of N-linked
glycosylation to a complex type. The result is a 120 kDa mature transmembrane protein
[Nawrocki et al., 1988, Froese et al., 1987]. The soluble CD30 (sCD30) is produced by
cleavage of the extracellular domain of CD30 through membrane-anchored metalloprotease
[Hansen et al., 2000, Josimovic-Alasevic et al., 1989]. The sCD30, which is found in high
concentrations in the serum of patients with CD30+ malignancies, has a size of 85 kDa.
The CD30 ligand (CD30L) has a size of 40 kDa and is found on activated T and B cells,
macrophages, and dendritic cells [Maŕın and Garćıa, 2017, Hendrickson et al., 2007].
3.3.1 Signaling
The interaction of CD30 with CD30L leads to activation through receptor trimeriza-
tion which is a common feature of all TNFRs [Smith et al., 1994]. The C-terminal do-
main of CD30 reveals significant homologies to TNF receptors I, II, CD27 and CD40
[Smith et al., 1993]. Similar to the other TNF-receptors, the intracellular domain of
CD30 possesses no intrinsic enzymatic domain. The members of the TNFR-associated
factor (TRAF) family and various TRAF-binding proteins are the only mediator of sig-
nal transduction [Schneider and Hübinger, 2002]. TRAF 1, 2, 3 and 5 bind one of the
two different intracellular binding sites of CD30 [Boucher et al., 1997, Lee et al., 1996].
These two intracellular domains activate differentially the canonical and alternative NFκB
pathway in human lymphocytes [Buchan and Al-Shamkhani, 2012]. Additionally, CD30
induces signaling through the mitogen activated protein kinase (MAPK) pathway. This
leads to different anti-apoptotic and pro-survival signaling. Further, there seems to be a
positive feedback loop between the MAPK/extracellular signal-regulated kinases (ERK)
pathway and the nuclear transcription factor JunB which promotes cell survival but also
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CD30 expression [van der Weyden et al., 2017].
3.3.2 Function
Little is known about the function of CD30. The knowledge which derived from different
lymphoma cell lines is contradictory. Studies which used the monoclonal antibody Ki-1 to
activate CD30 signaling reported decreased proliferation and increased apoptosis in ALCL
whereas cells lines derived from HL remained unaffected [Hirsch et al., 2008]. Analysis of
the gene expression profile of both cell lines revealed strong differences in these two cell
lines upon CD30 stimulation. This study revealed only a response in cell lines from ALCL
and not from HL. Further, Hirsch et al. show that ALCL cell lines respond with activation
of caspases and NFκB-mediated survival upon CD30 stimulation [Hirsch et al., 2008]. It
is assumed that the ability to activate the NFκB signaling governs the outcome in these
cells [Mir et al., 2000]. Another hypothesis is that the outcome upon activation of CD30
signaling depends on the activation of different regions on the cytoplasmic tail of CD30.
As shown in different kind of lymphoma cell lines, the signaling mechanism are also ac-
companied with paracrine, juxtacrine, and autocrine regulatory loops between CD30L
and CD30 expressing cells [Hsu and Hsu, 2000]. Therefore, the microenvironment is crit-
ical in order to predict the influence of CD30 signaling.
In the immune system, CD30 acts as co-stimulatory molecule together with the CD3/T
cell receptor (TCR) complex in T cells. Knock out mouse models reveal a role of CD30
during regulation of memory T cells [Muta and Podack, 2013]. Additionally, without
CD30, the capacity of sustaining GC responses is impaired and the memory antibody
response is reduced [PODACK et al., 2002, Gaspal et al., 2005]. Further, the interaction
of CD30-CD30L is involved in the negative selection process of autoreactive T cells in the
thymus [Chiarle et al., 1999, Gilfillan et al., 1998, Amakawa et al., 1996]. However, the
active CD30 signaling on human Th0, Th1, and Th2 also results in increased prolifera-
tion rates and cytokine production [Del Prete et al., 1995, Tarkowski, 2003]. Murine B
cells which encounter CD30 stimulation combined with either IL4 or IL5, react with pro-
liferation and enhanced antibody production and secretion [Shanebeck et al., 1995]. In
vitro studies with human B cells revealed impeded CD40L induced class switch. Besides,
it was shown that CD30L expressing human B cells receive inhibitory signals from CD30+
T cells which can result in hampered class switch and reduced production of IgA, IgG and




The two known human gammherpesviruses EBV and KSHV have a high association
with different B cell lymphomas like DLBCL and PEL, respectively. A known murine
virus which also belongs to the subfamily of Gammaherpesvirinae is the murine gamma-
herpesvirus 68 (MHV-68). The Gammaherpesvirinae are further assigned to the family of
Herpesviridae. This family is ancient, widely distributed, and has a large double-stranded
DNA genome. The Herpesviridae are characterized by four main biological properties.
They share a large pool of enzymes which are associated with the nucleic acid metabolism,
DNA synthesis, and processing of proteins [Fields et al., 2007]. In the nucleus, the viral
DNA synthesis and capsid assembly takes place. However, the final processing of the virion
occurs in the cytoplasm. Further, the production of the progeny virus leads always to the
destruction of the infected cell. Finally, the herpesviruses are able to persist in a phase
of latency in their natural hosts. While doing this, the viral genome remains as closed
circular molecule and just a few viral genes are expressed. This stage is reversible, meaning
the viruses preserve the ability to replicate and can cause a disease in the lytic phase
upon reactivation. All herpesviruses stay latent in a specific cell subset. But this subset
varies and depends on the virus. Gammaherpesviruses remain latent mainly in lymphoid
tissue, especially in B cells [Fields et al., 2007]. This subfamily is partly associated with
lymphoproliferative diseases and lymphomas but also non-lymphoid malignancies. It is
assumed that the DLBCL in elderly is caused by a defective immune surveillance of EBV
infected B cells [Montes-Moreno et al., 2012]. In cHL, all EBV positive cases carry BCR
with crippled mutations which preclude their functional expression. Since B cell cannot
survive without a BCR, the EBV infection is a precondition for these cells to survive
and undergo malignant transformation. Otherwise, these cells would undergo apoptosis.
Further, EBV intervenes with epigenetic and transcriptional processes which leads to
growth and survival independent of transforming mutations [Shannon-Lowe et al., 2017].
MHV-68 was first isolated from voles in Slovakia [Blaskovic et al., 1980, Nash et al., 2001].
It infects laboratory mice and a variety of tissue culture cell lines [Blaskovic et al., 1980,
Virgin et al., 1997]. In mice, the virus establishes a lifelong latent infection in B cells,
macrophages and splenic dendritic cells. The natural infection route is unknown but
it is assumed to be over the respiratory tract. A frequently applied technique in the
laboratories, intranasal inoculation, leads to a lytic replication in the lung accompanied
by infection of alveolar epithelial cells. After the peak of viral titers is reached at day (d) 7,
the infection spreads to distal organs like the spleen with the help of B cells. The acute
phase of virus replication in the spleen is cleared between d 14-16 post infection (p.i.). In
the early phase of latency, between d 16-18, around 1 of 100 splenocytes carry the virus.
Also during this time, different sub-populations of B cells are found to be infected. These
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are naive (sIgD+) B cells, GC (PNA+, CD95+) B cells, and isotype switched memory B
cells. However, upon three months p.i., the number of infected naive B cells diminishes
constantly. Now, a steady level of 1 among 10.000 cells is infected which are mainly
composed of isotype-switched memory B cells [Barton et al., 2011]. Without B cells,
latency in macrophages can only be established if the virus is applied intraperitoneally
(i.p.). Only in particular immune-compromised mice, infection with MHV-68 leads to
lymphoma development [Nash et al., 2001].
3.4.2 γ-Herpesviruses in disease
EBV and KSHV belong to two different subgroups of the γ-Herpesviruses. EBV is as-
signed to the lymphocryptoviruses and KSHV to the rhadinoviruses. EBV is found in
almost all cases of endemic BL and partly in PEL and HL. The in vitro infection of
B cells with EBV leads to immortalized proliferating lymphoblastoid cell lines (LCL)
[Toplin et al., 1966]. LCL express two groups of viral antigens: six nuclear antigens de-
clared as Epstein-Barr nuclear antigens (EBNA) and three membrane proteins cited as
latent membrane proteins (LMP). LMP1, known as an oncogene, is one of these and is
essential, but alone not sufficient for immortalization of B cells. It belongs to the TNF-
receptor superfamily, needs no ligand for active signaling due to self-oligimerization in
the plasma membrane, and its functions resemble a constitutively active CD40 receptor
[Klein et al., 1999]. The signaling domain of LMP1 consists of two effector sites called
CTAR1 and CTAR2 interacting with TRAF. CTAR1 induces the non canonical NFκB
pathway and CTAR2 is necessary to activate c-Jun N-terminal kinase (JNK) and the
canonical NFκB pathway [Kieser and Sterz, 2015].
The cellular counterpart of LMP1 is CD40 which is expressed for example on the surface
of B cells. The interaction is performed with CD40L expressing T cells. Active CD40
signaling in B cells induces the initiation of the GC reaction. Further in the LZ of the
GC, CD40L bearing T cells participating in the positive selection process of centrocytes.
In contrast to in-vitro derived LCL, the expression profile of EBV-infected cells in vivo is
much more restricted. These profiles depend on the differentiation profile of the affected B
cell and are categorized in three stages of latency. At the different latency stages, distinct
sets of genes are expressed. EBV can adopt all three stages in B cells. After infection of
a naive B cell, EBV accesses the latency stage III. There it expresses EBNA 3A, 3B, 3C,
and Leader protein (LP), LMP1 and LMP2a+b and Epstein–Barr virus-encoded small
RNAs (EBER)1+2. This leads to the transformation of the B cell into a proliferating
blast. Afterwards, EBV restricts the expression profile to latency stage II or the so called
default programme. Here, EBNA 1, LMP1, LMP2a+b and the EBERs are expressed
which induces the B cell to differentiate into a memory B cell. The latency stage I, which
follows, comprises only the expression of the EBERs and EBNA 1.
KSHV is present in almost all cases of Kaposi´s sarcoma, and it is associated with the
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development of PEL. Until now, infection of B cells with KSHV did not lead to immortal-
ization in-vitro. KSHV lacks clear homologs of EBV genes which lead to transformation
of B cells. As KSHV, also MHV-68 belongs to the group of rhadinoviruses. Several sim-
ilarities among MHV-68, KSHV and EBV proof MHV-68 as a good model to study the
biology of γ-herpesviruses in mice. Various genes like v-cyclin, vBcl-2, vGPCR, LANA,
and RTA which are involved in latency establishment and reactivation, are well conserved
between primate and rodent viruses [Gauld et al., 2013]. Also, studying the unique gene
products of herpesviruses revealed conservation of key functions [Damania et al., 2000].
Finally, all γ-herpesviruses are lymphotrophic and share the same strategy of persisting
in their hosts [Barton et al., 2011]. The highly conserved innate and adaptive immune
response between mice and human appoint MHV-68 as a good model for studying the
nature of γ-herpesvirus infections.
3.5 The LMP1/CD30flSTOP mouse strain
The low number of CD30 expressing cells in human and mice complicates the task of
studying the effect of CD30. Further, as described above, some human B cell lymphomas
highly express CD30, and the role of CD30 in these diseases is still unknown. For these
reasons, Petra Fiedler in the lab of Dr. Zimber-Strobl developed the LMP1/CD30flSTOP
mouse strain. Here, the fusion gene LMP1/CD30 consists of the transmembrane domain
of the viral protein LMP1 and the cytoplasmic domain of murine CD30. Due to the
self-oligomerization of LMP1, the CD30 ligand is not needed to induce CD30 signaling.
Instead, a chronic signaling is established in the respective cell in which the fusion gene
is expressed. The transgene was inserted into the Rosa26 locus under the control of the
endogenous Rosa26 promoter. The fusion gene is preceded by a loxP site flanked STOP-
cassette ensuring a cre-dependent expression of LMP1/CD30. An IRES-hCD2 (internal
ribosomal entry site-human CD2) cassette was inserted downstream of LMP1/CD30. The
inserted hCD2 is truncated. This enables monitoring the LMP1/CD30 expression in any
given cell by surface staining for hCD2.
In previous work, the LMP1/CD30 strain was crossed to the CD19cre strain in order to
achieve a B cell specific LMP1/CD30 expression. These mice developed already with eight
weeks a mild splenomegaly evoked by significant higher B cell numbers. Nevertheless, the
splenic follicle structure of these mice displayed a normal organization regarding B and T
cell zone. In contrast, the B cell sub-populations displayed a significant increased CD43+,
CD23low, IgM+, IgDlow population resembling a B1 cell population. Additionally, the PC
population in BM and spleen was enhanced, accompanied by higher IgM, IgG2a, IgG3
and IgA serum titers. Immunization with the TD antigen (4-hydroxy-3-nitrophenyl)acetyl
(NP)-Chicken Gamma Globulin (CGG) led to significant reduced GC and significant
reduced IgG1 PC. Finally, the LMP1/CD30 mice developed in 80% of aged mice a mono-
4 AIM 18
or oligoclonal lymphoma with B cells consisting only of the expanded CD43+, CD23low
cells [Sperling et al., 2019].
4 Aim
CD30 was first identified 1982 with a monoclonal antibody obtained by using a HL derived
cell line [Schwab et al., 1982]. Afterwards, CD30, a transmembrane glycoprotein receptor,
was cloned, characterized as a 120kD protein, and assigned to the tumor necrosis factor
receptor superfamily [van der Weyden et al., 2017]. The variable expression on normal
cells in comparison to malignant cells on different hematopoietic lymphomas raised the
question of the pathogenic mechanisms of CD30 upregulation and its interference in the
process towards lymphoma development. The restricted expression of CD30 on specific
malignant cells resulted in the attempt to use it as therapeutic target for lymphoma ther-
apy. However, the knowledge about the function of CD30 is restricted so far. To study the
physiological and pathophysiological function of CD30, Petra Fiedler generated a trans-
genic mouse line LMP1/CD30 which allows for conditional expression of a constitutive
active CD30 receptor in the targeted cells. The loxP flanked STOP-cassette enables a
cre-recombinase dependent expression. Petra Fiedler crossed the LMP/CD30 line to the
CD19cre mouse line and analyzed the influence of the LMP1/CD30 expression in all B
cells. Thereby, she detected an expanded population with a B1 like phenotype and a
block of the GC reaction in the LMP1/CD30//CD19cre mice upon TD immunization.
My aims were the following:
AIM 1: Elucidate the role of chronic CD30 signaling in B1 and B2 cells.
The LMP1/CD30 expression resulted in more B1 and PC in these transgenic mice. Here,
we will characterize the expanded B1-like population further and analyze its response
towards in vitro stimulation. Also, LMP1/CD30 expressing B2 cells will be investigated
upon stimulation regarding differentiation and signaling pathways. Further, TI immu-
nization of LMP1/CD30 mice should illuminate the role of CD30 signaling during the
immune response. Additionally, we will cross LMP1/CD30 mice with Cγ1-cre mice to
induce deregulated CD30 signaling in GC B cells upon TD immunization. Following, the
role of CD30 during the GC reaction and its impact regarding the cell fate decision of B
cells will be investigated.
AIM 2: Analyze the lymphoma development of LMP1/CD30//Cγ1-cre
mice upon TD immunization and herpesviral infection.
LMP1/CD30//CD19cre do not develop GC upon TD immunization. In order to model
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GC derived CD30+ human lymphoma, LMP1/CD30//Cγ1-cre mice will be adopted. The
infection with MHV-68, a murine γ-herpesvirus, will be used to study the contribution
of herpesviral infection in B cell lymphoma development. Infected cells will be examined
by cloning a nerve growth factor receptor (NGFR) expressing MHV-68. Two groups of
either immunized or infected LMP1/CD30//Cγ1-cre mice will be compared and analyzed.
Thereby, we will elucidate the impact of deregulated CD30 signaling in GC B cells re-
garding lymphomagenesis alone and combined with the γ-herpesviral infection. The mice
will be analyzed after 2 weeks, 2 months and after becoming ill in order to follow the
influence of deregulated CD30 signaling and the virus infection over time.
AIM 3: Investigation of the additional effect of LMP1 during MHV-68
infection.
LMP1 plays an important role in the malignant transformation of B cells during an EBV
infection. Genetically engineered mouse models, analyzed already the expression of LMP1
in B cells which revealed its oncogenic potential [Wirtz et al., 2016, Zhang et al., 2012,
Kulwichit et al., 1998].However so far, no model which induces the LMP1 expression upon
viral infection was established. Therefore, we aimed to use MHV-68 as a tool to express
LMP1 in a herpesviral context in murine cells. Since MHV-68 does not express a homo-
logue of LMP1, two recombinant MHV-68 viruses will be cloned. One virus will contain
LMP1wt and the other LMP1mut, a LMP1 with truncated signaling domain which will
serve as control. We will investigate the influence of MHV-68-LMP1 in GC and non-GC
cells. Further, we will analyze the impact of the LMP1 expression in viral infected B cells
regarding lymphoma development in vivo (knowing that MHV-68 alone is not capable to
induce lymphomagenesis in wild type (wt) mice). Here, we will infect LMP1/CD30 mice
with the two viruses.
5 Results
5.1 CD30 expression on murine B cells
Until now, little is known about the expression of CD30 under physiological conditions.
Therefore, we analyzed the expression patterns of CD30 in B cells ex vivo and in vitro
under different conditions.
First, the B cell sub-populations of the spleen and the PerC were analyzed for their CD30
expression by flow cytometry (FACS). The B1 cells expressed more CD30 than the B2
cells in the PerC. Additionally, B1a cells were slightly higher in the CD30 staining in com-
parison to B1b cells. A similar constellation with a slight reduced distinctness was found
in the sub-populations of the spleen (Figure 1A). Second, since CD30 is expressed mainly
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on activated T and B cells [Dürkop et al., 1997], the question was if CD30 upregulation
differs under certain stimulating agents. Isolated splenic B cells reacted upon CD40/IgM
stimulation with the highest upregulation of CD30 after 3 d (Figure 1B) compared to
LPS, CD40, or IgM stimulation (data not shown). The expression of CD86 was used as
positive control for B cell activation. The cooperative effect between BCR engagement
and CD40 signaling regarding B cell activation, which was published recently, effects also
the CD30 expression [Haxhinasto et al., 2002, Bishop et al., 1995].
Due to the higher CD30 expression of naive B1 cells in comparison to B2 cells in vivo,
the question arose if B1 cells display a stronger upregulation of CD30 upon stimulation.
For this, B1 and B2 cells were sorted and cultivated with CD40/IgM stimulation and
analyzed for their CD30 expression. Both subtypes displayed an upregulation of CD30
after 1 d. Nevertheless, the staining for CD30 of B1 cells proofed a higher upregulation
in comparison to B2 cells (Figure 1C).
Analysis of in silico data of Shi et al. revealed a role of CD30 during murine PC differenti-
ation [Shi et al., 2015, Sperling et al., 2019]. The same could be shown upon investigation
of data derived from human PC [Jourdan et al., 2011, Sperling et al., 2019]. Therefore,
we immunized mice to induce PC differentiation in B cells. Indeed, developed PB charac-
terized by a positive staining for IRF4 revealed a higher CD30 expression in comparison to
IRF4− B cells (Figure 1D). This is concurrent with the co-expression of IRF4 and CD30
in human tonsil sections [Cattoretti et al., 2006]. In summary, CD30 is upregulated in
PB and in B1 cells which additionally reveal a stronger upregulation of CD30 upon stim-
ulation than B2 cells.
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Figure 1: (A): Isolated lymphocytes of the peritoneal cavity (PerC) and the spleen (SP) of
wildtype (wt) mice were stained for B2 (CD19+, B220+, CD5lo), B1a (CD19+, B220lo, CD5+),
and B1b (CD19+, B220lo, CD5lo) and determined for their level of CD30 via flow cytometry
(FACS), n=3; (B): B cells were isolated from splenocytes with the Pan-B cell isolation kit and
cultivated for three days (d) with CD40 and IgM stimulation and analyzed for their CD30
and CD86 expression via FACS, n=3; (C): B cells were isolated from the SP with the Pan-B
cell isolation kit and then sorted for B1 (CD19+, CD43+, CD23lo) and B2 (CD19+, CD43lo,
CD23+) cells. Cells were cultivated for 1 d with CD40 and IgM stimulation and CD30 and
CD86 expression was determined with FACS; (D): Wt mice were immunized with NP-LPS
intraperitoneally (i.p.), at d 3 post infection (p.i.) after intracellular IRF4 staining, splenocytes
were analyzed with FACS, n=3.The experiment was performed in cooperation with Markus
Lechner from the laboratory of Dr. Zimber-Strobl.
5.2 Chronic CD30 signaling drives plasma cell differentiation
In the following analysis, we used heterozygous BALB/c LMP1/CD30STOPfl//CD19cre
mice designated LMP1/CD30 thereafter, and as control either CD19cre or wt BALB/c
mice.
The previous work of Petra Fiedler displayed already higher PC numbers and an enriched
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B1 like population with higher BLIMP-1 expression in LMP1/CD30 mice
[Sperling et al., 2019]. Also, the co-expression of IRF4 and CD30 hints to a role of CD30
during PC differentiation. Therefore, the aim was to investigate the role of CD30 during
PC differentiation further after in vitro stimulation and immunization.
5.2.1 Chronic CD30 signaling drives plasma cell differentiation in vitro
Isolated B cells of LMP1/CD30 and control mice were kept in culture for 5 d without
stimulation, CD40, or LPS stimulation. The cells were analyzed for PB differentiation
after 1, 3, and 5 d via FACS. Surprisingly, even without further stimulation, B cells of
LMP1/CD30 mice differentiated towards PB (CD138+, B220lo) (Figure 2). Also, the
CD40 stimulation which normally does not support PB differentiation led to significant
higher percentages of PB among these cells (Figure 2).
Figure 2: B cells of control (ctrl) and LMP1/CD30 mice were isolated with the Pan-B cell kit,
cultivated for 5 d either without (w/o) stimulation or with an agonistic anti-CD40 antibody, the
percentages of PB (TO-PRO3−, CD138+, B220lo) were determined with FACS at d 1, 3, and 5,
shown is one representative experiment, n=3.
Additionally, the B cells of LMP1/CD30 mice stimulated with LPS differentiated to
a higher extent towards PB than control B cells (Figure 3A, 3B). Due to the reduced
CD138 expression of LMP1/CD30 expressing PB after LPS stimulation, we also checked
for further markers. Nevertheless, CD22 was downregulated and TACI was upregulated,
proving them as proper PB (Figure 3A). Further, the IgM titers of the supernatant of the
cultivated B cells confirmed the differentiation towards ASC and reflect the percentage
of developed PB (Figure 3C). The unstimulated LMP1/CD30 B cells secreted significant
more antibodies in comparison to unstimulated control mice. But still, the LPS stimulated
LMP1/CD30 B cells produced significant more than the unstimulated LMP1/CD30 B
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cells.
Figure 3: (A): B cells of ctrl and LMP1/CD30 mice were isolated with the Pan-B cell kit,
cultivated for 3 d either w/o stimulation or with LPS, the percentages of plasmablasts (PB)
(TO-PRO3−, CD138+/B220lo or CD138+/CD22lo or CD138+/TACI+) were determined with
FACS, n=3; (B): The percentages of PB (TO-PRO3−, CD138+, TACI+) are shown in the
graph at d 3; (C): The graph shows the amount of the IgM antibodies in the supernatant
after cultivation for 3 d w/o or with LPS stimulation which were determined by Enzyme-linked
Immunosorbent Assay (ELISA).
Usually PB differentiation is correlated with proliferation. In order to determine these,
Carboxyfluorescein succinimidyl ester (CFSE) staining was used. Notably, a certain per-
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centage of PB of LMP1/CD30 did not lose the CFSE staining after LPS stimulation even
after 5 d of cultivation indicating that they developed to PC without cell division (Figure
4). It is known that some splenic B1 cells are able to differentiate without further prolifer-
ation towards PB [Yang et al., 2007]. To investigate whether the B1 cells are responsible
for the phenotype, CD43+ B1 cells were depleted. Using the remaining B cells for the
same LPS experiment showed that all PB displayed a reduction of the CFSE staining
which means they proliferated (Figure 4). Therefore, the source of the undivided PB
were most likely CD43+ cells in the LMP1/CD30 mice. This might indicate that the
CD43+ B cell population of LMP1/CD30 contains precursors of PB which are able to
differentiate without further proliferation towards PB in vitro.
Figure 4: B cells of ctrl and LMP1/CD30 mice were isolated with the Pan-B cell kit or the
CD43 depletion kit, stained with CFSE and cultivated for 5 d with LPS, displayed are the CFSE
histograms of living cells at d 1 and of PB (TO-PRO3−, CD138+, B220lo) at d 3 and 5, shown
is one representative example, n=3.
For this reason, we compared now the percentages of CD138+ PB in the CD43+,
CD23lo and in the CD43lo, CD23+ cell population of LMP1/CD30 and control mice.
Here, we found that the CD43+, CD23lo population of both genotypes contained more
PB than the corresponding B2 cells. But additionally, the CD43+, CD23lo population of
LMP1/CD30 mice contained significant higher percentages of PC than the same popula-
tion of control mice (Figure 5A). To add, the CD43+, CD23lo cells of LMP1/CD30 mice
displayed a significant higher IRF4 median fluorescence intensity (MFI) than the popula-
tion of the control mice, whereas the B2 cells revealed only a slight increased level (Figure
5B). Further, a larger percentage of the CD43+, CD23low population of LMP1/CD30 mice
expressed high levels of TACI, known as being upregulated in PB, in comparison to the
related control population (Figure 5C) [Pracht et al., 2017].
To study whether the B1 cells are responsible for the spontaneous PB differentiation,
we compared sorted B1 and B2 cells with regard to PB differentiation in vitro without
stimulation for 3 d. This experiment designated the CD43+, CD23lo cells of LMP1/CD30
mice as source for the developed PB (Figure 5D). Almost 5% of PB arose in the B1 cell
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population of these mice compared to almost 2% in the B2 cell population. To rule out
the high amounts of CD138+, B220lo cells in this population as cause for these PB, we
sorted again only for CD138lo, CD43+, CD23lo cells (Suppl. 1). Still, a significant higher
percentage of these LMP1/CD30 expressing cells differentiated after 3 d without stimula-
tion towards PB in comparison to control B1 cells (Figure 5E). This indicates that CD30
signaling drives PC differentiation in B1 cells without further stimulation.
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Figure 5: (A): These FACS plots show the CD138 and B220 staining as an overlay of splenic B1
(CD19+, CD43+, CD23lo) and B2 (CD19+, CD43+, CD23lo) cells of ctrl and LMP1/CD30 mice,
the numbers show the percentages of PB (CD138+, B220lo) within the B1 cell population; (B):
The graph shows the relative median fluorescence intensity (MFI) of IRF4 of splenic B1 (CD19+,
CD43+, CD23lo) and B2 (CD19+, CD43lo, CD23+) cells, the MFI was normalized to the MFI
of ctrl B2 cells which was set to 1, n=3; (C): The histogram shows the TACI expression as an
overlay of splenic B1 and B2 cells of ctrl and LMP1/CD30 mice, one representative example
is displayed, n=5; (D): B cells of LMP1/CD30 mice were isolated with the Pan B cell kit and
sorted for B1 (CD19+, CD43+, CD23lo) and B2 cells (CD19+, CD43lo, CD23+), the cells were
cultivated for 3 d w/o stimulation and analyzed for the percentages of PB (TO-PRO−, CD138+,
B220lo) via FACS, the numbers show the mean with SD of the percentages of PB, n=4; (E): B
cells of ctrl and LMP1/CD30 mice were isolated from splenocytes with the Pan B cell kit and
sorted for B1 cells (CD19+, CD43+, CD23lo) excluding CD138+ cells. Cells were cultivated w/o
stimulation and analyzed for PB differentiation, the FACS plot shows the percentage of PB of
one representative experiment, the graph compiles the percentages of all experiments, n=3.
Unlike the CD43+, CD23lo population of LMP1/CD30 mice, B2 cells did not differ-
entiate towards PB without stimulation. In contrast, CD40 stimulation of LMP1/CD30
expressing B2 cells led to significant higher percentages of PB compared to control cells
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(Figure 6A). Additionally, around of 16% B2 cells from LMP1/CD30 mice adopted a
CD43+, CD23lo phenotype which was significant more than in control cells (Figure 6B).
This population contained in both genotypes more CD138+ B cells, expressed higher levels
of CXCR4, and lower levels of CD22, being in accordance to a plasmablastic phenotype
(Figure 6C+D) [Minnich et al., 2016]. Taken together, CD40 stimulation of LMP1/CD30
expressing B2 cells leads to a CD43+, CD23lo population composed of PB and their pre-
cursors. Therefore, the expanded CD43+, CD23lo population in LMP1/CD30 mice can
be generated by both B1 and activated B2 cells. Further, B2 cells of LMP1/CD30 mice
are not able to differentiate spontaneously to PB like LMP1/CD30 expressing B1 cells
but display enhanced PB differentiation upon CD40 stimulation in comparison to control
B2 cells. Thus, we think that the expanded population is a mixture of B1 cells and PB.
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Figure 6: (A+B): B cells of ctrl and LMP1/CD30 mice were isolated from splenocytes with the
Pan B cell kit, sorted for B2 cells (CD19+, CD23+, CD43lo) and cultivated for 3 d with anti-
CD40 antibody. Subsequently, they were analyzed for PB and CD43/CD23 expression. Numbers
represent the mean and SD of the percentages of the affiliated marked population, n=4; (C):
This FACS plot shows the CD138/B220 staining of the two populations gated as shown in 6B
of ctrl and LMP1/CD30 mice, numbers represent the percentages of the populations of one
representative example; (D): These histograms show the CD22 and CXCR4 expression as an
overlay of the two populations from 6B, n=3, one representative example is shown.
Next, we examined the responsible signaling pathways for the enlarged PC differen-
tiation in LMP1/CD30 mice. We found significant higher pSTAT3 and pSTAT6 levels
in LMP1/CD30 expressing B2 cells after 10 min and 2 h of CD40 stimulation (Fig-
ure 7A). Also, the amounts of p65 and IRF4 were significantly increased in the nucleus
of the B2 cells of LMP1/CD30 mice after 10 min of CD40 stimulation in comparison
to control B cells (Figure 7B+C). The phosphorylation of STAT3 plays a crucial role
in PC differentiation by up-regulating BLIMP-1 and IRF4 is a known NFκB target
[Grumont and Gerondakis, 2000, Reljic et al., 2000, Diehl et al., 2008]. To sum this up,
CD30 signaling further increases pSTAT3 and pSTAT6 levels as well as the translocation
of p65 into the nucleus upon CD40 stimulation. This in turn drives the upregulation of
5 RESULTS 29
IRF4 and BLIMP-1.
Figure 7: B2 cells of ctrl and LMP1/CD30 mice were isolated from splenocytes with the CD43
depletion kit and stimulated with anti-CD40 antibody, (A): Nuclear levels of pSTAT3 and
pSTAT6 were determined with WES and normalized to LaminB at the indicated time points;
(B+C): Nuclear and cytoplasmic levels of p65 and IRF4 were determined and normalized to
αβ-Tubulin or LaminB and standardized to their respective value obtained w/o stimulation,
n ≥ 3.
During IL4 induced class switch recombination (CSR), pSTAT6 is an essential fac-
tor [Linehan et al., 1998]. Therefore, we asked if CD30 signaling might be able to replace
CD40 signaling regarding the class switch recombination and proliferation. The encounter
with IL4 and anti-CD40 antibody induces class switch recombination of B cells in vitro
[Cerutti et al., 1998]. For this reason, we sorted FoB (CD21+, CD23+, CD19+) from
LMP1/CD30 and control mice and stimulated them with IL-4 alone or in combination
with anti-CD40 antibody for 3 and 5 d (Figure 8A). Surprisingly, even with IL-4 alone,
around 3% of the LMP1/CD30 expressing FoB switched towards IgG1. The percentage
of isotype switched B cells in the control group was below 1% and thus significantly re-
duced. But compared to the combined stimulation of IL-4/CD40, the number of switched
cells was significantly lower in both genotypes (Figure 8B+D). The same was true for
the proliferation of the cultivated FoB. The division index of FoB of LMP1/CD30 mice
stimulated with IL-4 was significantly higher in comparison to control B cells but still
clearly reduced in comparison to the combined stimulation with IL-4/CD40 (Figure 8C).
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Also, after stimulation with IL-4 and CD40, the extent of isotype switching and prolif-
eration seemed to be increased in the LMP1/CD30 expressing FoB when compared to
control FoB. This means that CD30 signaling alone cannot replace CD40 signaling but
might have an additive effect in terms of proliferation and switching. The higher pSTAT6
levels found in the B2 cells of LMP1/CD30 mice were probably responsible for the higher
percentage of switched cells. Additionally, the proliferation induced by the combination
of constitutive CD30 signaling and IL4 was necessary to enable IgG1 isotype switching
[Hasbold et al., 1998]. The higher proliferation might be realized through higher pSTAT3,
pSTAT6 and p65 levels upon anti-CD40 antibody encounter.
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Figure 8: (A): Sorting strategy of FoB cells, B cells were isolated with the Pan B cell kit
from splenocytes of ctrl and LMP1/CD30 mice and sorted, first doublets were excluded, then
the lymphocytes were gated, afterwards CD19+, CD23+, CD21mid were sorted as FoB, after
sorting, lymphocytes were gated again and then checked for CD19, CD21, and CD23 expression;
(B): Sorted FoB of ctrl and LMP1/CD30 cells were stained with CFSE, cultivated for 5 d in
the presence of IL4 alone or in combination with CD40 stimulation, the FACS plots show one
representative example of IgG1 switched B cells, the division index (C) and the percentages of
IgG1 switched cells (TO-PRO3−, B220+, IgG1+) (D) were determined by FACS and FlowJo.
The values are summarized in the graph with mean and SD, n=3.
5.2.2 Chronic CD30 signaling drives plasma cell differentiation upon T-cell
independent immunization
Given the data of the previous experiments, the question arose if LMP1/CD30 mice re-
spond with a stronger immune response upon antigen administering. Here, we immunized
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mice with NP-Ficoll, a TI-2 antigen to which B1 and MZB respond. 14 d post immu-
nization (p.im.), FACS analysis from mice revealed a further expansion of PC and B1a
cell population in LMP/CD30 mice in comparison to immunized control mice but also
to not immunized LMP/CD30 mice (Figure 9A). Furthermore, the antigen specific IgM
and IgG3 secreting PC were significantly increased in the spleen and NP-specific IgM se-
creting PC in the BM of LMP1/CD30 mice in comparison to the immunized control mice
(Figure 9B+C). Also, the serum titers of IgM were significantly higher whereas the IgG3
titers were slightly but not significantly increased in LMP1/CD30 mice (Figure 9D). This
leads to the conclusion that immunization with NP-Ficoll results in an increased immune
response with further expansion of B1 cells and PC in mice with a chronic CD30 signaling
in B cells.
Figure 9: Ctrl and LMP1/CD30 mice were immunized with NP-Ficoll and analyzed after 14 d,
(A): The graphs show the percentages of PC (Gr1−, Thy1.2−, Mac1−, CD138+, B220lo) (up-
per diagram) and B1a cells (CD19+, CD5+, B220lo) (lower diagram) of untouched (n.i.) and
immunized mice in the SP; (B+C): The graphs show the number of low affinity IgM and IgG3
secreting PC of immunized mice among splenocytes and bone marrow (BM) cells which were
determined by ELISpot; (D): The graphs show the amount of IgM and IgG3 antibodies in the
serum. Every dot in the graphs represent the value of one mouse, the mean is represented by
the bar.
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5.2.3 LMP1/CD30 expression drives plasma cell differentiation in germinal
center B cells
The induction of a GC reaction by NP-CGG administration led to a block in the GC estab-
lishment in LMP1/CD30 mice which was shown by Petra Fiedler [Sperling et al., 2019].
In order to analyze the influence on the GC reaction further, we wanted to study the
permanent GC found in the PP. PP are secondary lymphoid tissue in the mucous
membrane of the small intestine. Due to steady encounter with antigens through vi-
ral and bacterial influx by nutrition and by the microbiome, PP maintain continual GC
[Reboldi and Cyster, 2016]. In the PP, we discovered significantly reduced percentages of
GC B cells in LMP1/CD30 mice in the PP compared to control mice (Figure 10A). If we
pregated the B cells of LMP1/CD30 mice for hCD2, the difference between control and
LMP1/CD30 mice was even more prominent (Figure 10B). To add on this, the deletion
efficiency of the floxed-STOP-cassette in all B cells was at around 96 %. In contrast, the
deletion efficiency in GC B cells of the spleen amounted to 75% and in the PP around
60% indicating a counter selection of LMP1/CD30 expressing GC B cells (Figure 10C).
Figure 10: (A): The germinal center (GC) B cells (CD19+, CD38lo, CD95+) of the peyers
patches (PP) of ctrl and LMP1/CD30 mice were analyzed and shown as a FACS plot; (B): The
percentages of GC B cells (CD19+, CD38lo, CD95+, hCD2+ (LMP1/CD30 only)) of PP of ctrl
and LMP1/CD30 mice were analyzed and shown as graph which displays the percentages of
all analyzed samples; (C): This graph shows the deletion efficiency of GC and non GC cells of
LMP1/CD30 mice analyzed by staining for the reporter hCD2 in the SP and the PP. Every dot
represents the value of one mouse, the bar represents the mean of the percentages.
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In order to be able to study the role of the CD30 signaling in the GC B cells, we crossed
the LMP1/CD30StopF l mice with Cγ1-cre mice, named LMP1/CD30//Cγ1-cre hereafter.
In the Cγ1-cre strain, a cre-coding sequence is inserted into the Cγ1 locus. Cells with
a GC cell fate have a sterile transcription of this gene locus which is independent of the
expressed isotype upon CSR. This results in the deletion of the STOP-cassette only in
GC B cells followed by the LMP1/CD30 expression in these cells [Casola et al., 2006].
As control mice, we used R26/CAG-CAR∆1StopF mice crossed with Cγ1-cre mice. The
GC B cells of these mice express a truncated version of the human coxsackievirus ade-
novirus receptor (CAR) upon cre mediated recombination [Heger et al., 2015]. These
mice are entitled as CAR//Cγ1-cre. CAR//Cγ1-cre and LMP1/CD30//Cγ1-cre mice
were immunized with NP-CGG, this resulted in the deletion of the STOP-cassette and
in the expression of the transgenes, CAR and LMP1/CD30 or hCD2, respectively. The
LMP1/CD30//Cγ1-cre mice developed more reporter+, CD19+ cells than control mice
after NP-CGG immunization at d 5 and 14 (Figure 11).
Figure 11: The histograms (left panel) show the gating strategy of the reporter expres-
sion, the threshold was determined by hCD2 and CAR staining of CAR//Cγ1-cre and
LMP1/CD30//Cγ1-cre mice, respectively. CAR-expression in CAR//Cγ1-cre (black line:
LMP1/CD30//Cγ1-cre; red line CAR//Cγ1-cre). hCD2-expression in LMP1/CD30//Cγ1-cre
mice (black line: CAR//Cγ1-cre; red line: LMP1/CD30//Cγ1-cre). The diagram (right panel)
shows the percentages of reporter+ cells among the CD19+ lymphocytes after NP-CGG immu-
nization in the SP of LMP1/CD30//Cγ1-cre and CAR//Cγ1-cre mice, the bar represents the
mean of the percentages.
In contrast to LMP1/CD30 mice, GC of LMP1/CD30//Cγ-cre mice were clearly vis-
ible and correctly placed in the follicle upon NP-CGG immunization (Figure 12).
5 RESULTS 35
Figure 12: The pictures show representative splenic sections of NP-CGG immunized
LMP1/CD30//Cγ1-cre and CAR//Cγ1-cre. The sections were stained for PNA (blue) and
IgM (brown) 14 d p.im..
But compared to control mice, the percentages of reporter+ GC were significantly
reduced at d 5 and still slightly reduced 14 d p.im. (Figure 13A). Also, the percentages of
the NP+, reporter + GC were decreased in the LMP1/CD30//Cγ1-cre mice in comparison
to the CAR//Cγ1-cre mice (Figure 13B).
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Figure 13: LMP1/CD30//Cγ1-cre and CAR//Cγ1-cre mice were immunized with NP-CGG
and analyzed after 5 and 14 d p.im.. (A): The FACS plots show the gating strategy of the GC
B cells (reporter+, CD38lo, CD95+) (left panel), the graph shows the percentages of splenic GC
B cells among all reporter+ cells (right panel); (B): The FACS plots show the gating strategy
(left panel), the graph shows the percentages of NP+ cells among all reporter+, GC cells in the
SP (right panel). Every dot in the graphs represent the value of one mouse, the bar represents
the mean of the percentages.
However, within the reporter+ lymphocytes, the percentages of GC B cells and NP+
cells were comparable between LMP1/CD30//Cγ1-cre mice and controls which means
that the higher percentages of reporter+ cells in LMP1/CD30//Cγ1-cre were caused by
NP− non GC B cells (Figure 14).
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Figure 14: The graph shows the percentages of NP+, GC B cells and reporter+ cells among all
lymphocytes of LMP1/CD30//Cγ1-cre and CAR//Cγ1-cre mice 5 and 14 d p.im. in the SP.
The induction of the LMP1/CD30 expression only in GC B cells allowed the for-
mation of GC B cells in LMP1/CD30//Cγ1-cre mice upon NP-CGG immunization.
The percentages of the GC B cells were comparable in both analyzed genotypes. The
LMP1/CD30//Cγ1-cre mice revealed a higher percentage of reporter+ cells due to more
reporter+ non GC B cells. The non GC B cells displayed a CD43+, CD23lo phenotype.
The reporter+ cells of LMP1/CD30 mice revealed higher percentages of CD43+, CD23lo
cells and CD138+, B220lo cells in comparison to control mice (Figure 15A). All CD138+,
B220lo cells had a CD43+, CD23lo phenotype and a lower CD19 expression in comparison
to CD43+, CD23lo cells and all reporter+ B cells (Figure 15B). Still, a certain fraction
of the CD43+, CD23lo population kept CD19 expression, indicating them as deleted B1
cells or PC progenitors (Figure 15B). In summary, the induction of CD30 signaling in the
GC B cells led to only slight reduced percentages of reporter+ GC B cells in comparison
to control mice. However, the increased percentage of LMP1/CD30 expressing cells was
compiled of CD43+, CD23lo and PC (CD138+, B220lo).
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Figure 15: LMP1/CD30//Cγ1-cre and CAR//Cγ1-cre mice were immunized with NP-CGG
and analyzed 5 and 14 d p.im. (A): The percentages of CD43+, CD23lo cells (left panel), and
PC/PB (CD138+, B220lo) (right panel) among the reporter+ cells were analyzed in the SP, all
samples are shown in the graphs below, the FACS plots show the gating strategy, every dot
represents the value of one mouse, the bar represents the mean; (B): The FACS plots show
an overlay of reporter+ cells and CD138+, B220lo, reporter+ cells of a CD43/CD23 staining
from splenocytes (left panel), the histograms show one example of a CD19 staining of the three
indicated populations (right panel).
In order to analyze if the higher percentage of PC in the LMP1/CD30//Cγ1-cre mice
also results in higher percentages of ASCs specific for the given antigen, NP specific
ELISA and ELISpots were performed. The immunization of LMP1/CD30//Cγ1-cre mice
resulted further in higher percentages of NP-specific IgM secreting PC but similar NP-
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specific IgG1 secreting PC in comparison to control mice. Serum titers of NP-specific IgM
and total IgG1 were enhanced in LMP1/CD30//Cγ1-cre mice whereas high affinity NP-
specific IgG1 titers were comparable with CAR//Cγ1-cre mice. Concluding, LMP1/CD30
expression in GC extents the differentiation towards NP-specific IgM and short lived NP-
specific IgG1 secreting PC which may only be detectable through their serum titers at d
14 (Figure 16).
Figure 16: The graphs show the amount of total (NP13) IgM, total IgG1, and high affinity
(NP4) IgG1 NP-specific antibody secreting splenic cells at d 14 p.im. of LMP1/CD30//Cγ1-cre
and CAR//Cγ1-cre mice. Additionally, the serum titers of NP-specific antibodies are shown in
the lower line. Every dot represents the value obtained from one mouse, the bar represents the
mean.
Due to the block of GC seen in LMP1/CD30 mice, the question was if the chronic
CD30 signaling in the GC influences their organization regarding the percentage of cen-
troblasts and centrocytes. The distribution of both compartments exposed a stronger
trend towards centroblasts in the LMP/CD30//Cγ1-cre in comparison to control mice
(Figure 17A+B) [TARLINTON, 1995].
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Figure 17: (A): The graph shows the distribution of DZ and LZ reporter+ GC B cells of
LMP1/CD30//Cγ1-cre and CAR//Cγ1-cre mice in the SP, every dot represents the value ob-
tained from one mouse, the mean of the percentages is represented by the bar; the populations
were stained and gated for centrocytes (CC) (CD86lo, CXCR4+) and centroblasts (CB) (CD86+,
CXCR4lo) as indicated in (B).
Due to the strong and fast up-regulation of IRF4 detected in vitro after CD40 stim-
ulation in LMP1/CD30 mice, we investigated whether IRF4 is upregulated upon TD
immunization in LMP1/CD30 expressing GC B cells, driving the differentiation of PC.
Not all LMP1/CD30 expressing cells revealed higher levels of IRF4 but higher percentages
of IRF4+ cells were present in comparison to control mice (Figure 18A). The IRF4+ cells
were mainly localized at the T/B cell border at d 5, hinting their origin either towards
early GC [Zhang et al., 2018], or activated pre-GC B cells. The localization at the edge
of the GC or follicle at d 14 suggests an exit of the B cells from the GC (Figure 18B).
The initiation of PC differentiation seems to be located in the LZ, however, BLIMP-1+
and IRF4+ cells are also found in the DZ [Kräutler et al., 2017]. Surprisingly, both the
centrocytes and the centroblasts located in the LZ and the DZ, respectively, contained
a higher fraction of IRF4+ cells in LMP1/CD30//Cγ1-cre mice in comparison to control
mice (Figure 18A). In summary, CD30 signaling seemed to contribute to the up-regulation
of IRF4 in B cells of the GC which in turn drives them towards PC. The higher number
of PC among the LMP1/CD30 expressing B cells in comparison to control cells supported
this hypothesis.
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Figure 18: (A): The percentages of the IRF4+ cells of CB and CC of immunized
LMP1/CD30//γ1-cre and CAR//γ1-cre mice is shown, every dot represents the value ob-
tained from one mouse, the mean is represented by the bar; (B): Splenic sections of immunized
LMP1/CD30//γ1-cre and CAR//γ1-cre mice were stained for IRF4, B220 and GL7 5 and 14 d
p.im. The histology was performed together with Markus Lechner in the laboratory from Dr.
Zimber-Strobl.
Besides PC, also memory B cells result from the GC reaction. The B cell population
which was positive for IgG1, B220 and CD19 were defined as memory B cells. Therefore,
we analyzed the percentages of IgG1+ B cells in both genotypes. IgG1 is the main iso-
type of memory B cells. The percentages of IgG1+ cells were dramatically decreased in
the LMP/CD30//Cγ1-cre mice (Figure 19A+B). Therefore, the increased differentiation
towards PC of LMP1/CD30 expressing cells seems to reduce the differentiation towards
memory B cells.
Figure 19: (A): The FACS plots illustrate the gating strategy of splenic memory B cells (B220+,
IgG1+) which were pre-gated for reporter+ and CD19+ cells; (B): The graph shows the distri-
bution of all analyzed mice regarding their percentages of memory B cells, the mean of the
percentages is represented by the bar.
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5.3 Influence of MHV-68 infection on the development of CD30
positive lymphomas
Petra Fiedler and I could show that around 80% of aged mice developed lymphomas which
are reminiscent to DLBCL or FL in histology [Sperling et al., 2019]. This is the first time
that we provide evidence for the oncogenic potential of deregulated CD30 signaling in
B cells. However, the GC reaction is impaired in these mice. But as described CD30+
lymphoma derive from germinal or post-GC B cells. Further, HL as well as PEL are
associated with EBV and KSHV infection.
This resulted in the questions, whether LMP1/CD30 expression induced in GC B cells
leads to lymphoma development and whether an additional γ-herpes-viral infection in
combination with the deregulated CD30 signaling generates a further impact during lym-
phoma development.
To answer these questions, we aged cohorts of LMP1/CD30//Cγ1-cre mice after immu-
nization with NP-CGG or infection with MHV-68. Since EBV and KSHV do not infect
murine B cells, we instead used the murine γ-herpesvirus MHV-68 in combination with
LMP1/CD30//Cγ1-cre mice. Further, two cohorts of CAR//Cγ1-cre mice, either infected
with the MHV-68 or immunized with NP-CGG, served as controls.
5.3.1 Cloning of the reporter virus MHV-68-NGFR
A virus which expresses a detectable reporter enables the tracking of infected cells ex vivo.
To generate a MHV-68 reporter virus, we introduce the sequence of the human NGFR
with a truncated signaling domain into a bacterial artificial chromosome (BAC) contain-
ing the complete MHV-68 genome under the control of the SFFV (spleen focus-forming
virus) promoter. MHV-68-NGFR was generated by the two-step mutagenesis procedure.
Firstly, the sequence for the human truncated NGFR was cloned in a shuttle plasmid
between sequences coding for open reading frame (Orf) 27 and Orf29 (Figure 20A). Pre-
viously, this locus was used by others and proved to tolerate insertions of foreign sequences
[Krug et al., 2007, Collins et al., 2009]. Secondly, the NGFR cassette was inserted by a
recombination process into the complete MHV-68 BAC. The parental BAC-derived virus
served as control virus. First, the question was if the NGFR infection results in reporter
expression in infected cells. Therefore, mouse fibroblast cells (NIH3T3) were infected,
stained for NGFR, and analyzed by FACS 3 d p.i.. 44% of NGFR expressing cells could
be detected upon infection with the constructed reporter virus (Figure 20B). Thus, the
NGFR efficiently marked viral infected murine cells in vitro. To study the fitness of
the reporter virus, BALB/c mice were infected and splenic cells were analyzed for the
number of viral DNA copies per cellular DNA copies. In the spleen and the PerC, the
copy numbers were slightly higher after infection with the parental virus in comparison
to MHV-68-NGFR virus infected mice (Figure 20C). Further, the number of splenocytes
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from which the virus could be reactivated was lower in MHV-68-NGFR infected mice
than in mice infected with the parental virus suggesting that the biological activity of
the newly generated reporter virus is slightly impaired (Figure 20D). This reduction is
often observed after insertion of transgenes into the viral genome. The staining for NGFR
revealed 1.6% of NGFR+ cells among the B cell population in mice infected with MHV-
68-NGFR (Figure 20E). This was in line with the infection rate found upon infection
with MHV-68 of mice [Barton et al., 2011]. Summing up, MHV-68-NGFR was able to
efficiently infect cells in vitro and in vivo. Further, NGFR+ cells could be detected upon
infection with MHV-68-NGFR. The reached percentages of positive cells were similar to
values as published before [Barton et al., 2011].
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Figure 20: Cloning strategy of the MHV-68-NGFR (A): A SFFV-hNGFR cassette was inserted
by shuttle mutagenesis in the MHV-68 genome between open reading frame (Orf)27 and 29; (B):
FACS histogram of NGFR expression, NIH3T3 were infected with either the MHV-68-NGFR
or the parental virus. After 3 d p.i. cells were stained with an anti-hNGFR antibody. The
experiment was performed in two independent experiments; (C): Genomic load determined from
cells isolated from the SP and PerC; quantitative PCR of the viral gene (gB) and the cellular
gene (L8) was performed with DNA of cells isolated from mice infected either with the parental
or the MHV-68-NGFR virus. The analysis was performed at d 14 p.i.; (D): The graph shows the
results of the reactivation assay comparing parental virus and MHV-68-NGFR infected mice,
single splenocyte suspensions were prepared and analyzed in the ex vivo reactivation assay for the
cytopathic effect (CPE) in every well, splenocytes from three mice were pooled per group, CPE
was identified by identification of rounded detached fibroblasts causing a disrupted fibroblast
monolayer in the well; (E): NGFR+ cells which were pregated for B220+ cells are displayed
in a FACS plot. Shown are B cells from BALB/c mice infected with either parental virus or
MHV-68-NGFR and analyzed 14 d p.i., n=3, numbers represent the mean and the SD of the
percentages.
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5.3.2 Viral infection of the LMP1/CD30//Cγ1-cre mice results in the dele-
tion of the STOP-cassette
As already shown in chapter 3.2, the immunization of LMP1/CD30//Cγ1-cre mice with
NP-CGG induced the deletion of the STOP-cassette and the generation of LMP1/CD30
expressing GC B cells. The following part focuses on the influence of the herpesviral
infection during the GC reaction in combination with the chronic CD30 signaling in
these B cells. In order to address this issue, two sets of LMP1/CD30//Cγ1-cre mice and
CAR//Cγ1-cre mice were either immunized with NP-CGG or infected with MHV-68-
NGFR and analyzed after 14 d. To test if the infection with the MHV-68-NGFR virus
induces the deletion of the STOP-cassette. B cells of LMP1/CD30//Cγ1-cre mice and
CAR//Cγ1-cre mice were stained for hCD2 and CAR, respectively (Figure 21A). Both
immunization with NP-CGG and the viral infection led in both analyzed genotypes to the
deletion of the STOP-cassette in the spleen and the PerC resulting in the expression of
the reporter genes (Figure 21B+C). The percentage of reporter+ cells was comparable in
immunized and infected mice but higher in the LMP1/CD30//Cγ1-cre than in the control
mice in the spleen (Figure 21B). In the PerC, the percentage of reporter expressing cells
was significantly higher in the MHV-68-NGFR infected LMP1/CD30//Cγ1-cre mice com-
pared to the immunized mice and their respective control mice (Figure 21C). Therefore,
the infection with the MHV-68-NGFR virus resulted in the deletion of the STOP-cassette
in LMP1/CD30//Cγ1-cre and control mice with the highest reporter expression in the
LMP1/CD30//Cγ1-cre mice in comparison to the other groups.
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Figure 21: LMP1/CD30//Cγ1-cre and CAR//Cγ1-cre mice were either immunized with NP-
CGG or infected with the MHV-68-NGFR virus and analyzed after 14 d. (A): The histograms
show the gating strategy of the reporter expression, the threshold was determined by hCD2
and CAR staining of CAR//Cγ1-cre and LMP1/CD30//Cγ1-cre mice, respectively. CAR-
expression in CAR//Cγ1-cre (grey histogram: LMP1/CD30//Cγ1-cre; red line CAR//Cγ1-
cre). hCD2-expression in LMP1/CD30//Cγ1-cre mice (grey histogram: CAR//Cγ1-cre; red
line: LMP1/CD30//Cγ1-cre); (B+C): The diagrams show the percentages of all reporter+ cells
among the B cell population in the SP and the PerC. Every dot represents the value obtained
from one mouse, the bar represents the mean of the percentages.
The splenic weight of the immunized LMP1/CD30//Cγ1-cre and the CAR//Cγ1-cre
mice was similar at d 14 p.im. but was higher than in unimmunized mice (Figure 22A).
The infected mice revealed a further expansion of the splenic weight in comparison to the
immunized mice due to higher B and T cell numbers (Figure 22B+C). Additionally, larger
numbers of B and T cells were visible in the PerC of infected mice in comparison to the
immunized mice (Figure 22D+E). However, both after immunization and infection, B and
T cell numbers were comparable between LMP1/CD30//Cγ1-cre and the CAR//Cγ1-cre
mice in spleen and PerC.
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Figure 22: LMP1/CD30//Cγ1-cre and CAR//Cγ1-cre mice were infected with either MHV-
68-NGFR or immunized with NP-CGG and analyzed after 14 d, (A): The diagram shows the
splenic weight of the indicated mouse groups; (B+D): The graphs display the B cell numbers
(CD19+) in the SP and the PerC; (C+E): In this graph, T cell numbers (Thy1.2+) in the SP
and the PerC are indicated. Every dot represents the value obtained from one mouse, the bar
represents the mean of the cell numbers.
NGFR+ cells could be detected within the reporter+ and reporter− B cells indicating
that the virus infection does not necessarily induce the deletion of the STOP-cassette
both in the LMP1/CD30//Cγ1-cre and in the CAR//Cγ1-cre mice. The percentages of
NGFR+ were higher in the reporter+ compartment of the spleen and the PerC (Figure
23A+C). However, calculating the total numbers of NGFR+ cells revealed a higher number
within the reporter− B cells in both genotypes due to the higher total numbers of reporter−
B cells in the spleen (Figure 23B). In the PerC, the total cell numbers were comparable
in all subsets besides the outlier of the LMP1/CD30//Cγ1-cre mice (Figure 23D).
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Figure 23: LMP1/CD30//Cγ1-cre and CAR//Cγ1-cre mice were infected with MHV-68-NGFR.
After 14 d, NGFR+ cells were detected by FACS after staining of B cells from the SP and
the PerC in the reporter+ (CAR or hCD2) and the reporter− B cells (CD19+), (A+B): The
diagrams show the percentages and the cell numbers of NGFR+ cells in the spleen in both
genotypes; (C+D): The graphs show the percentages and the cell numbers of the NGFR+ B
cells in the PerC. Every dot represents one mouse, the bar is the mean of the percentages or the
cell numbers.
5.3.3 Virus infection leads to a germinal center reaction in
LMP1/CD30//Cγ1-cre mice
Next, I tested if the MHV-68-NGFR infection can generate a GC reaction in
LMP1/CD30//Cγ1-cre mice. The GC were comparably formed in LMP1/CD30//Cγ1-cre
and control mice (Figure 24A). However, the percentages of GC B cells were significantly
higher in the mice infected with MHV-68-NGFR virus in comparison to the immunized
mice (Figure 24A). In accord, total GC B cell numbers were significantly higher in the in-
fected LMP1/CD30//Cγ1-cre and CAR//Cγ1-cre mice in comparison to the immunized
mice (black bars Figure 24B). However, less deleted cells were found within the GC B cell
population of infected mice in comparison to immunized mice. Thus, only a small por-
tion of GC B cells expressed the reporter in both genotypes of the infected mouse groups
(grey bars Figure 24B). In contrast to the immunized mice, most of the reporter express-
ing cells of the MHV-68-NGFR infected mice displayed a non GC phenotype (CD38+,
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CD95lo) (Figure 24C+D).
To sum this up, the infection with MHV-68-NGFR induced a GC reaction in
LMP1/CD30//Cγ1-cre and control mice. The total percentages of GC B cells were higher
in infected than in immunized mice, but, the virus infection revealed a reduced deletion
efficiency of the STOP-cassette in the GC B cells. The total numbers of reporter ex-
pressing GC B cells were comparable after immunization and infection. In comparison to
immunized mice, more reporter+ displayed a non-GC B cell phenotype after infection.
Figure 24: (A): The diagram displays the percentages of GC B cells (PNA+, CD95+) pregated
for CD19+ cells; (B): The diagram shows the cell numbers of splenic GC B cells (PNA+, CD95+)
gated for CD19 (black bars) and of reporter+ cells within the GC B cells (grey bars), n ≥ 3.
Every dot represents the value obtained from one mouse, the bar is the mean of the percentages;
(C): The diagram shows the percentages of the reporter+, non GC B cells (CD38+) of the
analyzed mouse groups; (D): The FACS plots show the GC staining of reporter+ B cells of the
indicated genotypes.
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5.3.4 The virus infection further drives the expansion of LMP1/CD30 ex-
pressing B1 and plasma cells
In order to characterize the phenotype of the reporter expressing non GC cells, further
staining for B1 cells and PC were performed. PC as well as CD43+, CD23lo B cells
were significantly enriched in LMP1/CD30//Cγ1-cre mice in comparison to CAR//Cγ1-
cre mice both after immunization and infection (Figure 25A+B). MHV-68-NGFR infec-
tion resulted in a further increase of LMP1/CD30 expressing PC and B1 cells/PB. A
similar trend was visible in the PerC of these mice (Figure 25C). Therefore, the viral
infection seemed to have an additional effect on the expansion of PC and B1 cells in
LMP1/CD30//Cγ1-cre mice.
Figure 25: (A): Reporter+ splenocytes were stained with CD138 and B220, the percentages of
PC (CD138+, B220lo) is depicted; (B): Reporter+, CD19+ cells of the spleen were stained with
CD43 and CD23, the percentages of reporter+ B1 cells/PB (CD43+, CD23lo) is depicted; (C):
The diagram shows the percentages of CD43+, CD23lo pregated for reporter+, CD19+ cells in
the PerC. Every dot represents the value obtained from one mouse, the bar represents the mean
of the percentages.
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5.3.5 NGFR positive B cells are found in different sub-populations
During the acute phase of virus infection, B cells of different sub-populations are infected
with MHV-68 [Barton et al., 2011]. In order to analyze the phenotype of NGFR+ B cells,
FACS analysis was used. Virus infected B cells were found among all reporter+ mature B
cell populations (Figure 26A). In both the LMP1/CD30//Cγ1-cre mice and control mice,
the highest percentages of NGFR+ cells were found in the PC-precursor (CD138+, B220+).
But the percentage was significantly reduced in the LMP1/CD30//Cγ1-cre mice compared
to the controls. In contrast, NGFR+ cells were nearly absent in PC in both genotypes.
B1 cells of the LMP1/CD30//Cγ1-cre mice contained significantly more NGFR+ cells
compared to the cells of the control mice as well as to the other sub-populations. NGFR+
cells were also detected in the reporter+ GC B cells. 2 to 3% NGFR+ cells were identified
in the reporter+ GC B cell population (Figure 26B).
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Figure 26: (A): The splenic sub-populations from infected LMP1/CD30//Cγ1-cre and
CAR//Cγ1-cre mice indicated in the diagram were analyzed for their cell numbers (grey bars)
and the percentages (black bars) of NGFR+ cells after pregating for reporter+ cells, n=3; (B):
The FACS plots show one example of NGFR expression of GC B cells. At d 14 p.i., splenic
GC B cells (CD19+, reporter+, CD95+, PNA+) of infected LMP1/CD30//Cγ1 and CAR//Cγ1
mice were stained with anti-hNGFR, n=3.
In summary, the infection with MHV-68-NGFR led to the deletion of the STOP-
cassette followed by LMP1/CD30 expressing GC B cells in infected mice. This resulted
in similar cell numbers of reporter expressing GC B cells as detected upon immunization.
Some of the GC B cells carried the virus, making this mouse model suitable to study the
pathogenesis of deregulated CD30 signaling and γ-herpesvirus infection initiated in GC B
cells. Additionally, a high percentage of MHV-68-NGFR infected cells could be detected
in the PC progenitors (CD138+, B220+) and in the CD43+, CD23lo population, whereas
the virus was nearly absent in PC.
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5.3.6 Ongoing virus infection in LMP1/CD30//Cγ1-cre mice leads to the
expansion of B1a and B1b cell populations
To analyze the long term effect of the virus infection and immunization in
LMP1/CD30//Cγ1-cre and control mice, we studied the mice after 2 months. Both,
after immunization and infection, the splenic weight, B and T cell numbers were higher
in LMP1/CD30//Cγ1-cre mice mouse groups compared to their respective control mice
indicating that LMP1/CD30 expression resulted in the expansion of B cells over time
(Figure 27A-C).
Figure 27: LMP1/CD30//Cγ1-cre and CAR//Cγ1-cre mice were immunized with NP-CGG
or infected with the MHV-68-NGFR virus i.p.. After 2 months, the mice were sacrificed and
analyzed; (A): This diagram shows the spleen weight of the analyzed mice. The data was
obtained in three independent experiments; (B+C): The graphs show the cell numbers of CD19+
B cells or Thy1.2+ T cells in the indicated groups in the SP. Every dot represents the value
obtained from one mouse, the bar represents the mean of the cell numbers.
In the PerC, the B cell and T cell numbers of the LMP1/CD30//Cγ1-cre mice infected
with MHV-68-NGFR were higher than in control mice and immunized LMP1/CD30//Cγ1-
cre mice (Figure 28A+B) suggesting that the virus infection in the LMP1/CD30//Cγ1-cre
mice led to a further T and B cell expansion in the PerC.
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Figure 28: (A): This diagram shows the cell numbers of CD19+ B cells in the PerC of the
indicated groups. The cells were isolated by flushing the abdominal cavity; (B): This diagram
shows the cell numbers of Thy1.2+ T cells in the PerC of the indicated groups. Every dot
represents the value obtained from one mouse, the bar represents the mean of the cell numbers.
In the spleen and in the PerC, the percentages and the cell numbers of reporter+ B
cells were much higher in the LMP1/CD30//Cγ1-cre mice in comparison to their respec-
tive control mice (Figure 29). Strikingly, the percentages of LMP1/CD30 expressing B
cells reached 50-80% in the PerC (Figure 29C). Therefore, the reporter+ cells expanded
in the LMP1/CD30//Cγ1-cre mice stronger than in control mice. The MHV-68-NGFR
infection seemed to have an additional effect on the increase of LMP1/CD30 expressing
B cells in the PerC upon 2 months.
Figure 29: (A+B): The diagrams show the cell numbers and the percentages of reporter+ cells
in the SP of the depicted analyzed groups; (C+D): The diagrams show the cell numbers and the
percentages of reporter+ B cells (CD19+) in the PerC. Every dot represents the value obtained
from one mouse, the bar represents the mean of the percentages or cell numbers.
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The percentages of NGFR+ cells among the reporter expressing cells revealed no
difference between CAR and LMP1/CD30//Cγ1-cre mice neither in the spleen nor in
the PerC (Figure 30A). However, considering the total cell numbers, significantly more
NGFR+ cells were detectable in the spleen and the PerC of the LMP1/CD30//Cγ1-cre
mice in comparison to control mice (Figure 30B). The expansion of reporter+ B cells in
the LMP1/CD30//Cγ1-cre mice resulted in higher total NGFR+ cell numbers. These
data indicate that the herpesviral infection in combination with the deregulated CD30
signaling contributes to the expansion of B cells.
Figure 30: (A+B): The diagrams show the percentages and the cell numbers of NGFR+ cells
among the reporter+ B cells in the SP and the PerC of the infected LMP1/CD30//Cγ1-cre
and CAR//Cγ1-cre mice. Every dot represents the value obtained from one mouse, the bar
represents the mean of the percentages or the cell numbers.
Next, I analyzed the phenotype of reporter+ B cells 2 months after immunization or
infection. As expected, the percentages of total GC B cells were lower after 2 months
than after 14 d (Figure 31A, see Figure 24A). However, in control mice around 20% of
reporter+ cells still had a GC phenotype (Figure 31B+C). In contrast, only 2% of the
LMP1/CD30 expressing cells revealed a GC phenotype. Therefore, the chronic CD30
signaling seemed to block the re-entry into the GC.
Following, we asked, if the expanded reporter+ B cells in LMP1/CD30//Cγ1-cre still have
a PC and CD43+, CD23lo phenotype as displayed after 2 weeks.
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Figure 31: The diagram shows the percentages of GC B cells of CD19+ (A) or of reporter+ B
cells (B). Every dot represents the value obtained from one mouse, the bar represents the mean
of the percentages; (C): Reporter+ cells of the four indicated mouse groups were gated for GC
B cells (GL7+, CD95+) in the SP. Plots were pregated on CD19+, reporter+ cells.
The percentages of the reporter+ PC and of the CD43+, CD23lo were significantly
higher in the LMP1/CD30//Cγ1-cre compared to control mice both upon immunization
and infection (Figure 32A-C). There was no clear difference in the percentages of the
PC of the LMP1/CD30//Cγ1-cre between immunization and infection but after infection
the percentage was tendentiously a bit lower. However, the percentages of reporter+,
CD43+, CD23lo cells were higher in LMP1/CD30//Cγ1-cre mice than in controls in the
PerC (Figure 32C). The LMP1/CD30 expression resulted in an expanded PC population
in the spleen and an increased CD43+, CD23lo population in the spleen and the PerC.
The MHV-68-NGFR infection seemed not to interfere with the PC differentiation after 2
months but contributed to an extended CD43+, CD23lo population in the PerC.
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Figure 32: (A): Reporter+ lymphocytes of the four indicated mouse groups were gated for PC
(CD138+, B220lo); (B): The diagram shows the percentages of reporter+ PC in the spleen of the
analyzed mice in the four groups; (C): The graphs show the percentages of reporter+ B1 cells
(CD43+, CD23lo) of the analyzed mice in the four groups in the SP (middle) and in the PerC
(right). Every dot represents the value obtained from one mouse, the bar represents the mean
of the percentages.
The B1 cell population, which was characterized as CD43+, CD23lo so far, is divided
into B1a and B1b cells which can be discriminated by CD5 surface expression. To ana-
lyze whether B1a and/or B1b cells were expanded in the spleens of LMP1/CD30//Cγ1-cre
mice in comparison to control mice, we performed further staining (Figure 33). We found
that deregulated CD30 expression results in an expansion of both B1a and B1b cells.
Moreover, MHV-68-NGFR infection induced an additional increase of B1a cells in com-
parison to the immunized mice (Figure 33B).
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Figure 33: (A): The FACS plots show the gating strategy for B1a and B1b cells. Splenic
cells were gated for reporter+ B cells (CD19+) and then gated for B1a (CD5+, B220lo), B1b
(CD5lo, B220lo) and B2 cells (CD5lo, B220+), the numbers indicate the mean and the SD of
the percentages of the B1a or B1b populations, indicated significance are calculated towards the
respective control mice, n ≥ 5; (B+C): The diagrams display the cell numbers of B1a and B1b
cells of the indicated mouse groups, gated as indicated in (A). Every dot represents the value
obtained from one mouse, the bar represents the mean of the percentages.
The infected as well as the immunized LMP1/CD30//Cγ1-cre mice displayed signifi-
cantly lower percentages of IgG1+ memory B cells compared to their respective controls
(Figure 34A). However, the infected mouse groups revealed slightly higher percentages
of memory B cells (IgG1+) than the immunized groups. Calculating total cell numbers
revealed elevated memory B cell numbers in the infected LMP1/CD30//Cγ1-cre mice
compared to their control mice and to the immunized LMP1/CD30//Cγ1-cre mice (Fig-
ure 34B).
Figure 34: (A+B): The graphs show the cell numbers and the percentages of memory B cells
(IgG1+, CD38+, reporter+, CD19+) in the depicted mouse groups in the SP. Every dot represents
the value obtained from one mouse, the bar represents the mean.
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In summary, B and T cell numbers were higher in the infected and the immunized
LMP1/CD30//Cγ1-cre mice in comparison to control mice (see Figure 27B+C). Addi-
tionally, the chronic CD30 signaling resulted in an expanded reporter+ cell population
with a B1 cell and a PC phenotype in these mouse cohorts (see Figure 29, Figure 32C).
The virus infection in the LMP1/CD30//Cγ1-cre mice induced an additional expansion of
the B1a cell population when comparing infected and immunized LMP1/CD30//Cγ1-cre
mice (see Figure 33A+B). Due to the virus infection, the differentiation towards memory
B cells was significantly higher in the LMP1/CD30 expressing B cells upon 2 months (see
Figure 34B). In contrast, the LMP1/CD30 expressing cells revealed a lower commitment
towards a GC phenotype in comparison to control mice reflecting the block of the re-entry
of these cells into the GC (see Figure 31).
5.3.7 Aged mice
The long term effect of constitutive CD30 signaling induced in GC B cells, alone or in
combination with a viral infection, was investigated. The LMP1/CD30//Cγ1-cre mice
were examined after they developed signs of disease like swollen abdomen, sunken flanks,
or accelerated breathing but latest after 18 months. Every LMP1/CD30//Cγ1-cre mice
was analyzed with a control CAR//Cγ1-cre mouse.
5.3.7.1 Viral infection leads to an additive effect in CD30 driven lymphoma
development
The next question was whether LMP1/CD30 expression induced in GC B cells leads to
lymphomagenesis and whether MHV-68 infection further enhances lymphomagenesis. The
CAR//Cγ1-cre mouse cohort infected with MHV-68-NGFR was comprised of 12 mice, 2
of them died during the experiment. The CAR//Cγ1-cre mouse cohort immunized with
NP-CGG consisted of 15 mice, 2 of them could not be used for the experiment. The
LMP1/CD30//Cγ1-cre mouse cohort infected with MHV-68-NGFR and immunized with
NP-CGG started with 13 and 14 mice respectively, in each group one mouse was taken
out from experiment. The mice of the four aged cohorts were analyzed for mono-or oligo-
clonal B cell expansion by southern blot analysis using a radioactive labeled Jh4 probe.
Thereby, 5 of 12 of the virus infected LMP1/CD30//Cγ1-cre mice and 2 of 13 of the
immunized group displayed a mono- or oligoclonal B cell expansion (Figure 35A). The
results of the southern blot analysis of the remaining mice is displayed in Supplementary
2. Therefore, the virus infected LMP1/CD30//Cγ1-cre mice developed with a signifi-
cantly higher incidence a lymphoma compared to the immunized ones. Additionally, in
two of the virus infected LMP1/CD30//Cγ1-cre mice, a strong expansion of lymphocytes
in the PerC was noted. These were also tested in the southern blot analysis. In #17, the
same clone found in the spleen predominated also the PerC. In contrast, #50 had another
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clone growing out to a tumor population in the PerC. However, also both in the infected
and the immunized control mouse cohort, one mouse was detected with a mono- or oligo-
clonal expansion. Further, the incidence of sickness in both LMP1/CD30//Cγ1-cre mice
was compared (Figure 35B). The MHV-68-NGFR infected LMP1/CD30//Cγ1-cre mice
displayed a median survival of 14 months, the immunized LMP1/CD30//Cγ1-cre mice
survived 16 months on average.
Figure 35: (A): The graph shows the tumor incidence of all analyzed mice. The lymphomas
were detected by southern blot with a radioactive probe spanning the region between JH4 and
Eµ of the IgH locus, n ≥ 10, the lower picture shows one example of a southern blot, the stars
indicate additional band besides the germline band at 6 kB; (B): The diagram displays the mice
of both LMP/CD30//Cγ1-cre mouse cohorts which became sick over the analyzed time, n ≥ 12.
5.3.7.2 CD30 signaling leads to the expansion of B and T cells in aged mice
To further determine the phenotype of lymphomas, we analyzed the B cell compart-
ment of aged mice. Both groups of LMP1/CD30//Cγ1-cre mice displayed a significantly
higher splenic weight than their respective control groups (Figure 36A). Both, the cell
numbers and the T cells, were significantly increased in the LMP1/CD30//Cγ1-cre in
comparison to their respective controls (Figure 36B+D). But only the NP-CGG immu-
nized LMP1/CD30//Cγ1-cre developed significantly higher B cell numbers (Figure 36C).
The mice with a detected mono- or oligoclonal expansion had in most cases a stronger
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splenomegaly and higher splenic cell numbers than mice without clonal expansion. The
immunized and infected mice with lymphomas displayed higher T cell numbers than their
respective control mice (red icons in Figure 36).
Figure 36: Infected and immunized LMP1/CD30//Cγ1-cre and CAR//Cγ1-cre mice were aged
until the LMP1/CD30//Cγ1-cre showed signs of sickness. Always one LMP1/CD30//Cγ1-cre
mouse was analyzed together with a CAR//Cγ1-cre control mouse, all red colored dots represent
a mouse with a detected mono- or oligoclonal expansion, the red significance was determined by
using only the tumor samples. The graphs show the splenic weight (A), total splenic cell numbers
(B), total splenic B cell numbers (CD19+) (C), and total splenic T cell numbers (Thy1.2+) (D)
of all analyzed mice in the depicted groups. Every dot represents the value obtained from one
mouse, the bar represents the mean.
The cell number of the PerC was slightly higher in infected LMP1/CD30//Cγ1-cre
mice in comparison to control and the immunized mice (Figure 37A). Additionally, the B
and T cell numbers were tendentiously increased in these mice (Figure 37B+C). The mice
of the infected LMP1/CD30//Cγ1-cre mouse group which were detected with a tumor
displayed the highest increase of the cell number in the PerC (red points Figure 37C).
Among the immunized LMP1/CD30//Cγ1-cre mice, the mice with the tumor were not
among the mice with the highest cell number.
5 RESULTS 62
Figure 37: The graphs show the total cell numbers (A), the cell numbers of B cells (CD19+)
(B), and the cell numbers of total T cells (Thy1.2+) in the PerC (C) of the PerC of the aged
mice. Every dot represents the value obtained from one mouse, the bar represents the mean.
Furthermore, the percentages of the reporter+ cells were significantly enriched in both
groups of LMP1/CD30//Cγ1-cre mice in the spleen as well as in the PerC in compari-
son to CAR//Cγ1-cre mice (Figure 38). Mice that had developed lymphomas showed in
most cases a very high percentage of reporter+ B cells in the spleen (between 70%-95%).
The percentages of cells expressing hCD2 were much higher in the PerC than in the spleen.
Figure 38: (A+B): The graphs show the percentages and the cell numbers of reporter+ B cells
(CD19+) in the SP of aged mice; (C+D): The graphs show the percentages and the cell numbers
of reporter+ B cells (CD19+) in the PerC of aged mice. Every dot represents the value obtained
from one mouse, the bar represents the mean.
To get an overview of the expansion of reporter+ B cells in the spleen and the PerC
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over time, we compiled the percentages of reporter+ B cells at the analyzed time points in
one graph. Additionally, we assembled the cell numbers of reporter+ cells in the analyzed
mouse groups in the spleen and the PerC of different time points. In LMP1/CD30//Cγ1-
cre mice, the numbers and percentages of reporter+ cells increased between 2 months and
13 months in the spleen (Figure 39A). The increase of reporter+ cells was stronger in in-
fected than in immunized mice. The number of reporter+ cells increased only marginally
in control mice. In the PerC, cell numbers of LMP1/CD30-expressing cells increased con-
tinuously in immunized LMP1/CD30//Cγ1-cre mice. The infected LMP1/CD30//Cγ1-
cre mice showed already high number of reporter expressing cells after 2 months but
afterwards they did not further increase and dropped below the cell numbers of the
immunized LMP1/CD30//Cγ1-cre mice in the aged cohort (Figure 39B). The percent-
ages of reporter+ cell in the PerC were very high in both the immunized and infected
LMP1/CD30//Cγ1-cre mice at each time point reaching between 50% and 70% already
after 2 months. The cell numbers and percentages of hCD2+ cells from infected and im-
munized LMP1/CD30//Cγ1-cre mice were at all time points higher than in the CAR+
cells of the respective control mice.
Figure 39: The diagrams display the time course of the cell numbers or the percentages of re-
porter expressing cells in the four indicated mouse groups starting from 2 weeks until completion
of the experiment in the SP (A) and the PerC (B).
To sum this up, aged LMP1/CD30//Cγ1-cre mice revealed a splenomegaly, increased
B and T cell numbers in the spleen and in the PerC. The LMP1/CD30 expressing cells
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expanded stronger than CAR expressing cells both in immunized and infected mice. The
infected LMP1/CD30//Cγ1-cre mice displayed a stronger increase of reporter+ cells in
the spleen in comparison to the immunized mice. In the PerC, the cell numbers of
LMP1/CD30 expressing cells of the immunized mice was higher. Most of the mice detected
with a clonal expansion were characterized by a stronger splenomegaly in comparison to
other aged mice and almost 100% reporter expression among the B cells.
5.3.7.3 CD30 signaling leads to higher numbers of virus infected B cells
Next, we analyzed the distribution of the NGFR+ cells. Notably, the percentages of
reporter+, NGFR+ cells were nearly similar in SP, LN, and PerC from LMP1/CD30//Cγ1-
cre and control mice (Figure 40A). Only in virus infected LMP1/CD30//Cγ1-cre mice,
the percentages of the NGFR+ were significantly higher in the spleen than in the PerC.
However, the higher percentages of reporter expressing B cells in the spleen and the
PerC from LMP1/CD30//Cγ1-cre mice in comparison to controls resulted in higher per-
centages of NGFR+ cells among all B cells in LMP1/CD30//Cγ1-cre mice (Figure 40B
grey bars). Also, the total numbers of NGFR+ cells were significantly higher in the
LMP1/CD30//Cγ1-cre mice in comparison to the CAR//Cγ1-cre mice and increased
during aging (Figure 40C+D). The highest number of NGFR+ cells could be detected in
mice with a tumor (Figure 40D, red icons). This means that the chronic CD30 signaling
resulted in an expanded population of infected cells in the spleen and the PerC.
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Figure 40: (A): The graph shows the percentages of reporter NGFR+ cells gated for CD19+,
reporter+ cells of the infected LMP1/CD30//Cγ1-cre and CAR//Cγ1-cre mice in the lymph
node (LN), spleen (SP), and the PerC; (B): The graph illustrates the percentages of NGFR+
cells and reporter+ cells within the B cell population (CD19+) in the SP and the PerC of
the indicated genotypes. (C) The diagram displays the time course of the cell numbers of
NGFR expressing reporter+ B cells in the indicated mouse groups starting from 2 weeks until
termination of the experiment; (D): The graph shows the cell numbers of NGFR+ cells gated
for CD19+, reporter+ cells of the infected LMP1/CD30//Cγ1-cre and CAR//Cγ1-cre mice in
the SP and the PerC.
5.3.7.4 CD30 signaling leads to a further expansion of the B1a and B1b cell
populations in aged mice
The reporter expressing B cells were further characterized regarding their surface marker
expression. All groups displayed similar percentages of GC B cells among the reporter
expressing population (Figure 41A). The B1/PB cell population (CD43+, CD23lo) was
strongly enhanced in both groups of the investigated LMP1/CD30//Cγ1-cre mice in com-
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parison to controls in the spleen and the PerC (Figure 41B+C). Both, the B1a and the
B1b cells, were expanded (Figure 41D+E). All mice detected with a lymphoma revealed
a high number of B1b cells (Figure 41E, red icons).
Figure 41: (A): The graph illustrates the percentages of GC B cells (CD38lo, CD95+) of
reporter+ cells in the SP; (B+C): The graphs show the percentages of CD43+, CD23lo B cells
pregated for reporter+, CD19+ cells of the depicted mouse groups in aged mice in the SP and
the PerC; (D+E): The graph shows the cell numbers of B1a (CD5+, B220lo) and B1b (CD5lo,
B220lo) cells of reporter+, CD19+ cells of the aged mice in the SP. Every dot represents the
value obtained from one mouse, the bar represents the mean.
The chronic CD30 signaling drove strongly the expansion of PC after 2 weeks and
after 2 months after immunization and infection of LMP1/CD30//Cγ1-cre mice (Figure
42A, lower diagram). Thus, we also evaluated the PC of these B cells in aged mice. The
percentages of PC were not increased in the LMP1/CD30//Cγ1-cre mice in comparison to
control mice (Figure 42A). The percentages of PC of the infected LMP1/CD30//Cγ1-cre
mice were even lower in comparison to their respective control mice. Under physiological
conditions, BLIMP-1 represents, together with IRF4, the key transcription factor during
PC differentiation [Klein et al., 2006]. Further, BLIMP-1 is a known tumor suppres-
sor [Nie et al., 2008]. Thus, we analyzed BLIMP-1 and IRF4 expression in the reporter
expressing B cells with FACS analysis. In comparison to naive B cells, the reporter ex-
pressing cells of all groups revealed higher BLIMP-1 expression. Nevertheless, immunized
LMP1/CD30//Cγ1-cre mice displayed decreased BLIMP-1 and IRF4 expression (Figure
42B+C). In the B cells with a mono- or oligoclonal expansion, BLIMP-1 was tendentiously
downregulated in comparison to the mice free of tumor in the same group and control
mice (Figure 42B, red icons), whereas IRF4 levels were comparable between lymphoma
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and non-lymphoma mice. These data suggest that LMP1/CD30-expressing lymphoma
cells are activated and upregulate IRF4. In comparison to non-lymphoma cells, BLIMP-
1 is less upregulated in lymphomas, suggesting that lymphoma cells are attenuated in
a (pre)-plasmablastic stage and do not differentiate to PC. This is in accord with our
observation that the percentages of PC found in mice with lymphomas were the lowest
compared to the whole group (Figure 42A, red icons).
Figure 42: (A): The diagram shows the percentages of PC (CD138+, B220lo) in the depicted
mouse groups which were pregated for reporter+ cells in the SP, the lower graph displays the
percentages of the PC at the analyzed time points; (B+C): This diagram displays the normalized
median of BLIMP-1 (B) and IRF4 (C) of reporter+ cells in the SP of the illustrated mouse groups,
the dotted line represents the median of naive B cells (reporter−), the histograms display an
example of a BLIMP-1 and IRF4 staining of naive B cells, reporter+ cells of a CAR//Cγ1-cre,
and a LMP1/CD30//Cγ1-cre mouse.
After establishment of latency, MHV-68 is mainly found in isotype switched memory B
cells [Barton et al., 2011]. Therefore, we determined the percentages and the cell numbers
of memory B cells in all four analyzed mouse cohorts in aged mice. The percentages of
memory B cells in the immunized LMP1/CD30//Cγ1-cre mice was decreased in compari-
son to the control mice and to the infected LMP1/CD30//Cγ1-cre mice (Figure 43A+B).
Total cell numbers were higher in the infected LMP1/CD30//Cγ1-cre mice in comparison
to the CAR control mice. But the distribution within the infected LMP1/CD30//Cγ1-cre
mice was very broad (Figure 43C). Two of the infected mice with a tumor displayed a
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strong increase in the percentages of the memory B cells in comparison to the other mice
in the cohort. It would be interesting to stain for NGFR+ memory B cells to determine the
virus infection in this population, unfortunately this staining was not performed in this
constellation. These data suggest that MHV-68 drives the expansion and transformation
of IgG1-memory B cells.
Figure 43: (A): The FACS plots illustrate the gating strategy of the IgG1+ memory B cells
(CD19+, reporter+, CD38+, IgG1+) in the SP; (B+C): The diagrams show the percentages
and the cell numbers of splenic memory B cells in the four analyzed mouse groups. Every dot
represents the value obtained from one mouse, the bar represents the mean.
5.3.7.5 Virus infection and chronic CD30 signaling induce development of
exhausted CD8+ memory T cells
Due to the expansion of T cells, found in the cohorts of LMP1/CD30//Cγ1-cre mice, we
further wanted to investigate the T cell sub-populations. Especially CD8+ T cells play an
important role in the host defense against viral infection [Kalia et al., 2013]. Thus, the
analysis focused mainly on the CD8+ T cells. The total numbers of CD4+ T cells were
significantly higher in the immunized and infected LMP1/CD30//Cγ1-cre mice in compar-
ison to their respective control mice (Figure 44A). The immunized LMP1/CD30//Cγ1-
cre mice displayed significantly expanded CD8 T cell numbers in comparison to CAR
mice (Figure 44A, right diagram). Two of the infected LMP1/CD30//Cγ1-cre mice
with a tumor burden revealed elevated CD8+ T cells compared to the aged mice of this
group. Surprisingly, the percentages of the effector CD8+ T cells (CD62Llo, CD44mid/+)
were significantly higher in the immunized LMP1/CD30//Cγ1-cre mice in comparison
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to their controls. This difference was not visible in the infected mice (Figure 44C).
However, in the infected LMP1/CD30//Cγ1-cre mice, memory CD8+ T cells (CD62L+,
CD44+) were significantly increased in comparison to control mice and to the immunized
LMP1/CD30//Cγ1-cre mice (Figure 44C, right diagram).
The expanded population of effector and memory T cells hinted towards a stronger T cell
activation due to CD30 signaling alone and in combination with the virus infection. To
analyze whether this results in T cell exhaustion, different exhaustion markers were stud-
ied in CD8+ T cells. The percentages of Tim3+ T cells were significantly higher in both
cohorts of LMP1/CD30//Cγ1-cre mice (Figure 44D). The infected LMP1/CD30//Cγ1-
cre mice displayed also significantly more KLRG+ CD8+ T cells in comparison to their
respective controls. One example of the gating strategy of both markers are displayed in
the supplementary 3. The expression pattern of the analyzed exhaustion markers revealed
parallel expression of KLRG1 and Tim3. This indicated that the CD30 signaling results
in higher percentages of functional exhausted CD8+ T cells. Surprisingly, the additional
virus infection did not amplify this development.
Figure 44: (A): The graphs show the cell numbers of CD4+ and CD8+ T cells pregated for
Thy1.2+ cells in the SP; (B): The FACS plots show the gating strategy of memory (Thy1.2+,
CD8+, CD44+, CD62L+) and effector (Thy1.2+, CD8+, CD44+, CD62lo) T cells; (C+D): The
diagrams show the percentages of effector and memory CD8+ T cells of the four analyzed mouse
groups in the SP; (D): The graph shows the percentages of exhausted (KLRG1+/TIM3+) CD8+
T cells of the analyzed aged mice in the SP.
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5.3.7.6 Expansion of CD30 expressing cells correlates with increasing splenic
weight in aged mice
Of note, there was a strong correlation between splenic weight and the cell number of
reporter+ cells in both LMP1/CD30//Cγ1-cre groups (Figure 45A). In contrast, the per-
centages of CD19+ B cells declined gradually in number with increasing splenic weight
and percentage of reporter+ cells (Figure 45B). This means more LMP1/CD30 express-
ing cells resulted in a stronger expansion of non B cells. The red arrows in the diagram
represent the mice which were detected with a mono- oligoclonal expansion. Despite their
increased percentages of reporter expressing cells among the B cell population, B cells
were not the dominating cell population in the spleen of these mice. Therefore, the B
cells were not responsible for the splenomegaly.
Figure 45: (A+B): The graphs show the correlation of splenic weight (left y-axes) and percent-
ages of reporter+ and CD19+ cells (right y-axes) of each analyzed NP-CGG immunized and each
MHV-68-NGFR infected LMP1/CD30//Cγ1-cre mouse in the SP, the red arrows illustrate the
mice which were analyzed with a mono- or oligoclonal expansion.
5.3.8 Lymphoma characterization
The lymphomas were characterized by a splenomegaly and strongly elevated total splenic
cell numbers (see Figure 36, red icons). The percentages of either B or T cells were
dramatically increased with one exception in #10. Figure 46 illustrates an overview
of all analyzed lymphomas with their corresponding total cell numbers, T and B cell
numbers and the reporter+ cell numbers among the B cells in the spleen and the PerC.
The percentages of reporter+ B cells were in all detected lymphomas higher than 60%
despite one exception at #63. Among both LMP1/CD30//Cγ1-cre mouse cohorts, the
mice detected with the lymphoma revealed the highest total cell numbers in the spleen (see
also red icons in Figure 36A+B). Within the lymphoma, the distribution of the analyzed
cell populations varied strongly. #10 and #17 did not display an expanded splenic T cell
population in comparison to the other groups. #29 and #31, on the other hand, revealed
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no increased splenic B cell population. The distribution of cell population in #50 differed
in the PerC and the spleen. In the spleen, the B cell population of this mouse dominated,
in the PerC, the T cells were strongly expanded. However, #17 displayed a clear enhanced
B cell population in the spleen and the PerC. In #17 and #50, in the spleen and the PerC,
a mono- or oligoclonal expansion could be detected. #17 revealed the same clone whereas
in #50 two different clones could be detected in the spleen and the PerC. This was already
reflected in the distribution of the cell populations between spleen and PerC in these two
samples.
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Figure 46: (A+B): The graph shows an overview of all analyzed lymphomas from the infected
and immunized LMP1/CD30//Cγ1-cre mice. The total cell number, T cell numbers (Thy1.2+),
B cell numbers (CD19+), and the reporter+ cell numbers among the B cell numbers in the SP
(A) and the PerC (B) depicted. The table shows the numbers of the cells.
In order to further characterize the tumor population, FACS analyses of surface mark-
5 RESULTS 73
ers were performed. Here, all reporter+ B cells demonstrated a strong expansion of the
CD21lo, CD23lo population. In comparison to the total aged cohort, the mice detected
with a lymphoma revealed the highest percentage of CD21lo, CD23lo cells (Figure 47C,
right diagram). Most of the cases were positive for CD43 and low for CD23 but also low
in CD5 and B220, hinting to a B1b cell phenotype. Thus, two of the lymphomas were low
in all these markers resembling an unknown aberrant B cell population. Also in terms
of IgM/IgD surface expression, IgM positive as well as negative cases were represented
among the lymphoma incidences (Figure 47A-D). The IgM negative cases might have
switched to another isotype e.g. IgG1. Figure 47 illustrates the observed different pheno-
types. The sample number above belongs to the depicted FACS plot and the numbers in
brackets refer to samples which are similar to the ones shown.
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Figure 47: The FACS plots display different B cell sub-populations in the SP of two different
lymphoma samples and a CAR control, cells were pregated for CD19+ and reporter+ (A): The
cells were analyzed for B1a (CD5+, B220lo), B1b (CD5lo, B220lo) and B2 (CD5lo, B220+) cells;
(B): The cells were analyzed for CD43+/CD23lo, CD43lo/CD23lo, CD43lo/CD23+); (C): The
splenic cells were analyzed for CD21lo/CD23lo, CD21+/CD23lo, CD23+/CD21+, the diagram
on the right side shows the percentages of CD21lo, CD23lo cells of reporter+ CD19+ cells in
aged mice in the SP; (D): The cells were analyzed for IgM+, IgM+/IgD+, and IgMlo /IgDlo,
the numbers above refer to the mouse number the FACS plot was taken from, the numbers
in brackets refer to mice which looked similar to the depicted plot, blue for NP-CGG, red for
MHV-68-NGFR infected mice.
Some reporter expressing cells were negative for the IgM expression. HL expresses
high levels of CD30, are associated with EBV infection and are characterized by a
loss of B cell specific gene expression profile, including the BCR [Schwering et al., 2003,
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Aldinucci et al., 2010]. To discriminate whether in IgM− cells the BCR components are
downregulated like in HL or whether the cells have switched to another isotype we stained
for the BCR-signaling domain CD79β (Igβ) which is associated with the BCR indepen-
dent of the switched isotype [Murphy et al., 2012]. The mice detected with a lymphoma
revealed a high expressed CD79β (Figure 48A), indicating that they express an isotype
switched BCR on their cell surface. The cell size of the LMP1/CD30 expressing B cells
in mice with a tumor was clearly increased in comparison to controls which was detected
by the forward scatter (FSC) of these cells in comparison to control B cells (Figure 48B).
Figure 48: (A): The histograms show an overlay of CD79β expression of non B cells, reporter+
cells of a CAR//Cγ1-cre mouse, and the different LMP1/CD30//Cγ1-cre tumor samples as
indicated, the numbers in the red boxes are infected mice, numbers in the blue boxes indicate
immunized mice; (B): The histogram shows one representative example of the FSC of reporter+
cells of one LMP1/CD30//Cγ1-cre tumor sample (black line) and one control (grey).
The increased cell size of degenerated reporter+ cells characterizes activated cells.
Therefore, we tested CD95 as activation marker. Here, we compared CD95 expression of
the reporter positive versus negative B cells. In aged LMP1/CD30//Cγ1-cre mice without
a mono- or oligoclonal cell expansion, CD95 was upregulated in LMP1/CD30 expressing
cells in comparison to control CAR expressing cells. In burdened mice, CD95 was further
upregulated in both hCD2+ and negative B cells. In some cases, the reporter− B cells
even demonstrated a similar upregulation of CD95 like the reporter expressing B cells
(Figure 49A). This hints to an activation of normal cells by the tumor cells. Furthermore,
among the analyzed mice, the burdened mice exposed the highest percentage of CD95+
reporter+ B cells (Figure 49B).
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In order to examine whether the lymphoma cells infiltrate the BM, the percentages of
reporter+ B cells in the BM were determined. All mice with a lymphoma displayed
higher percentages of LMP1/CD30 expressing B cells compared to the tumor-free sam-
ples. Especially, in lymphomas of infected LMP1/CD30//Cγ1-cre mice, up to 75% B cells
were reporter+ indicating that the lymphoma cells infiltrated the BM (Figure 49C).
Figure 49: (A): The histogram shows an overlay of CD95 expression of hCD2+ and hCD2−
B (CD19+) cells of an aged mouse (grey+black) and a tumor mouse (blue+red); (B): The
diagram shows the percentages of CD95+ reporter+ B cells in the SP; (C): The graph shows
the percentages of reporter+ cells in the BM. Cells were pregated for lymphocytes and CD19+
cells. Every dot represents the value obtained from one mouse, the bar represents the mean of
the percentages.
In order to assess the lymphomas further, histology was performed on frozen and
paraffin embedded spleen sections. The staining on the paraffin embedded sections was
performed in cooperation with Dr. Feuchtinger and Dr. Parzefall from the Core Facility
Analytical Pathology. Generally, the splenic sections of the analyzed LMP1/CD30//Cγ1-
cre mice displayed similar alterations (Figure 50). The Hematoxylin/Eosin staining re-
vealed a disrupted splenic structure. This was caused by a large infiltration of neoplastic
cells in the white pulp, provoking a compression of the red pulp. The expanded cell
population was composed of heterogeneous cells. In the HE staining, large, often blastic
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B cells were intermingled with small lymphocytes, monocytes, macrophages, mesenchy-
mal spindal cells, few granulocytes, extramedullary erythrohemopoietic cells and various
numbers of multinucleated giant cells. The B220 staining was greatly diminished in the
lymphoma samples. This was already visible in the FACS analysis (see Figure 47). Also,
no clear location of the B cells in the B cell zone was visible. The CD3 expressing T
cells remained comparable in number but lost their localization in the T cell zone in some
cases (Figure 50).
Figure 50: The histology images show staining of paraffin embedded SP samples. The tissue
was stained with Hematoxylin/Eosin, anti-CD3 (T cells), and anti-B220 (B cells). In both
LMP1/CD30//Cγ1-cre groups, one aged without lymphoma and one tumor sample is shown,
respectively. On the right side, one control mouse from each group is depicted.
Some multinucleated giant cells which were visible in the white pulp resembled the phe-
notype of the Reed-Sternberg cells in HL. Therefore, we asked if the developed lymphoma
resemble HL. Further staining was performed to characterize these large cells (Arrows,
Figure 51A). These cells were partially positive for CD79α but negative for CD19, CD30
and CD45R (Figure 51A). Following, these cells were stained for the von Willebrand
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factor (vWF). The positive staining for this factor characterized them as megakaryocytes
rather than Reed-Sternberg cells [Chuang et al., 2000]. To add on this, an increased CD30
expression, distributed throughout the expanded cell population, was observed (Figure
51B). Thus, we wanted to typify the CD30+ cells further.
Figure 51: (A+B): Representative histology of spleens of one LMP1/CD30//Cγ1-cre mice which
was detected with a mono- or oligoclonal expansion. Tissue was stained with CD19, CD79α,
HE, CD45R, CD30, and vWF. Bars = 50 µm.
The staining for CD30 in the paraffin embedded splenic sections was run by Dr. Parze-
fall from the Core Facility Analytical Pathology. Figure 52A compares a wt spleen section
with a tumor (#29) spleen section. In both staining, no co-stained CD3 and CD30 cells
were visible. Therefore, the effects which were examined in the LMP1/CD30//Cγ1-cre
mice can probably be attributed to the CD30 expression of B cells. The detection of
reporter+ cells was carried out on the splenic sections embedded in OCT. CD30 expres-
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sion was monitored by staining for hCD2 (Figure 52B). First, we examined the aged mice
without a tumor burden. Here, the hCD2 expressing B cells were mainly found within the
follicle or at the border of it assuming a pre-plasmablast phenotype. The mouse of the left
picture revealed 7% hCD2+ cells in the FACS analysis and the mouse from the right pic-
ture 19% proofing the correctness of the staining. The expression pattern seemed unequal
among the cells. There were also clusters differing in size and location with a higher hCD2
expression compared to the remaining reporter positive cells. In the lymphoma samples
on the other hand, only big clusters of hCD2 expressing B cells, scattered throughout the
splenic tissue, were visible. There was no clear follicle structure discernible in order to
characterize the location of the degenerated B cells within the spleen. But also clusters
expressing higher levels of hCD2 were distributed among this population.
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Figure 52: (A): Paraffin embedded splenic tissue was stained for CD3 (red) and CD30 (green),
shown is one ctrl section and one tumor sample (#29); (B): OCT embedded splenic tissue
was stained with anti-hCD2 and anti-Laminin. From the LMP1/CD30//γ1-cre groups one
representative example of an aged and a tumor mouse is depicted.
5.4 Infection of mice with MHV-68-LMP1wt virus leads to its
elimination
EBV is the first described lymphoma associated virus [Palmer et al., 1964]. In several B
cell lymphomas, NK-, and T- non HL as well as epithelial derived malignancies, EBV
5 RESULTS 81
occurrence could be identified [Thorley-Lawson and Gross, 2004]. LMP1 is expressed in
most of these malignancies and is considered to contribute to the malignant transfor-
mation. LMP1 is known to be the key factor in driving cell proliferation and promot-
ing metastasis, apoptotic resistance, and immune modulation. Until now, the effect of
LMP1 could only be analyzed through transgenic expression in B cells of mice, in LCLs
in vitro, or by infecting humanized immunodeficient mice [Middeldorp and Pegtel, 2008].
The cloning of LMP1 in a recombinant MHV-68, and the subsequent infection of mice
with this virus, appears to be a model mimicking much more the physiological condi-
tion found in EBV associated lymphomas. Therefore, a recombinant MHV-68 expressing
LMP1 was constructed by BAC technology which was performed by Wei Zhang in H.
Adlers laboratory. The virus is named MHV-68-LMP1wt thereafter (Figure 53A). Addi-
tionally, another recombinant MHV-68 containing the LMP1 sequence with mutations in
both signaling domains was used as control, named MHV-68-LMP1mut hereafter. Both,
LMP1wt and LMP1mut are expressed under the control of the CMV promoter. First,
we analyzed the lytic replication of the constructed viruses in vitro. Both LMP1 vari-
ants attained similar titers as the parental virus at the different time points (Figure 53B).
Therefore, the replication of the MHV-68-LMP1wt and -LMP1mut viruses seemed not af-
fected by the insertion of the LMP1 sequence. The expression of LMP1 induced through
viral infection was shown by western blot analysis of infected NIH3T3. The LMP1wt
protein run at 63 kDa whereas the LMP1mut was slightly underneath located due to the
shortened amino acid sequence (Figure 53C).
Figure 53: (A): The LMP1wt or the LMP1mut, with a mutated signaling domain, were ex-
pressed under the control of the CMV promoter and inserted between Orf27 and 29 in the
MHV-68 BAC by homologous recombination; (B): NIH3T3 were infected with the indicated
viruses at a multiplicity of infection (MOI) of 0.1. At the different time points after infection,
cells and supernatants were harvested. The virus titers were detected by plaque assay on BHK-
21 cells; (C): NIH3T3 were infected with either MHV-68-LMP1wt or MHV-68-LMP1mut virus.
3 d p.i., protein was isolated and analyzed for LMP1 expression by western blot.
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5.4.1 MHV-68-LMP1wt infection leads to a terminated splenic GC reaction
in mice
LMP1 mimics the CD40 receptor of B cells but needs no ligand for an active signaling
[Rastelli et al., 2008, Uchida et al., 1999]. On the other hand, chronic CD40 as well as
chronic LMP1 expression in B cells leads to a block in the GC reaction
[Hömig-Hölzel et al., 2008, Uchida et al., 1999]. However, there are some GC B cells with
active CD40 signaling due to the initiation of positive selection through CD40L expressing
T cells. Also LMP1+ B cells are found in the GC [Tsai et al., 2018, Thorley-Lawson, 2015].
Therefore, the question was if GC are developed in mice infected with MHV-68-LMP1wt.
The infection with MHV-68 induces a GC reaction in C57BL/6 mice
[Sunil-Chandra et al., 1992]. The GC formation was analyzed by FACS and histology.
For this, C57BL/6 mice were infected with the parental virus, MHV-68-LMP1wt, or
MHV-68-LMP1mut and analyzed after 14, 17, and 21 d (Figure 54A). At d 14, the per-
centages of GC B cells were comparable in the spleen in all three groups of mice. However,
at d 17 and 21, the percentages of GC B cells were strongly decreased in the spleen of
mice infected with MHV-68-LMP1wt (Figure 54A+C). MHV-68-LMP1mut infected mice
displayed a similar percentage of GC B cells as parental virus infected mice at d 17 p.i..
However, at d 21 p.i., the percentage of GC B cells was reduced when compared to mice
infected with parental virus. In contrast, at all analyzed time points, the GC formation,
investigated in the LN, was increased in the MHV-68-LMP1wt infected mice in comparison
to the groups infected either with the parental virus or MHV-68-LMP1mut (Figure 54B).
The peak was reached at d 21 p.i., the percentage of GC B cell in the MHV-68-LMP1wt
infected mice was almost fourfold higher than in the two other groups. This could hint
to a stronger persistence in the LN rather than in the spleen of the MHV-68-LMP1mut
virus in comparison to the control viruses.
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Figure 54: Mice were infected with parental virus, MHV-68-LMP1wt and MHV-68-LMP1mut
intranasally (i.n.) and analyzed at d 14, 17, and 21 p.i. (A): The splenocytes of mice infected
with the indicated viruses or n.i. were stained for GC B cells (PNA+, CD95+); (B): The LN
cells of mice infected with the indicated viruses or n.i. were stained for GC B cells (PNA+,
CD95+); (C) The FACS plots show one representative example of the gated GC B cells at d 17
p.i. of SP and LN, numbers indicate the percentages, n ≥ 3.
The development of the GC in the spleen could be confirmed by histology at d 17
p.i.. Staining with PNA proved the reduction of GC in the spleens of MHV-68-LMP1wt
infected mice in comparison to the parental virus and the MHV-68-LMP1mut (Figure
55A). Furthermore, the staining of LMP1 revealed positive stained cells in the center of
the follicle and at the border between B and T cell zone (Figure 55B). Summing up,
the infection of mice with MHV-68-LMP1wt induced a GC reaction but displayed a fast
decline in the spleen at d 17. However, the percentage of GC B cells in the LN was
increased in these mice at d 17 and expanded further until d 21. Further, we found
evidence for LMP1 expressing B cells in the splenic follicle. In contrast, the infection
with MHV-68-LMP1mut displayed a faster decline of GC B cells in comparison to the
parental virus.
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Figure 55: At d 17 p.i., splenic sections of parental virus, MHV-68-LMP1wt and MHV-68-
LMP1mut infected mice were embedded. (A): Splenic sections were stained with anti-PNA
(blue) and anti-IgM (brown); (B): Splenic sections were stained with anti-IgM (brown) and
anti-LMP1 (blue), shown is one representative example.
5.4.2 MHV-68-LMP1wt showed impaired lytic replication in the lungs of
infected mice and no reactivation ex vivo
After intranasal inoculation, MHV-68 replicates lytically in the lung
[Sunil-Chandra et al., 1992]. After the peak of the lytic replication at d 7, the virus
infection spreads towards the other organs like the spleen and the LN. The splenic weight
represents a strong indicator for lymphoproliferation which occurs during MHV-68 infec-
tion and peaks around d 17 [Sunil-Chandra et al., 1992]. Therefore, we monitored the
splenic weight over three weeks starting at d 7 p.i. (Figure 56A). Interestingly, the splenic
weight in the LMP1wt infected mice remained equal compared to the mice infected with
both control viruses until d 10. However, at d 17, no further increase of the splenic weight
was detectable, displaying almost similar values as in uninfected control mice. This was
in strong contrast to the parental virus and MHV-68-LMP1mut infected mice. Thus, the
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splenic weight as well as the percentages of GC B cells followed an analogous trend in
MHV-68-LMP1wt infected mice. The splenic weight of the mice infected with MHV-68-
LMP1mut was similar compared to parental virus infected mice until d 14 p.i.. At d
17 p.i., the splenic weight was slightly reduced. In order to further investigate the perfor-
mance of the different viruses in these mice, the reactivation capacity was determined at
d 17 p.i.. The ex vivo reactivation assay of splenic cells isolated from the three analyzed
groups revealed an almost similar reactivation capacity of the MHV-68-LMP1mut virus
compared to the parental virus (Figure 56B). In contrast, MHV-68-LMP1wt displayed no
reactivation. This means that there was probably no reactivation-competent virus present
in the spleen of MHV-68-LMP1wt infected mice. To answer the question if there was virus
present at any time in the spleen, the genomic load was determined. Comparably to the
results obtained before, the genomic load was decreased in MHV-68-LMP1wt infected
mice at d 10 and 17 in the spleen (Figure 56C). However, at d 21 p.i., the levels were
similar between all three groups in the spleen. In the LN, the genomic load of MHV-68-
LMP1wt was comparable with the control viruses at d 10 p.i., but decreased dramatically
at d 17 p.i.. At d 21 p.i., the genomic load was similarly decreased in MHV-68-LMP1wt
and LMP1mut in comparison to the mice infected with the parental virus (Figure 56D).
Therefore, the MHV-68-LMP1wt virus did not undergo latency establishment and was
already cleared at d 17 p.i.. Finally, the virus titers of the lytic phase in the lung were
determined by plaque assay. The MHV-68-LMP1wt revealed reduced lytic replication in
the lung compared to the control viruses (Figure 56E).
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Figure 56: (A): The graph shows the splenic weight of n.i. mice or mice infected with the
indicated viruses at different time points, n ≥ 3; (B): At d 17, splenocytes of mice infected with
the indicated viruses were isolated and analyzed in an ex vivo reactivation assay. The splenocytes
of three mice were pooled; (C+D): The genomic load of splenic and LN cells was determined by
real time PCR upon isolation of DNA, the viral copies were quantified by amplifying viral copies
(gB) and cellular copies (L8); (E): The lungs of infected mice were harvested at the indicated
time points p.i., the virus titers of the homogenized lungs were determined by plaque assay,
n ≥ 3.
The genomic load was reduced in MHV-68-LMP1wt infected mice in the spleen and
the LN. This was presumably triggered due to clearance of virus infected cell mediated
by immune cells. Therefore, the PerC, another side of latency establishment of MHV-68,
was examined. In the B cells of the PerC, the levels of the viral DNA were similar in
all three groups at d 16 p.i. (Figure 57A). These levels were as high as detected in the
spleen of parental virus infected mice at d 17. Also, the non B cells isolated from the
PerC carried similar amounts of viral DNA in all three groups (Figure 57B). Therefore,
despite the clear reduction of MHV-68-LMP1wt in the spleen and the LN, the virus was
still detectable with even similar amounts as the control viruses in the PerC (Figure 57).
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Figure 57: The genomic load of the cells isolated from the PerC was determined by real time
PCR, the viral copies were quantified by amplifying gB and cellular copies by amplifying L8. B
cells were isolated with the Pan B cell kit at d 16 p.i.. The genomic load was also determined
from the non B cell fraction.
In summary, the expression of LMP1 in virus infected B cells caused a reduction of
these cells starting between d 10 and d 14. Hereby, the LMP1 signaling can be ascribed as
responsible due to the use of LMP1mut as control. The vanishing of the virus resulted in a
total lack of reactivation capacity, reduced genomic load, and a reduced splenomegaly at d
17. Further, the reduced GC B cells in the MHV-68-LMP1wt infected B cells can probably
be attributed to the low amounts of the virus in the spleen of these mice. However, cells
carrying MHV-68-LMP1wt DNA to the same extent as the control viruses were detectable
in the PerC.
5.4.3 LMP1wt infected B cells obtain survival signals in vitro
LMP1 activates, similar to active CD40 signaling, NF-κB transcription factors and in-
hibits apoptosis [Rastelli et al., 2008, Uchida et al., 1999, Cahir-McFarland et al., 2004].
Thus, cells expressing LMP1 should receive an enhanced survival signal. The reason for
the fast disappearance of cells infected with the MHV-68-LMP1wt is therefore difficult to
understand. To study the survival of MHV-68-LMP1wt infected B cells without the influ-
ence of other immune cells, we infected naive splenic B lymphocytes with MHV-68-NGFR,
MHV-68-LMP1wt, or MHV-68-LMP1mut in vitro. This was realized with a co-culture
of murine fibroblasts supporting lytic replication of the viruses. Due to the infection
with MHV-68-LMP1wt, the B cells express LMP1wt with active signaling. The infection
with MHV-68-LMP1mut induces expression of LMP1 in the infected B cells with silenced
signaling. The cell numbers of splenic B lymphocytes were monitored for 7 d. The cell
numbers were higher in the MHV-68-LMP1wt infected B cells with the greatest differ-
ence at d 7 p.i. (Figure 58A). The cell numbers of MHV-68-LMP1wt infected splenocytes
remained almost stable between d 1 and d 7 whereas the cell numbers of B cells infected
with either MHV-68-NGFR or MHV-68-LMP1mut decreased over time. The staining
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for LMP1 revealed 16% LMP1+ B cells at d 3 and 34% LMP1+ B cells at d 5 (Figure
58A, lower panel). The analysis of living cells showed only a difference at d 7 between
the analyzed viruses (Figure 58B). Here, the percentage of living cells remained stable
between d 4 and 7 p.i.. In contrast the cells infected with the control viruses revealed a
drop in the percentage of living cells in this period of time. This means that infection of
B lymphocytes with MHV-68-LMP1wt evoked a proliferation and survival advantage.
Figure 58: (A): Cell survival and proliferation was determined by counting cells with trypan
blue at the indicated d p.i. with the indicated viruses. B cells were obtained by magnetic cell
separation (MACS) sorting with the Pan B cell kit from splenocytes of wt mice and incubated in
co-culture on a monolayer of NIH3T3, the lower histogram displays an overlay of LMP1 staining
of the B cells infected with the indicated viruses n=3; (B): The graph shows the percentages
of the living cells (TO-PRO3−) upon infection with the indicated viruses at the indicated time
points.
5.4.4 T cells reveal a stronger response to LMP1wt infected B cells
There was no negative selection of MHV-68-LMP1wt infected cells in vitro. We asked
now whether the infected cells are eliminated by T cells. Another question was if T
cells respond stronger upon MHV-68-LMP1wt infection than towards MHV-68-LMP1mut
infection. Here, we used an Enzyme Linked Immuno Spot Assay (ELISpot) to determine
the frequency of IFNγ producing T cells isolated from the spleens of infected mice upon
in vitro restimulation with epitope specific peptides. The secretion of IFNγ can be used
as a marker for T cell responsiveness towards a specific antigen [Halminen et al., 1997].
Orf6 and Orf61 were chosen due to their different expression patterns during MHV-68
infection. Orf6 is mainly expressed in the lytic phase, and Orf61 during establishment
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of latency [Woodland et al., 2001]. Orf6 elicited a comparable IFNγ response from the
analyzed T cells (Figure 59A). However, the T cell response of MHV-68-LMP1wt infected
mice towards Orf61 was dramatically reduced in comparison to both control groups. This
means only a small number of T cells was primed against the antigen which is mainly
expressed in later stages of MHV-68 infection. This is consistent with the finding that the
viral genomic load after infection with MHV-68-LMP1wt was reduced at d 17 p.i. (see
Figure 56D+E).
In order to discover and compare the direct response of T cells with regard to B cells
harboring MHV-68-LMP1wt, these cells were used as target in the ELISpot. For this, T
cells from mice infected with parental virus or MHV-68-LMP1wt were isolated and co-
cultured with B cells which were infected with one of the three viruses in vitro. Afterwards,
the T cell response was measured by the frequency of IFNγ secreting T cells. The reaction
towards the three different types of B cells was determined for every mouse. A clear
stronger answer towards the MHV-68-LMP1wt infected B cells in comparison to the two
other types of B cells was detectable in all analyzed mice (Figure 59B+C). This was
true for the T cells isolated from parental virus infected (Figure 59B) and from MHV-
68-LMP1wt infected mice (Figure 59C). As control, the reaction towards naive B cells
was measured. Neither the T cells from mice infected with parental virus nor the T cells
from mice infected with MHV-68-LMP1wt responded with IFNγ secretion to these B cells
(data not shown). Therefore, the LMP1 signaling seemed to induce a mechanism in the
B cells which triggers a stronger immunogenic response of the T cells.
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Figure 59: (A): Splenic T cells were isolated from wt mice which were infected with the indicated
viruses and plated onto ELISpot plates at d 17 p.i.. The plates were coated with either Orf6
or Orf61. IFNγ producing T cells were detected after 18 h incubation. The pictures show one
representative example of two independent experiments. n=6; (B+C): T cells were isolated
from the SP of parental virus or MHV-68-LMP1wt infected mice and were plated together with
B cells which were infected 4 d before with either parental virus, MHV-68-LMP1wt, or MHV-
68-LMP1mut in a ratio of 2:1 onto ELISpot plates. Plates were coated with IFNγ capturing
antibody (AN18). IFNγ secreting T cells were detected after 18 h, every line represents the
number of IFNγ secreting T cells of one mouse, the experiment was performed in two independent
experiments.
5.4.5 MHV-68-LMP1wt infected B cells cannot be rescued in TCRβδ KO
mice
Due to the stronger response of T cells towards MHV-68-LMP1wt infected B cells and
their important role during the latency establishment of MHV-68, we wanted to test
whether a hyper-activated T cell response is responsible for the reduced numbers of MHV-
68-LMP1wt infected B cells in vivo. We used TCRβδ KO mice lacking all T cells and
infected them with parental virus, MHV-68-LMP1wt, and MHV-68-LMP1mut. After i.n.
viral inoculation of wt mice, the virus establishes latency predominantly in the spleen.
This coincides with a transient splenomegaly, caused by a massive expansion of B and T
cells [Nash et al., 2001]. First, we determined the splenic weight 17 p.i.. The spleens of
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the MHV-68-LMP1wt infected mice revealed the highest splenic weight in comparison to
the two other groups due to higher B cell numbers in these mice (Figure 60A+B). The
splenic weight of the mice infected with the parental virus was indicative for a splenic
atrophy. The splenomegaly which is found upon MHV-68 infection in laboratory mice
is probably driven by CD4+ cells. Additionally, B cells as well a CD4+ T cells are
necessary for the evolution of the splenomegaly upon infection [Usherwood et al., 1996,
Nash et al., 2001]. Mice lacking CD4+ T cells displayed no splenomegaly upon MHV-
68 infection [Ehtisham et al., 1993]. Also, IFNγR KO mice display a splenic atrophy
which correlates with the severity of the infection [Ebrahimi et al., 2001]. This means
the stronger the viral load the stronger the reduction of the cell number in the spleen.
Our findings upon infection of the TCRβδ KO mice could hint to a similar mechanism
due to the observed splenic atrophy upon infection with the parental virus. Therefore,
the viral genomic load was determined to analyze the amount of virus which persists in
the splenocytes. There was nearly no viral DNA detectable in the splenocytes isolated
from mice infected with MHV-68-LMP1wt (Figure 60C). In contrast, the viral load in
the two other groups was 50 to 100 times higher than usually detected in infected wt
mice, confirming the important role of T cells in controlling the infection. As expected
there was no reactivation detectable upon infection of wt mice with MHV-68-LMP1wt.
In contrast the reactivation capacity of MHV-68-LMP1wt could be partly restored upon
infection of TCRβδ KO mice (Figure 60D). Thus, the T cells appeared to play a role in
the clearance of MHV-68-LMP1wt infected cells. However, there seemed to be additional
cells which contribute to the eliminate of MHV-68-LMP1wt infected cells.
5 RESULTS 92
Figure 60: (A): The graph indicates the splenic weight of n.i. and infected TCRβδ KO mice
with the indicated viruses at d 17 p.i., n=3; (B): The graph displays the B cell number (CD19+)
from the SP isolated from mice infected with the indicated viruses at d 17 p.i.; (C): DNA was
isolated from splenocytes. Real-time PCR was performed to detect the genomic load at d 17
p.i.; (D): At d 17 p.i., splenocytes of mice infected with the indicated viruses were isolated and
applied on NIH3T3 in a serial dilution. 24 wells per dilution were plated in 96 well plates.
The splenocytes of three mice were pooled. The reactivation was determined by analyzing the
cytopathic effect in every well.
5.4.6 NK cells contribute to the clearance of MHV-68-LMP1wt infected B
cells
The control of MHV-68 infection seems to be independent of NK cells [Adler et al., 2014].
However, LMP1 expression may result in the upregulation of surface molecules leading
to the activation of NK cells. These cells could be responsible for the early and stronger
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clearance of MHV-68-LMP1wt infected B cells. Therefore, we stained the NK cells of
the infected TCRβδ KO mice for activation markers 17 d p.i.. CD69 is upregulated on
activated NK cells. Induced signaling of CD69 leads to cytotoxic activity and proliferation
of NK cells [Borrego et al., 1999]. The expression of CD69 was upregulated on NK cells
of infected mice in comparison to uninfected mice but similar between MHV-68-LMP1wt
and MHV-68-LMP1mut infected TCRβδ KO mice (Figure 61A). NK1.1− cells were used
as negative control. However, the percentage of NK cells expressing CD107 was increased
in MHV-68- LMP1wt infected mice (Figure 61B). CD107 surface expression correlates
with cytokine secretion and targeted cell lysis [Alter et al., 2004]. Thus, the NK cells
seemed to display a stronger activity in MHV-68-LMP1wt infected mice.
Figure 61: TCRβδ KO mice were infected with either MHV-68-LMP1wt or MHV-68-LMP1mut
and analyzed at d 16 p.i., (A): Splenic NK cells (NK1.1+) of LMP1wt (red) and LMP1mut
(black) were stained for CD69 and compared to NK1.1− cells (negative control); (B): Splenocytes
were stained with anti-NK1.1 and anti-CD107, numbers indicate the mean and the SD of the
percentages of granulated NK cells (NK1.1+, CD107+), n=3.
In order to identify the NK cells as possible cause for the elimination of MHV-68-
LMP1wt infected cells, we depleted NK cells in TCRβδ KO mice by injecting an anti-
NK1.1 antibody twice a week starting one d before viral infection. As control, an isotype
control antibody was injected. Mice were analyzed at d 14 p.i.. The comparison of the
percentages of NK cells in the analyzed mouse groups revealed a reduction of NK cells of
63% in the antibody depleted mice (Figure 62A). This means that despite the depletion,
around 2.2% of NK cells were still present in these mice. The NK cell depleted MHV-
68-LMP1wt infected mice showed slightly higher splenic weights compared to the isotype
treated mice (Figure 62B). Further, the splenic weight was significantly higher in the NK
cell depleted MHV-68-LMP1wt infected mice in comparison to the MHV-68-LMP1mut
infected mice. Additionally, the percentage of splenic B cells was significantly higher in
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the NK cell depleted MHV-68-LMP1wt infected mice in comparison to the two other
groups (Figure 62C). To answer the question if the presence of the MHV-68-LMP1wt
might be responsible for this effect, the reactivation assay was conducted at d 17 p.i..
The reactivation increased considerably after depletion of NK cells when compared to
the MHV-68-LMP1wt infected mice treated with the isotype control (Figure 62D). The
detected CPE was almost similar at the highest splenic cell concentration in the two mouse
groups. Further, the depletion of NK cells evoked a tendentiously increased genomic load
when compared to the isotype treated groups (Figure 62E). We concluded from this data
that both NK and T cells contributed to the elimination of the MHV-68-LMP1wt infected
B cells in mice. Nevertheless, there were further unknown mechanisms which played a
role in this phenomenon.
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Figure 62: TCRβδ KO mice were infected with either MHV-68-LMP1wt or MHV-68-LMP1mut
and analyzed at d 14 p.i.. MHV-68-LMP1wt infected mice were either depleted with anti-NK1.1
antibody or the isotype control twice per week starting one d before infection, (A): The FACS
plots show the mean and the SD of the percentage of NK cells NK1.1+, B220lo of the indicated
groups; (B): Splenic weight of the three mouse groups; (C): The graph shows the percentages of
B cells (CD19+) among all lymphocytes of the infected mice; (D): Splenocytes of mice infected
with the indicated viruses were isolated and applied on NIH3T3 in a serial dilution. 24 wells
per dilution were plated in 96 well plates. The splenocytes of three mice were pooled. The
reactivation was determined by analyzing the cytopathic effect in every well, data are from two
independent experiments; (E): DNA of splenocytes was isolated and used in real-time PCR to
determine the genomic load at d 14 p.i..
6 Discussion
High CD30 expression of a large B cell population is patho-physiological and related to
several B cell lymphomas. Despite this, the physiological regulation and expression of
CD30 in B cells in still mainly unknown. The use of CD30 KO mice did not lead to
conclusive results, and the low amount of CD30 expressing B and T cells in vivo restricts
the possibilities of investigation in wt mice. The generation of a mouse model with a
constitutively active CD30 signaling in B cells enabled us to study CD30 from another
point of view. In this work, the role of CD30 in B cells in general and especially in the
GC B cells could be illuminated. Additionally, the influence of chronic, in GC B cells
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induced, CD30 signaling on lymphoma development was examined. Finally, the additional
effect of a herpesviral infection on B cell lymphoma development was investigated. This
knowledge is not only relevant from the biological and diagnostic perspective but could
also be helpful for the ongoing studies using CD30 as treatment target. Currently, an
anti-CD30 antibody coupled to a microtubule inhibitor (brentuximab vedotin) is part
of several studies analyzing the degree of applicability in different B cell lymphomas
[Küppers, 2005].
6.1 LMP1/CD30 expressing cells are encouraged to plasma cell
differentiation
Petra Fiedler showed that the chronic LMP1/CD30 expression in B cells induces an ex-
pansion of B1 cells and PC, accompanied by higher serum titers of IgM, IgA, and IgG3
[Sperling et al., 2019]. In this work, we demonstrate that the expanded B1 cell population
is intermixed with higher percentages of PB when compared to control mice. Further, this
population can differentiate towards PB in vitro without stimulation and partly without
proliferation. Moreover, LPS stimulation of LMP1/CD30 expressing B cells induces the
expansion of PB in vitro. Similar effects were also observable in vivo. The TI immuniza-
tion drove the enlargement of the B1 cell and the PC population in LMP1/CD30 mice.
This appeared together with higher IgM and IgG3 titers (see Figure 9). Recently, it was
shown that also splenic control B1 cells contain a fraction of PB [Yang et al., 2007]. The
authors could also provide evidence that a part of B1 cells differentiate towards ASC
without proliferation in vitro. Additionally, also human B1 cells seem to display some
features of pre-PB [Covens et al., 2013].
The pre-activated status of B1 cells seems to be further promoted due to the LMP1/CD30
expression and favors the fast differentiation towards PB and PC. This is also supported
by the higher expression of TACI, a known marker of PC differentiation, of the B1 cell
population of LMP1/CD30 mice [Pracht et al., 2017].
Besides B1 cells, also B2 cells were affected by the chronic CD30 signaling. CD40 stimu-
lation of LMP1/CD30 B2 cells yielded more PB and CD43+, CD23lo B cells compared to
control cells in vitro. This population was lower in CD22 and higher in CXCR4 in both
LMP1/CD30 and control mice in comparison to FoB cell population. This is in accord with
pre-PB or activated B1 cell phenotype [Minnich et al., 2016, Moon et al., 2012]. Further,
the possibility of the trans-differentiation from B2 into B1 cells was recently shown by
Graf et al. [Graf et al., 2019]. Together, this data supports the theory that LMP1/CD30
expressing B2 cells reveal an enhanced differentiation towards a B1 or pre-PB population
upon CD40 stimulation. Afterwards, we wanted to elucidate the responsible signaling
pathway leading to the higher number of PB in LMP1/CD30 mice. Here, we found
higher levels of pSTAT3 and pSTAT6 in the nucleus of LMP1/CD30 expressing B2 cells
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when compared to controls upon short term CD40 stimulation. Further, stronger nuclear
translocation of p65 and IRF4 were detected in these cells in comparison to control cells.
Therefore, we concluded that the chronic CD30 signaling in B2 cells seems to cooperate
with the CD40 signaling in driving PB differentiation by a higher activation of pSTAT3
which upregulates BLIMP-1 which in turn induces PC differentiation in the GC reaction.
The activation of the NFκB pathway induces the IRF4 expression which was demonstrated
previously [Diehl et al., 2008, Reljic et al., 2000, Grumont and Gerondakis, 2000]. Also
during class switching, the LMP1/CD30 expression appeared to have a small additive
effect with CD40 signaling in combination with IL4. This was revealed by a higher differ-
entiation towards IgG1+ B cells upon CD40/IL4 stimulation in vitro. The effect might be
mediated due to the higher pSTAT6 expression upon CD40 stimulation in LMP1/CD30
expressing B cells. As STAT6 is an important factor during IL4 induced class switch
recombination [Linehan et al., 1998]. Additionally, recently was shown that IL4 induces
CD30 expression in a STAT6 mediated manner [Mokada-Gopal et al., 2017]. This might
trigger a positive feedback loop in LMP1/CD30 expressing cells upon CD40/IL4 stimu-
lation and result in the enhanced differentiation towards IgG1 positive B cells in vitro.
Regarding class switch towards IgG1, CD30 signaling seemed to be able to substitute the
CD40 signaling, at least partly.
The TD immunization of LMP1/CD30 mice revealed a block in the GC which was shown
by Petra Fiedler [Sperling et al., 2019]. Also, the steady GC reaction of the PP displayed
a clear counter-selection of LMP1/CD30 expressing cells in this side. This led us to the
assumption that CD30+ B cells are hampered in entering the GC reaction. Therefore, we
crossed the LMP1/CD30 mice with a Cγ1-cre mice in order to induce the chronic CD30
signaling directly in the GC B cells. Thereby, we could provide prove that GC reaction was
developed upon TD immunization in this mouse model. LMP1/CD30 expressing GC B
cells adopted to a higher extent a CD43+, CD23lo phenotype when compared to controls.
This population was again intermixed with PB and PC. Both populations were expanded
in the LMP1/CD30//Cγ1-cre mice in comparison to CAR//Cγ1-cre mice. Therefore,
also the induction of chronic CD30 signaling in GC B cells drives them towards the same
phenotype as found in the LMP1/CD30//CD19cre mice. The PC differentiation in GC
cells is mediated by IRF4. Therefore, we analyzed the expression of IRF4 in the GC by
histology. Higher percentages of IRF4+ B cells were detected in the DZ and the LZ but
also at the border of the GC of the immunized LMP1/CD30//Cγ1-cre mice in compar-
ison to control mice. The CD40L expressing T cells in the GC reaction might induce,
together with the active CD30 signaling, the IRF4 expression during positive selection of
GC B cells. This could lead, through the upregulation of BLIMP-1, mediated by IRF4, to
the escape from the GC reaction. Thus, BLIMP-1 could downregulate BCL6 and PAX5
which could than result in more PC in the LMP1/CD30//Cγ1-cre mice. Under physio-
logical conditions, IRF4+ cells are mainly found among the centrocyte population and to
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a lesser extent among the centroblasts [Falini et al., 2013]. It is assumed that PC derive
from the IRF4+ centrocytes [Cattoretti et al., 2006]. Recently, the CD30+ cells in the
GC were characterized as positively selected centrocytes receiving signals from CD40L
expressing T cells [Weniger et al., 2018]. Upon migrating into the DZ, they might switch
off CD30 signaling, due to the contact loss towards T cells, and undergo further rounds
of hypermutation and proliferation. In contrast, LMP1/CD30 expressing B cells are not
able to turn of the chronic CD30 signaling. Due to the expression of PC fate inducing TF,
the CD30 signaling might negatively influence the fate decision towards memory B cells
which are reduced in LMP1/CD30//Cγ1-cre mice. The use of the newly identified mem-
ory B cell precursor marker CCR6 could further elucidate the origin and the localization
of memory B cells emerging in LMP1/CD30//Cγ1-cre mice [Suan et al., 2017].
6.2 Herpesviral infection amplifies the lymphoma development
in LMP1/CD30//Cγ1-cre mice
A high percentage of CD30+ B cell lymphomas originating from GC B cells are associ-
ated with EBV or KSHV infection. The question was if a herpesviral infection, together
with the deregulated CD30 signaling, have a synergistic effect in driving B cell lymphoma
development. Therefore, we combined a herpesviral infection with a chronic CD30 sig-
naling triggered in GC B cells. EBV does not infect murine B cells therefore we used
MHV-68 instead. MHV-68 is a murine γ-herpesvirus with a similar infection route and
latency establishment like EBV and KSHV. The detection of viral infected B cells was
realized by cloning a reporter MHV-68 which expressed NGFR (MHV-68-NGFR). First,
we proved that the infection of LMP1/CD30//Cγ1-cre mice induces the deletion of the
STOP-cassette and leads to a GC reaction which was a precondition to answer this ques-
tion. Mice were either immunized with NP-CGG or infected with the MHV-68-NGFR
virus and analyzed after 2 weeks, 2 months, or when mice were diseased. The question was
which influence has the GC induced chronic CD30 signaling on the lymphoma development
and if a additional infection acts synergistically in driving lymphomagenesis. Therefore,
both groups were analyzed in parallel. The CAR//Cγ1-cre mice served as control in both
groups. The virus infection induced a stronger GC reaction in both analyzed genotypes
in comparison to the immunization. However, only a third of the GC cells expressed the
CAR or hCD2 reporter in the infected mice. Besides, both LMP1/CD30//Cγ1-cre mice
revealed a significantly higher percentage of cre-recombinase induced reporter expression
than their control mice. The MHV-68 infection results in secretion of high amounts of
IFNγ by T cells which is necessary to restrict the latent infection [Canny et al., 2014]. In
the Cγ1cre mouse strain, the cre-recombinase is under the control of the endogenous IgG1
promoter. Yet, IFNγ impedes the induction of IgG1 expression [Kawano et al., 1994].
Therefore, also the expression of the sterile transcripts of the IgG1 locus could be affected
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and prevent the expression of the cre-recombinase leading to reduced percentages of re-
porter expressing B cells in the GC population. As the percentage of reporter expressing
B cells was still comparable with the immunized mice and NGFR+ reporter expressing B
cells were detectable, we did not assume a disadvantage by this mechanism. Additionally,
during infectious mononucleosis between 0.5-2% of the B cell compartment is positive for
EBV [Klein et al., 1976]. This is similar to the percentage of NGFR+ cells. We detected,
around 1.5% NGFR+ in the CAR//Cγ1-cre mice and around 1.1% NGFR+ among the
splenic B cells in the LMP1/CD30//Cγ1-cre mice.
In addition to the GC cells, NGFR expressing B cells were also found in the progenitor
cells of PC and in GC B cells. This was in contrast to the findings of Collins et al. ob-
tained with a YFP-MHV-68 [Collins and Speck, 2012]. Here, the most prominent amount
of virus positive cells was found in the GC B cells (PNA+, CD95+) and the PC (CD138+,
B220lo). However, these results were obtained at d 17 p.i., we analyzed the mice at d 14
p.i.. The CD38+, CD95+ population as well as CD138+, B220+ population might differ-
entiate towards GC and PC, respectively. Therefore, an analysis conducted at d 17 p.i.
might probably lead to similar results. Additionally, we stained for GC (CD38lo, CD95+)
cells using CD38 and CD95 instead of PNA and CD95 which could also lead to different
results. The percentage of NGFR+ cells was similar between the infected CAR//Cγ1-cre
and the LMP1/CD30//Cγ1-cre mice at all analyzed time points. This means either the
constitutive CD30 signaling had no additive effect on the virus expansion or the sponta-
neous differentiation towards PC, driven by active CD30 signaling and a following switch
towards the lytic cycle of the virus, could be the reason. However, due to the stronger
expansion of reporter expressing cells in the LMP1/CD30//Cγ1-cre mice, the total num-
ber of NGFR+ cells was clearly enhanced in this mice.
In humans, it could be shown that the differentiation of an EBV infected memory B cell to-
wards PC triggers the switch towards lytic replication of EBV
[Laichalk and Thorley-Lawson, 2005]. The detection of NGFR positivity might not in-
clude all virus bearing cells. Although, a magnetic cell separation (MACS) enrichment of
NGFR expressing cells, followed by a quantitative PCR, proofed a higher genomic load
in NGFR+ cells (data not shown). But still some NGFR− cells could contain the virus.
A further validation of the B cells of infected mice needs to be performed in order to rule
out possible counter regulation of the NGFR expression.
The expression rate of NGFR ranged around 4% in the aged cohort of LMP1/CD30//Cγ1-
cre mice and was only slightly higher than in control mice in the spleen. In the PerC, the
percentage was lower in the LMP1/CD30//Cγ1-cre mice than in controls. Despite that,
the expansion of hCD2 expressing cells yielded an expansion in total numbers of infected
cells in these mice. This could have several reasons. The LMP1/CD30 expressing cells
displayed a significantly reduced percentage of GC B cells compared to control mice two
months after infection. The reason might be the defective entry into the GC reaction
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as observed in the LMP1/CD30//CD19cre mice [Sperling et al., 2019]. Therefore, also
the re-entry of LMP1/CD30 expressing cells in the LMP1/CD30//Cγ1-cre mice might be
hampered. The virus infection seemed not to intervene with the process. Also, the differ-
entiation towards memory B cells was reduced in the LMP1/CD30//Cγ1-cre mice in com-
parison to the control mice 2 weeks and 2 months p.i.. All together, these processes might
have interfered with the latency establishment of MHV-68-NGFR in LMP1/CD30//Cγ1-
cre mice and hampered the spread of the virus, as MHV-68 predominantly survives in
GC and memory B cells [Flaño et al., 2002]. This could have also reduced the influence
of the virus towards lymphoma development.
The NGFR expression within the hCD2+ cells ranged around 3% in the
LMP1/CD30//Cγ1-cre mice detected with a tumor. However, it seemed that not all
reporter expressing cells are malignant in these mice. As the phenotype of the hCD2+
cells is not completely homogeneous in these mice. Therefore, the percentage of malignant
cells bearing MHV-68-NGFR might be higher and reach similar levels like EBV positive
B cell lymphoma in human. Previous analysis of EBV positive DLBCL revealed in 5-
40% of the malignant cells a positive EBER nuclear staining [Ziarkiewicz et al., 2016].
EBER are expressed in all EBV infected cells [Rezk and Weiss, 2007]. Also, in non HL,
different patterns of EBV positive cells was detected. In some lymphomas over 50% of
tumor cells bear EBV in other cases only 1-20% of the cells reacted positive for EBER
staining. The reasons for the reduced infection rate might be either the loss of the viral epi-
some which might during tumor progression lost the survival and proliferation advantage
[Quintanilla-Mart́ınez et al., 1997]. This process could be accelerated due to the expres-
sion of NGFR in MHV-68-NGFR infected cells. Another reason could be the occurrence of
the infection after the clonal expansion [Quintanilla-Mart́ınez et al., 1997]. This was also
reported for cytotoxic aggressive T cell lymphoma. The secondary infection with EBV was
assumed to result in a more aggressive behavior [Langer et al., 2010]. The chronic CD30
signaling promotes the expansion of the B1 cell population not only when expressed in all
B cells but also if it is induced in GC B cells. Infection resulted in a stronger expansion of
LMP1/CD30 expressing B1 cells than upon immunization. Thus, the B1a sub-population
was more than threefold increased in the infected LMP1/CD30//Cγ1-cre in comparison
to the immunized ones. The increase might be accompanied by the increase of PC in the
spleen of these mice. Higher percentages of PC in this side result in higher numbers of
cells with a B1a cell phenotype.
Despite the enlarged PC population in young unimmunized LMP1/CD30//CD19cre mice,
PC were not increased anymore in LMP1/CD30//CD19cre mice which had developed a
lymphoma. However, the lymphoma population revealed a pre-PB or PB phenotype sug-
gesting that the PC differentiation might be impaired in aged LMP1/CD30//CD19cre
mice [Sperling et al., 2019]. The reason might be a further mutation resulting in inhibi-
tion of PC differentiation and therefore accumulation of a pre-plasmablastic stage. Also
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LMP1/CD30 signaling, induced in the GC reaction, led to an intensified differentiation
towards PC which emerged stronger upon virus infection than upon NP-CGG immu-
nization. However, also in aged cohorts of these mice, the PC compartment was again
comparable with the control mice. Therefore, independent of the used transgenic mouse
model, a disrupted PC differentiation seems to develop in aged mice. And cells which were
unable to differentiate towards PC might have become tumor cells. The additional virus
infection appears not to intervene with this process but rather promoted it and resulted
in higher numbers of burdened mice. Of note, besides one exception, all lymphomas of
the infected LMP1/CD30//Cγ1-cre mice revealed significantly reduced levels of Blimp-1
expression. Blimp-1 is a known tumor suppressor [Boi et al., 2015]. Around a quarter
of human DLBCL reveal alterations in the Blimp-1 locus leading to reduced expression
levels and a block in the PC differentiation. Other DLBCL display a lack of BLIMP-1
protein without genetic alteration, hinting to other changed mechanisms affecting PRDM1
expression. Interestingly, this PRDM1 repression is only found in the ABC-DLBCL cases
and is independent of IRF4 expression [Boi et al., 2015]. This is similar to our cases which
revealed a strong downregulation of BLIMP-1 in mice with lymphomas in comparison to
the other mice of the cohort but unchanged IRF4 levels. Further the active NFκB pathway
in this lymphoma, which is also present in this model detected by higher CD95 expression,
seems to synergize with the lack of the Blimp-1 protein contributing to the pathogenesis
[Calado et al., 2010]. Anyway, it is assumed that the alteration of the Blimp-1 expression
alone is not sufficient to encourage the lymphoma pathogenesis. Therefore, the active
NFκB pathway and the adjustment of the Blimp-1 expression might be contributing to
the lymphomas detected in both immunized and infected LMP1/CD30//Cγ1-cre mice.
The LMP1/CD30//Cγ1-cre mice displayed a decreased differentiation towards memory
B cells upon NP-CGG immunization. The percentage of memory B cells remained
decreased over the observed time period in comparison to the control mice. The in-
fected LMP1/CD30//Cγ1-cre displayed similar percentages of memory B cells in the
aged cohorts as the control mice and even significantly higher percentages than the im-
munized LMP1/CD30//Cγ1-cre. MHV-68 establishes latency mainly in memory B cells
[Flaño et al., 2002]. If the memory B cells are triggered again, they differentiate towards
PC which might be promoted through the chronic CD30 signaling. Due to reduced PC dif-
ferentiation in the aged LMP1/CD30//Cγ1-cre mice, the memory B cell population might
be increasing induced through proliferation upon antigen encounter. Further investigation
of virus infection and analyzing the proliferation of the memory B cell compartment over
time could clarify this issue and might elucidate the underlying mechanism.
An active NFκB pathway is an important hallmark for several B cell lymphomas. CD95
is a direct target of this pathway [Ouaaz et al., 1999]. CD40 stimulation of LMP1/CD30
B cells induces higher NFκb activation than in control B cells. Besides, both aged co-
horts of LMP1/CD30//Cγ1-cre mice displayed significantly increased CD95 expression
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with the lymphoma samples being the highest. This hints to an active NFκB signaling
also in the aged mice. Further, in the burdened mice, the LMP1/CD30 expressing cells
seem also to induce the activation in the surrounding non-malignant reporter− B cells.
This is similar to what is found in the microenvironment of some lymphomas like the cHL
[Liu et al., 2014]. Some B cell lymphomas display deleterious mutations in the CD95 gene
which are favorable due to its role as tumor suppressor. Most of them are found in the
lymphomas with a (post-) GC phenotype. It is assumed that these mutations occur dur-
ing somatic hypermutations [Müschen et al., 2002]. However, there are other cancer cells
displaying high expression of CD95 but are resistant towards CD95 mediated apoptosis
like found in the multiple myeloma and non HL [Müschen et al., 2000]. In contrast, they
profit from higher proliferation, increased survival and higher invasiveness mediated by
active CD95 signaling. Besides, T cells use CD95L-CD95 interaction to control the spread
of viral infections like EBV and MHV-68. In apoptosis resistant B cell lymphoma cells,
CD95 signaling inhibits the lytic replication of γ-herpesviruses [Tan et al., 2016]. Also,
it is reported that an active NFκB pathway contributes towards latency establishment
rather than virus reactivation [Krug et al., 2007, Grossmann and Ganem, 2008]. There-
fore, the higher expression of CD95 in the infected LMP1/CD30//Cγ1-cre mice might
have hampered the spread of the MHV-68-NGFR due to a reduced lytic replication of
the virus. But it also secures the survival of the infected cell. This would be similar to
the processes in human. LMP1 is assumed to suppress the switch towards the lytic cycle
during EBV infection [Shannon-Lowe et al., 2017]. How the NFκB and CD95 signaling
influence the viral infection in our model needs further investigation. Also, the presence
of CD95L expressing T cells should be examined, considering previous results which dis-
played a downregulation of CD95 surface expression of tumor cells as escape mechanism
[French and Tschopp, 2002].
All mice which were diagnosed with a mono- or oligoclonal B cell expansion displayed to
a minor extent a subset of B cells without LMP1/CD30 expression. But also within the
fraction of LMP1/CD30 expressing B cells, phenotypic variances were present. Besides
the downregulated surface expression CD21 and CD23, the expression pattern of other
markers was not completely similar within the reporter+ B cells. Thus, the cell size and
the CD79β expression varied, assuming that the reporter+ cells contain a malignant and
nonmalignant population. The expression level of CD79β varied between the different
subgroups of B cell lymphoma but was not downregulated. This was in contrast to HL.
HRS cells are characterized by complete downregulation of CD79β [Küppers, 2012].
Histology on splenic section was used to determine the location of hCD2 expressing B cells
within the splenic follicle. In the aged mice which were not detected with a tumor, hCD2+
cells were mainly localized at the border of the follicle and partly within the follicle re-
gardless of immunization or infection. This hints to a PB phenotype [Pereira et al., 2010].
Aged LMP1/CD30//Cγ1-cre mice detected with a tumor, revealed large compact popula-
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tions of hCD2+ cells appearing like a follicle. These mice revealed a disrupted B and T cell
zone within the spleen. Therefore, no clear conclusion can be drawn about the positioning
of the malignant cells. Of note, small areas of cells with stronger anti-hcd2 staining were
detected which were found in burdened and aged mice independent of infection and immu-
nization. These cells might be PC which show stronger hCD2 expression (data not shown).
To test whether LMP1/CD30 expression resulted in the upregulation of CD30, we also
stained for CD30+ cells in histology. The number of CD30+ B cells was clearly increased
in the burdened LMP1/CD30//Cγ1-cre mice in comparison to wt mice. Also in GC B
cells, a stronger upregulation of CD30 expression could be demonstrated in FACS anal-
ysis of LMP1/CD30//Cγ1-cre mice in comparison to control mice [Sperling et al., 2019].
A co-staining of extracellular CD30 and hCD2 could provide insight into the relation of
their expression patterns on the B cells. However, the staining has to be repeated with
an antibody recognizing the extracellular tail of CD30. Therefore, LMP1/CD30 as well
as cells expressing endogenous CD30 were detected. The stronger CD30 expression is in
accord with a recently reported autocrine expression loop of CD30 which seems to be
induced by LMP1/CD30 expression as well [Watanabe et al., 2005]. Wt mice displayed
single CD30+ cells scattered throughout the follicle. LMP1/CD30//Cγ1-cre revealed
small compact populations of CD30 expressing cells. Besides, the staining of CD30 of
spleen sections of burdened mice was localized in the cytoplasm and the endoplasmic
reticulum. This was similar to wt mice. It is also in line other CD30+ B cell lymphomas
like ALCL and DLBCL [Stein et al., 2000, Gardner et al., 2001, Burger and Kipps, 2006].
Also in the human lymphoma, CD30 is localized in the cytoplasm and the endoplasmic
reticulum. Therefore, independent of endogenous CD30 signaling or LMP1/CD30 expres-
sion, the LMP1/CD30//Cγ1-cre mice revealed similar localization patterns as wt mice
and malignant cells in human lymphoma.
Both groups displayed increased CD4+ and CD8+ cell numbers in the aged cohorts.
Thereby, the CD8+ cells of the immunized LMP1/CD30//Cγ1-cre mice revealed to a
significant extent an effector phenotype, the CD8+ of the infected LMP1/CD30//Cγ1-cre
mice a memory phenotype. Nishimura et al. showed that the differentiation of mem-
ory T cells depends on CD30/CD30L signaling during a Listeria monocytogenes infection
[Nishimura et al., 2005]. Further, CD30 as part of the TNFR superfamily was shown to
provide crucial signals for the differentiation towards effector T cells [Croft, 2003]. Here,
we show expanded memory T cells in mice with chronic CD30 expression in B cells upon
virus infection. In contrast, immunized LMP1/CD30//Cγ1-cre mice revealed expanded
effector T cells in the spleen. This might mean that the differentiation towards mem-
ory T cells needs not only the CD30 signaling but also an additional trigger provided
by the infection. We have shown that the LMP1/CD30 expression also induces the en-
dogenous CD30 expression [Sperling et al., 2019]. Thus, histology of lymphoma samples
displayed no co-expression of CD30 and CD3. Besides, CD30L expressing T cells could
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receive reverse signaling from CD30 expressing B cells which might lead to similar results
[Kennedy et al., 2006]. Also, secondary effects of CD30 expression on B cells might also
influence the differentiation of T cells. This matter would need further investigation in
order to draw a conclusion from this information.
Besides this, we analyzed T cells in the aged cohorts for exhaustion markers. Exhausted T
cells were found during chronic infections but also in cancer patients [Jiang et al., 2015].
Due to overexpressed inhibitory receptors, decreased effector cytokine production, and cy-
tolytic activity, their capacity to eliminate cancer cells is strongly impaired
[Jiang et al., 2015]. The percentage of CD8+ T cells which were positive for TIM3 and
KLRG1 was increased in both aged cohorts of LMP1/CD30//Cγ1-cre mice in compari-
son to the CAR//Cγ1-cre control mice without a visible effect through the infection. The
burdened mice did not display a further expansion of exhausted CD8+ T cell populations.
Still, the chronic LMP1/CD30 expression could favor an inflammatory environment pro-
moting the development of exhausted T cells. Thus, the chronic CD30 signaling in B
cells could promote the lymphoma development due to impaired T cell function similar
to reduced T cell numbers. The most prominent example are patients with HIV. Besides
the non HL which are classified as AIDS related, also the cHL emerges 10-20 times more
often in combination with AIDS [Shannon-Lowe et al., 2017]. The higher incidence of
lymphoma development is associated with the decreased number of functioning T cells.
Therefore, the chronic LMP1/CD30 signaling might promote the lymphomagenesis by
affecting the surrounding T cells in a negative manner.
Aged LMP1/CD30 mice displayed with an incidence of 80% a mono- or oligoclonal lym-
phoma [Sperling et al., 2019]. The immunized LMP1/CD30//Cγ1-cre mice revealed in
15% of the analyzed cases a lymphoma, the infected mice with an incidence of 42%. The
virus infection had a significant impact in the lymphoma development of
LMP1/CD30//Cγ1-cre. All detected tumors consisted of a mono- or oligoclonal cell
expansion which was also similar to the lymphomas in the aged LMP1/CD30//CD19cre
mice. This means that also the chronic CD30 signaling induced in the GC reaction
is not competent to induce lymphomagenesis alone. A second mutation is needed to
drive this process. Also, the virus infection was not sufficient. However, the virus in-
fection seemed to enhance the lymphomagenesis indicated by the higher incidence of
lymphomas in the infected LMP1/CD30//Cγ1-cre mouse cohort. The virus could substi-
tute mutations leading to deregulated signaling pathways as assumed for the role of EBV
[Shannon-Lowe et al., 2017]. The sequencing of the malignant cells of the
LMP1/CD30//Cγ1-cre mice would be necessary to draw this conclusion. Besides the
higher incidence of lymphomas in the infected group, further phenotypic differences were
not visible in these two groups in FACS or histology. The virus seems to synergize
with the effect of the chronic CD30 signaling in this process. In summary, the tested
mouse model appears to be suitable to analyze the pathogenesis of EBV in the devel-
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opment of CD30 positive lymphomas. CD30 is overexpressed in cHL and ALCL. It is
assumed that overexpression induces the self-activation of CD30 expression which leads
to a ligand-independ, constitutively active signaling. A self-association of the extracel-
lular and intracellular domain of CD30 was demonstrated assuming a high density of
CD30 on the cells surface as condition [Horie et al., 2003]. This reported mechanism was
shown by in vitro experiments of isolated HRS cells and HEK293 cells overexpressing
CD30 [Horie et al., 2002b]. Also, cytoplasmic aggregation of TRAF proteins appears to
reflect constitutive CD30 signaling in HRS cells which was revealed by HRS derived cell
lines [Horie et al., 2002a]. The use of the LMP1/CD30//Cγ1-cre mouse model leads to
a chronic CD30 expression in a subset of activated B cells. Further, the similar pattern
of infection and latency establishment of MHV-68, EBV, and KSHV makes the MHV-68
infection of LMP1/CD30//Cγ1-cre mice a good tool to resemble the physiological pro-
cesses found in EBV or KSHV GC derived CD30+ B cell lymphoma. Further, the signaling
pathways NFκB and the JAK/STAT pathway are also active in the HL lymphoma similar
to our mouse model [Küppers, 2012]. Also, the Blimp-1 expression might be regulated
in EBV+ GC derived lymphoma [Vrzalikova et al., 2011]. But in order to finalize this
project, especially sequencing data of the lymphomas are necessary. These are necessary
to confirm that the lymphoma cells underwent the GC reaction and to confirm active
signaling pathways like NFκB and JAK/STAT. Also, a bigger mouse cohort would be
necessary to assure this observed effect of the infection in this environment. Additionally,
other, more sensitive methods besides the southern blot might be necessary to detect a
mono- or oligoclonal cell expansion, as especially the B cell compartment makes up only
a small part in the whole splenic tissue in some mice detected with a tumor.
Due to the optimized treatment therapy of chemotherapy and radiotherapy, alone and
in combination, HL are highly curable. However, still 10% of the diseased patients suf-
fer relapse making a new innovative treatment necessary. Bretuximab vedotin, a novel
antibody drug conjugate, is the first promising approach targeting CD30. The drug
binds to CD30 which leads endocytosis of the drug bound to the receptor. The con-
tact of the drug conjugate with the intracellular lysozyme induces the release of the
antimitotic agent mono- methylauristatin E. This causes the inhibition of the tubulin
formation and induces cell apoptosis [van der Weyden et al., 2017]. It leads to an over-
all response rate of over 75% in HL [Lambert Charles Q Morris, 2017]. However, the
side effects which are mainly neutropenia and neutropathy limit the the success of this
approach [Schirrmann et al., 2014]. Further, direct apoptosis of CD30 expressing cells
seems not to be the only capacity of Bretuximab vedotin. T cell activation and priming
and maturation of dendritic cells are reported effects of this treatment in mouse mod-
els [van der Weyden et al., 2017]. Additionally, the levels of CD30 expression cannot be
used as indicator for the treatment success of the coupled antibody therapy, as shown
in different studies [van der Weyden et al., 2017]. Therefore, more information about the
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different underlying signaling and regulating processes in CD30+ lymphomas are nec-
essary, especially to broaden the application spectrum and to individualize the therapy
depending on the specific needs. The here introduced approach could deliver some of this
information.
6.3 Active LMP1 signaling hampers the latency establishment
in mice
EBV is a B cell lymphoma associated virus [Shannon-Lowe et al., 2017]. The expression of
LMP1 seems to play an important role by inducing lymphomagenesis in human. Thereby,
LMP1 and LMP2A are shown to cooperate in order to promote lymphomagenesis but are
not essential [Ma et al., 2017]. LMP1 resembles a consitutively active CD40 receptor
and activates several downstream pathways which result into B cells proliferation and
resistance towards apoptosis [Rastelli et al., 2008]. Besides, if EBV is deficient in LMP1
expression, T cell help is required for malignant expansion [Ma et al., 2015]. Until now,
the function of LMP1 in vivo was only examined by using transgenic mouse models which
induced expression of LMP1 in murine B cells [Wirtz et al., 2016, Zhang et al., 2012,
Kulwichit et al., 1998]. In order to mimic more the physiological situation a MHV-68
expressing LMP1wt (MHV-68-LMP1wt) was constructed. Additionally, the cloning of
the MHV-68-LMP1mut, characterized by a lack of active LMP1-signaling, enabled the
direct comparison of the effect of the protein itself and with an active signaling. There-
fore, the two viruses should be a good tool to provide new information on the effect of
LMP1 during virus infection and its contribution towards lymphomagenesis. MHV-68
infection alone leads not to lymphomagenesis in wt mice. Surprisingly, infection of wt
mice with MHV-68-LMP1wt resulted in a complete loss of virus infected cells 17 d p.i.,
characterized by a lack of reactivation and no detectable genomic load in the spleen or in
the LN. In contrast, this effect was not visible upon infection with MHV-68-LMP1mut.
The results obtained with this virus were rather similar to the parental virus. Therefore,
the elimination of the virus was probably triggered by active LMP1 signaling. Surpris-
ingly, the genomic load of the B cells in the PerC was similar in mice infected with
MHV-68-LMP1wt, MHV-68-LMP1mut, and parental virus. Also, in the LN, the viral
clearance was delayed compared to the course found in the spleen. Thus, the depletion
of the infected cells might be caused by the specific micro-environment. The LN and
the PerC could provide a protective niche which secured at least temporarily the survival
of the virus. For example, HIV persists in the LN which are used as major anatomical
reservoir even upon combined anti-retroviral therapies [Huot et al., 2018]. The prolonged
persistence of LMP1 expressing cells might induce activation of surrounding cells. This
could have resulted in the longer maintenance of the GC reaction in mice infected with
MHV-68-LMP1wt.
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In order to analyze the effect of LMP1 expression, a survival curve of infected B cells was
generated in vitro. The expression of active LMP1 in B cells during infection resulted
in a significantly increased proliferation or rather survival of the B cells compared to the
B cells infected with MHV-68-LMP1mut or MHV-68-NGFR. This was in line with the
observed effects in human B cells, where LMP1 activates similar pathways as CD40 signal-
ing and provides survival signals [Klein et al., 1999]. Therefore, the expression of LMP1
probably induces processes which lead to the elimination by extrinsic and not intrinsic
factors. This hypothesis was corroborated by the stronger IFNγ release of T cells upon
encounter of MHV-68-LMP1wt infected B cells in comparison to the two control viruses.
The elimination of LMP1 expressing B cells was also reported by Zhang et al. using
a conditional transgenic LMP1 mouse model [Zhang et al., 2012]. They demonstrated
that the clearance was mainly mediated by T cells. But, it was recently shown, that in
comparison to EBNA1 and EBNA3C, the immunogenic response of CD4+ helper cells
towards LMP1 is much lower [Leen et al., 2001]. Therefore, the T cell response towards
LMP1 might be activated by secondary effects of LMP1 which are normally modulated
by miRNAs during EBV infection [Albanese et al., 2017]. In order to elucidate if T cells
are responsible for the elimination of MHV-68-LMP1wt infected cells, we infected TCRβδ
KO mice. Due to the lack of T cells, a reactivation capacity of 50% was reached with
the highest tested cell concentration in vitro from mice infected with MHV-68-LMP1wt
in comparison to MHV-68-LMP1mut. However, the genomic load was still not detectable
in T cell lacking mice upon infection with MHV-68-LMP1wt. On that account, T cells
seem to play a role in eliminating the LMP1 expressing cells. However, T cells are not the
major reason for it. NK cells are increasing in number upon MHV-68 infection but have
no function regarding clearing or controlling MHV-68 infected cells [Barton et al., 2011].
But, the NK cells of the MHV-68-LMP1wt infected mice displayed a higher proportion of
degranulated NK cells hinting to a participation at the elimination. Indeed, depletion of
NK cells in the TCRβδ mice resulted in a further increased reactivation of infected spleno-
cytes when compared to the non NK cell depleted MHV-68-LMP1wt infected mice. Also,
the genomic load was higher in these mice but still significantly reduced when compared
to MHV-68-LMP1mut infected mice implying still reduced levels of MHV-68-LMP1wt.
Most of the NK cells were successful depleted upon anti-NK1.1 antibody treatment. But
the depletion efficiency reached only 63%. The remaining NK cells might be still suffi-
cient to result in the elimination of the MHV-68-LMP1wt infected cells. The mechanism
behind the NK cell activation through LMP1wt infected cells remained still elusive. In
contrast to MHV-68, other herpesviruses infections like EBV are controlled by NK cells
[Biron, 1997]. Also, Zhang et al. reported that NK cells provide important immune pro-
tection against lymphomas derived from LMP1 expressing B cells [Zhang et al., 2012].
They further revealed the expression of NKG2D on the LMP1 expressing B cells which
mediated partially the killing by NK cells. Besides, they were unable to elucidate the
7 MATERIAL 108
driving factor leading to the elimination of LMP1 expressing B cells by T and NK cells.
Adler et al. determined the MHV-68 mediated upregulation of CEACAM 1 as driving
factor for the immune evasion from NK cells [Adler et al., 2014]. They further demon-
strated the inhibition of the cytotoxicity but not the degranulation of NK cells through the
expression of CEACAM1 of infected cells. Following, they suggested that the FAS/FASL
or the TNF-TNFR pathway mediate the killing of MHV-68 infected cells through NK
cells. LMP1 expression induces upregulation of Fas/CD95 which might result in an op-
timized killing by NK cells. The use of a Fas-Fc fusion protein has shown that also in
the transgenic mouse model with LMP1 expressing B cells NK cells are partly responsible
for the killing of the LMP1 expressing B cells [Zhang et al., 2012]. Preliminary results
displayed a reduced CEACAM1 expression of B cells infected with MHV-68-LMP1wt.
Taken together, the LMP1 expression in infected B cells might lead to reduced upregula-
tion of CEACAM1 and to a higher expression of CD95. This might hamper the immune
escape from NK cells and might support the killing mediated by NK cells. Therefore,
another NK cell depletion protocol might be worthwhile to implement in order to study
this hypothesis. A mouse model expressing LMP1 under the control of the Ig heavy
chain promoter and enhancer developed LMP1+ lymphomas. In young mice, the LMP1
expression was almost not detectable [Kulwichit et al., 1998]. This could hint to the need
of a more restricted LMP1 expression rather than a steady one to allow a LMP1 driven
lymphomagenesis without curtailing the immune system in such strong way. This means





The cre-recombinase was placed under the control of the B cell specific CD19 pro-
moter [Rickert et al., 1997]. If crossed with mice bearing a STOP-cassette flanked
by the loxP sites, a deletion efficiency of 75-80% in the BM and up to 95% in the
periphery in B cells is reached. In this work, CD19cre mice were either crossed to
LMP1/CD30flSTOP mice or used alone as control mice.
LMP1/CD30flSTOP BALB/c
The targeting construct was inserted into the Rosa26 locus under the control of the
endogenous Rosa26 promoter. The construct precedes a loxP site flanked STOP-
cassette ensuring a cre-dependent expression of LMP1/CD30. An IRES-hCD2 cas-
sette was inserted downstream of LMP1/CD30. This leads to the parallel expression
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of LMP1/CD30 and hCD2 [Sperling et al., 2019]. The fusion gene LMP1/CD30 con-
sists of the transmembrane domain of the viral protein LMP1 and the cytoplasmic
domain of murine CD30. Due to the self-oligomerization of LMP1 in the plasma
membrane, the CD30 ligand is not needed to induce CD30 signaling. Instead, a
chronic signaling is established in the respective cell in which the fusion gene is
expressed.
γ1-cre BALB/c
This mouse strain has a insertion of an IRES cassette followed by the cre-coding
sequence behind the last membrane-coding exon of the Igγ constant region gene
segment (Cγ1) locus [Casola et al., 2006]. Thereby a GC specific expression of genes
with a loxP site flanked STOP-cassette is reached. These mice were either crossed
with the R26CAR mice or with the LMP1/CD30flSTOP mice.
R26/CAG-CAR∆1StopF BALB/c
The sequence of CAR under the control of the CAG promoter with a precedent loxP
flanked STOP-cassette was inserted into the rosa26 locus
[Schmidt-Supprian and Rajewsky, 2007]. This strain allows to monitor cells which
underwent Cre dependent recombinase by staining for the receptor CAR. These mice
were crossed to the γ1-cre and served as control for the LMP1/CD30flSTOP//γ1-cre
mice.
TCRβδ KO C57BL/6
This mouse strain was purchased from the Jackson Laboratory with the stock num-
ber 002121. Mice homozygous for the targeted mutation in the TCRβtm1Mom and
TCRδtm1Mom gene do not express the αβ T-cell receptor nor any γδ T-cell receptor.
C57BL/6




8.1.1.1 Genomic DNA isolation from tissue
In order to perform genotyping from the transgenic mice, the DNA of ear or tail clippings
was isolated. The tissue was incubated over night at 56◦C while shaking with 500 µl lysis
buffer (100 mM Tris/HCl pH = 8, 5 mM EDTA, 0,2% SDS, 200 nM NaCl, 100 µg/ml
Proteinase K). At the next day, 170 µl of saturated NaCl (at least 5 M) was added to
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precipitate the protein. The samples were centrifuged for 10 min at 20.000xg at 4◦C. Then,
the supernatant was transferred into a new tube containing 500 µl of 100% (v/v) isopropyl
alcohol. After inverting the tube several times, tubes were centrifuged again. Afterwards,
the pelleted DNA was washed with 70% (v/v) ethanol and centrifuged another time. The
DNA was dried at 37◦C and dissolved in 100 µl TE (10 mM Tris pH = 7,9; 1 mM EDTA)
buffer at 37◦C while shaking for 2-3 h.
8.1.1.2 Genomic DNA isolation from whole splenocyte pellets
For the Southern Blot analysis, the genomic DNA of whole splenocyte pellets was isolated
in the following way. The pellets were digested as described in section 8.1.1.1. Afterwards,
50 µl of 3 M NaAc and 1.25 ml of 100% ethanol were added. The tube was then carefully
panned until the DNA was visible as silver ball. With the help of a bend glass cuvette,
the DNA was removed from the tube. The DNA was washed for 10 min in 70% ethanol
and then air dried. DNA was dissolved in 100 µl TE buffer while shaking at 37◦C.
8.1.2 Mouse genotyping
Depending on the transgenic mice, different genes needed to be amplified in a PCR reac-
tion in order to detect the specific genotype. The following tables show the primers used
(Table 1), the PCR mixtures (Table 2) and the programs (Table 3) which were run in the
thermal cyclers (Biometra) for all used mice. The primers were purchased from metabion,
DMSO from Carl Roth and the residual components from Thermo Fisher.
8.1.3 Agarose gel electrophoresis of DNA
Agarose gel electrophoresis was performed to detect amplified DNA products from a
PCR. The gels which were loaded with the DNA contained 1x TAE (40 mM Tris/HCl,
20 mM acetic acid, 1 mM EDTA pH 8.5), 5 µg/ml ethidium bromide, and 1.5 - 2%
(w/v) agarose (Biozym). The electrophoresis was performed in gel chambers (PEQLAB
Biotechnologie GmbH) containing 1x TAE buffer at 80 to 100 V for up to 1.5 h. The
ethidium bromide intercalated with the nucleic acids which could than be visualized under
a UV luminescence screen (Quantum ST-4).
8.1.4 Southern Blot
For the Southern blot analysis, the DNA was isolated as described in section 8.1.1.2.
25 µl DNA were digested with 3.5 µl enzyme buffer (NEB, 10x), 0.35 µl Bovine serum
albumin (BSA) (NEB, 100x), 0.35 µl spermidin (0.1 M, Sigma Aldrich), 0.35 µl DTT
(0.1 M, Promega), 0.15 µl RNase (10 mg/ml, Thermo Fisher), 3.3 µl water, and 2 µl
EcoRI (NEB, 100 Units/µl) for 16 h at 37◦C. DNA was applied on an agarose gel (0.8%)
and gel electrophoresis was performed at 50 V overnight. The DNA was depurinated
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Table 1: The table displays the used primer for every PCR reaction
PCR Oligonucleotide Sequence 5´-3´ direction
CD19
Cre7 tca gct aca cca gag acg g
CD19c aac cag tca aca ccc ttc c
CD19d cca gac tag ata cag acc ag
TCRβ
TCR-mut for-12834 gct act tcc att tgt cac gtc c
TCR-2-15243 cct aac cca gaa tga tct tg
TCR-wt-for-15242 ccc cac cca gta tag gac ag
TCRδ
TcRd 6916 cct ggg tgg aga ggc tat tc
TCRd 6917 agg tga gat gac agg aga tc
TCRd wt 8744 caa atg ttg ctt gtc tgg tg
TCRd wt 8745 gtc agt cga gtg cac agt tt
CAR
CAR for cag cca ctc gat gat gta cag cgg
CAR rev cag gag cga gag ccg cct ac
γ1-cre
IgG1 KPN1 tgt tgg gac aaa cga gca
Cre13 ggt ggc tgg acc aat gta aat a
IgG1 rev3 gtc atg gca atg cca agg tcg cta g
CD30
hCD2 rev gga gac tgc acc ttt gga ag
CD30c cag tga tcg tgg gct ctc tgt a
rosa
hCD2 rev gga gac tgc acc ttt gga ag
CD30c cag tga tcg tgg gct ctc tgt a
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Table 2: The table displays the volume of the ingredients per one PCR reaction
ComponentCAR CD30 CD19 γ1-cre TCRβδ
KO
rosa
dH20 18.85 µl 16.65 µl 18.55 µl 19 µl 17.65 µl 18.4 µl
Taq buffer
(10x)
2.5 µl 2.5 µl 2.5 µl 2.5 µl 2.5 µl 2.5 µl
MgCL2
(50mM)
0.5 µl 1 µl 1 µl 1 µl 1.3 µl 1.5 µl
dNTP
(10mM)
0.5 µl 0.5 µl 0.5 µl 0.5 µl 0.5 µl 0.5 µl
Primer
(100 µM)




0.15 µl 0.15 µl 0.15 µl 0.15 µl 0.15 µl 0.15 µl
DMSO
(100%)
- 0.5 µl - - 0.5 µl 0.25 µl
DNA
(5-10 ng)
2 µl 1 µl 2 µl 1 µl 1 µl 1.5 µl
Table 3: The table displays the different PCR cycles
Phases CAR CD30 CD19 γ1-cre TCRβδ
KO
rosa
Initial. 3´ 95◦C 5´ 95◦C 5´95◦C 2.30´95◦C 2´94◦C 5´95◦C
Denat. 15´´ 95◦C 45´´ 95◦C 45´´95◦C 40´´94◦C 20´´94◦C/
15´´94◦C
45´´95◦C
Hybrid. 30´´ 62◦C 45´´ 56◦C 45´´57◦C 40´´58◦C 15´´65◦C/
15´´60◦C
45´´58◦C










32 33 30 30 10/28 33
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by tossing the gel for 20 min in 0.25 M HCl. The gel was then passed on for 60 min
in transfer buffer (0.4 M NaOH, 0.6 M NaCl) to denaturate the DNA. The DNA was
blotted on a nylon membrane (Immobilon TM Ny+ membrane, Millipore) by applying
capillary pressure with the transfer buffer overnight. To neutralize the membrane, it was
rinsed twice with 2x SSC (0.3 M NaCl, 0.03 M Na Citrate, pH 6.5). Then, the membrane
was baked at 80◦C for 1 h to crosslink the DNA to the membrane. The membrane was
incubated at 65◦C overnight with the pre-hybridization buffer (1M NaCl, 50 mM Tris (pH
7.6), 10% (w/v) Dextransulfat, 1% (w/v) SDS, 250 µg salmon sperm DNA/ml (Sigma
Aldrich) incubated for 10 min at 100◦C and cooled down on ice for 1 min). Afterwards,
the probe was prepared. 200 ng of probe DNA (isolated from a Bluescript vector, isolated
with restriction enzymes NaeI and EcoRI by digest from the region between JH4 and
Eµ of the murine IgH locus) was filled up with water to 50 µl. Then, probe DNA was
denaturated for 5 min at 95◦C and cooled down on ice for 2 min. The probe DNA solution
was mixed with a Amersham ready-to-go DNA labeling bead (GE Healthcare) and 50 µCi
32P dCTP (Hartmann Analytic) and incubated for 45 min at 37◦C. The labeled probe was
separated from the non incorporated nucleotides by using Sephadex G-50 columns (GE
Healthcare). The efficiency of the incorporation of 32P dCTP in the probe was measured
with the bioscan QC 4000 XER. Probes with values starting from 35.000.000 dpm were
used. Afterwards, the probe was incubated at 99◦C for denaturation and cooled down
on ice for 5 min. Then, the probe was added to the membrane with the hybridization
buffer and incubated again over night at 65◦C. The membrane was washed with 0.5x SSC
and 0.5% SDS at 60◦C to remove unbound DNA. The washing was performed until the
membrane had a radioactivity of around 70 counts. The labeled DNA was visualized by
applying a radio-sensitive film (Biomax MS PE Applied Biosystems 35x43 cm, KODAK)
for 2 d at −80◦C in a Biomax cassette.
8.2 Mouse related assays
8.2.1 Preparation of murine lymphocytes
The mice which were used for analysis were euthanized with CO2 or killed by cervical
dislocation. After preparation, the spleen and the LN were kept in 1% B cell medium
(BCM) (1x RPMI 1640 containing 1% (v/v) heat-inactivated fetal calf serum (FCS) (PAA
Cell culture Company), 100 U/ml penicillin, 100 µg/ml streptomycin, 1 mM sodium
pyruvate, 2 mM L-glutamine, 1x non-essential amino acids, and 52 µM β-mercaptoethanol
(all purchased from Gibco)) on ice. BM cells were isolated by flushing the tight bone with
1% BCM medium using a cannula. The B cells from the PerC were isolated by filling
the peritoneum with 1% BCM with a cannula, slight shaking, followed by sucking up the
medium with a cannula. The blood was prepared directly from the opened heart with a
Pasteur pipette. Then the blood was either stored directly on ice for serum preparation or
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mixed with 10x of volume of PBS with 5 nM EDTA for FACS analysis. The spleen and the
LN were pushed through a 70 µm sieve to achieve a single cell suspension. Splenic and BM
cell suspension were lysed for 3 min with 1 ml of lysis buffer (1x RBC buffer, eBioscience)
to reduce the erythrocytes from the cell suspension. The reaction was stopped by adding
10 ml of 1% BCM and centrifuging at 1200 rounds per minute (rpm) for 10 min at 4◦C
(Rotanta 460-R, Hettich centrifuge). The cell suspension from the blood was lysed at
least 2 times with 3 ml of lysis buffer.
8.2.2 Isolation of B cells, T cells and B cell sub-populations
The isolation of B and T cells was either performed with MACS kits (Miltenyi Biotec) or
by cell sorting (FACS Aria III, Beckton Dickinson). For the MACS, the Pan B cell kit,
the CD43 depletion kit, or the Pan T cell kit were used. Cells were purified according to
the instructions of the manufacturer.
In order to reduce the time of cell sorting, first, B cells were enriched with the Pan B cell
kit and then stained with the necessary antibodies to separate the desired population by
sorting in the second step. The applied sorting strategy is explained under the according
figures.
8.2.3 Preparation of serum
For the determination of the antibody titers in the serum. Blood was kept on ice for at
least 3 h after isolation. Afterwards, the blood was centrifuged for 15 min with 14000 rpm
at 4◦C. Then, the supernatant (serum) was transferred into a clean tube and centrifuged
again. The supernatant was again transferred into a new tube. Finally, the serum was
stored at −80◦C.
8.2.4 ELISA (enzyme-linked immunosorbent assay)
For the detection of NP specific antibodies, NUNCTM plates (Nunc) were coated with
either NP3-BSA (10 mg/l in carbonate buffer, Biosearch technologies) or NP13-BSA
(10 mg/ml) diluted 1:2000 in carbonate buffer (0.1 M NaHCO3, pH 9.5) over night at
4◦C. At the next day, plates were washed three times with 200 µl of PBS/well and blocked
for 1 h with 50 µl/well blocking buffer (1% low-fat milk powder in PBS). Afterwards,
serum of immunized and unimmunized mice was diluted 1:10 in blocking buffer. In the
first row of the plate, 50 µl of diluted serum was pipetted and, with a 1:2 serial dilution,
distributed over 8 wells. After 1 h incubation and washing of the plate three times with
PBS, 1 µg/ml diluted in blocking buffer of the biotinylated antibody specific for the to
detecting isotype (anti-IgM R6-60.2, anti-IgG1 A85-1, anti-IgG3 R40-82, BD Biosciences)
was added and incubated for 30 min. The plate was washed again three time with PBS and
incubated for 1 h with 2.5 µg/ml streptavidin horseradish peroxidase Avidin D (Vector,
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A-2004) which was diluted in blocking buffer. Then, bound strepatvidin was detected
with o-Phenylenediamine (Sigma, P-7288) in substrate buffer (0.1 M citric acid, 0.1 M
Tris (Sigma)) with 0.015% H2O2. The plate was slightly shaken and measured with
the ELISA reader (Photometer Sunrise RC, Tecan) with of OD 405 nm and a reference
wavelength of 620 nm. In order to compare different assays between each other, internal
standards consisting of serum pools from NP-CGG immunized mice were used.
For the detection of antibodies in the supernatant of cultivated cells, the NUNCTM plates
were coated with 5 µg/ml Ig-specific rat anti-mouse IgM antibody (II/41, BD Bioscience)
diluted in carbonate buffer (0.1 M NaHCO3 pH 9.5). The supernatant of cultivated
cells was diluted 1:1 with blocking buffer before distributed on the plates. Despite this
exceptions, the detection followed the same procedure as described above.
8.2.5 ELISpot (enzyme-linked immunospot assay)
ELISpot of NP-specific ASC
In order to detect the number of ASC, an ELISpot was performed. Membrane plates
(Millipore) were coated with 50 µl of either 25 µg/ml NP3-BSA or NP13-BSA, in carbon-
ate buffer at 4◦C overnight. After washing the plate three times with PBS, plates were
blocked with BCM (containing 10% FCS (10% BCM)) for 2 h at 37◦C. 5x105 splenocytes
per well in 10% FCS BCM, were plated and incubated for 48 h at 37◦C. Afterwards, plates
were washed six times with PBS-T (PBS, 0,025% Tween 20). Then, a biotinylated anti-
body (anti-IgM, anti-IgG1, anti-IgG3) was diluted 1:500 in PBS/1% BSA and incubated
for 2 h at 37◦C. After washing again with PBS-T, streptavidin horseradish peroxidase
Avidin D was diluted 1:2000 in PBS/1% BSA and incubated for 45 min at RT. Follow-
ing, the plate was washed three times with PBS-T and three times with PBS. In 5 ml
distilled water, one tablet of each 3,3´-Diaminobenzidin peroxidase-substrate (0.7 mg/ml,
Sigma-Aldrich) and UREA H2O2 (2.0 mg/ml, Sigma-Aldrich) were solved. 50 µl of this
solution was pipetted in each well and incubated until spots were visible. Finally, the
plate was washed with water and left to dry. The spots were measured and counted with
the ELISpot reader AID Elispot3.2 and the appropriate software (Autoimmune Diagnos-
tika GmbH).
IFNγ ELISpot
The IFNγ ELISpot was performed with the Mabtech #3321-2AW Plus kit according to
the instruction manual. To analyze the reaction towards MHV-68 specific peptides, Orf6
or Orf61 in DMSO were added to the ELISpot plate with a final concentration of 10 µg/ml,
together with the splenocyte suspension. The percentage of T cells in the splenocyte sus-
pension was detected by FACS staining against CD3+ cells. Afterwards, 60.000 T cells
per well were seeded. Spots were detected 18 h after cell seeding.
In order to analyze the IFNγ secreting T cells in response to infected B cells, B cells
were infected with MHV-68 in a co-culture with NIH3T3 at 0.5 MOI for 4 d before the
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ELISpot assay (see section 8.7.5). MOI is the ratio of virus (pfu) to cells in the culture.
T cells were isolated with a Pan T cell isolation kit (Miltenyi). T and B cells were seeded
together on the coated ELISpot plate with a ratio of 1:2 (60.000:120.000 cells/well). Cells
were seeded in triplicates.
8.2.6 Flow cytometry
The flow cytometry analysis were performed with the FACS Calibur, the LSR Fortessa or
the FACSCanto all from Beckton Dickinson. The evaluation was done with the FlowJo 10
software. Per staining, 5 x 105-1 x 106 cells were distributed into one well of a FACS plate
(Greiner Bio One) and washed with MACS buffer by centrifuging for 5 min with 1200 rpm
(Rotanta 460-R, Hettich centrifuge). Then, the cells were stained with 25 µl of antibody
mix diluted in MACS buffer (BD) and incubated for 20 min in the dark on ice. The
antibodies were coupled to following fluorochromes: FITC, PE, PerCP, APC, Alexa Fluor
700, Horizon V450, Brilliant Violet 421, Pe-Vio 770 (Miltenyi), APC-Vio770 (Miltenyi).
The antibodies were specific for B220, Blimp-1, CD2 (human), CD19, CD21, CD23, CD25,
CD38, CD86, CD138, IgD, IgM, Irf4, Thy1.2-Bio, CD62L, CD44, CD79b, CD5, CD95
and were purchased from BD Biosciences. The antibody against CAR was purchased
from Santa Cruz and the antibody against LMP1 came from the antibody facility of
the Helmholtz Center. Afterwards, cells were washed again, diluted with MACS buffer,
and transferred into FACS tubes. If needed, cells were stained with TOP-RO3 (1:40000,
Molecular Probes) directly before measuring. The staining of intracellular molecules was
performed on fixed cells. Cells were washed with PBS and fixed with 2% PFA for 10 min
at RT. Then, cells were washed with PBS and centrifuged again. Afterwards, the cells
were resuspended in ice cold methanol (stored at −20◦C) and either stored in the freezer
covered with adhesive foil or directly used for staining. The cells were washed twice with
PBS and then stained for 1 h at RT.
8.3 Cell culture
Cell culture was performed under the sterile workbench (Bio Flow technique) with sterile
pipettes (Gilson/Eppendorf) and expendable materials. For the cultivation, 5 x 105-
1 x 106 cells were plated per well in a round or flat bottom plate (Nunc). The cultivation
was carried out at 37◦C, with 5% CO2, and 95% humidity in an incubator (Binder). The
cells were kept in 10% BCM with and without different kind of stimuli. Depending on
the assay, the following stimuli were added: anti-CD40 antibody (2,5 µg/ml, HM40-3,
eBioscience), IL4 (Interleukin-4, 10 ng/ml, Sigma-Aldrich), IgM (15 µ/ml, 115-006-020
Jackson Immunology Research), LPS (Lipopolysacharid, 50 µg/ml, Sigma-Aldrich). The
cells were incubated for up to 5 d. The proliferation of the cells was tracked by CFSE
(2,5 µmol, Molecular Probes) labeling. After entering the cell, the two acetate groups of
8 METHODS 117
CFSE are removed by intracellular esterase. As a result, CFSE becomes highly fluorescent.
After each cell division, the fluorescence intensity is halved in each daughter cell. The
staining was performed after Parrish et al. [Quah and Parish, 2010].
8.4 Immunohistochemistry and immunofluorescence
Parts of the spleen were embedded into tissue tek (VWR Chemicals), frozen on dry ice,
and stored at −80◦C. The splenic sections were cut into 7-8 µm thick slices with a cryostat
(Leica) and air dried for 15 min. Afterwards, sections were either stored at −80◦C or fixed
for 10 min with ice cold acetone and air dried for another 15 min. The tissue sections were
re-hydrated for 5 min in PBS and blocked for 20 min with 5% goat serum in PBS with 1%
BSA. After washing again with PBS, the sections were blocked with the Avidin-Biotin
blocking kit (SP-2001, Vector) if biotin coupled antibodies were used. The sections were
washed three times with PBS and the 1st antibody diluted into PBS with 1% BSA was
applied over night at 4◦C or for 1 h at RT. After incubation of all necessary antibodies, sec-
tions were developed with the AEC substrate Kit (Vector Laboratories SK-4200) and the
Alkaline Phosphatase Kit (Vector Laboratories SK-5300). Finally, the tissue sections were
air dried and embedded in Kaiser´s Gelatine (Merck KGaA). The following antibodies
were used: PNA-Bio (B-1075, Vector) with Streptavidin-Alkaline Phosphatase (S-2890,
Sigma-Aldrich), goat anti-mouse IgM POX (A-8786, Sigma-Aldrich), mouse anti-human
CD2-Bio (RPA-2.10, BD), rabbit anti-mouse Laminin (L9393, Sigma), goat anti-rabbit
POX (A5795, Sigma), and rat anti-LMP1 (1G6, IgG2a, Antibody facility, Helmholtz Cen-
ter Munich).
For immunofluorescence, tissue sections embedded in OCT were air dried and fixed with
3% PFA for 10 min and rinsed with PBS for 5 min. The rehydration was performed for 5
min with PBS+ (PBS and 50 mM NH4Cl). Then, slices were permeabilized and blocked
with 0.3% Triton X, 1% BSA, 2% goat serum in PBS for 20 min. The 1st antibody,
diluted in PBS with 1% BSA, was incubated for 1 h at RT, after rinsing with PBS. 3 x
5 min washing with PBS was followed by incubation of the 2nd antibody for 1 h at RT.
After washing, slices were embedded in SlowFade Gold (Thermo Fisher). The following
1st antibodies were applied: anti-B220-APC (RA3-6B2, BD), anti-GL7-FITC (GL7, BD),
anti-IRF4 (3E4, eBioscience). Anti-rat Alexa Fluor 594 (A-11007, Thermo Scientific),
and anti-FITC Alexa Fluor 488 (A-11094, Thermo Scientific) were used as secondary an-
tibodies. All staining combinations are shown in table 4.
Immunohistochemically stained splenic sections were evaluated with an Axioskop (Zeiss)
with a Zeiss Plan NEOFLUAR objective 10x/0.3. The images were obtained with an
AxioCam MRc5 digital camera in combination with AxioVision rel.4.6.3.0 software (Carl
Zeiss MicroImaging GmbH, Jena, Germany). The slices stained with immunofluorescences
were obtained with the Leica TCS SP5 II with an 8 kHz resonant scanner and a HCX PL
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APO CS 20x objective and the LAS AF software.
The staining of the paraffin embedded tissue were performed by the Research Unit Ana-
lytical Pathology of the Helmholtz Center Munich.
Table 4: The table displays the used combination of antibodies.










rabbit anti-mouse Laminin goat anti-rabbit POX AEC substrate Kit
rat anti-LMP1 anti-rat Bio Alkaline Phosphatase Kit
anti-B220-APC / /
anti-IRF4 Anti-rat Alexa Fluor 594 /
anti-GL7-FITC anti-FITC Alexa Fluor 488 /
8.5 Western Blot
About 3-7 x 106 isolated B cells were washed twice with PBS by centrifuging at 2400 rpm
at 4◦C for 5 min. For the nucleus cytoplasmic fractioning the NE-PER kit (Thermo Scien-
tific) was used according to the manufactures instructions. The protein concentration was
determined by nanodrop at 280 nm. The protein detection was performed with the WES
system, a fully automated western blot system (Protein Simple). The analysis and the
quantification was performed with the Compass Software (Protein Simple). Cytoplasmic
protein was standardized to αβ-tubulin and nuclear extracts with lamin B2. As basis
for the protein quantification, the area under the curve at the respective size was used
for the calculations. The area under the curve was calculated by the software. For the
normalization, area under the curve of protein of interest was divided by its respective
loading control. In order to secure a correct quantification of the protein of interest, the
concentration of the protein lysate needed to be adapted to the used antibody. First,
the protein lysate was tested in a dilution experiment to determine the optimal concen-
tration of the lysate which needed to be within the dynamically range on Wes. This
means, an increase or decrease of the protein lysate leads to an increase or decrease of
bound material in the capillary on the WES. Thereby, protein lysate dilutions ranged
from 0.12-3 µg/ µl in 5 steps and an antibody dilution of 1:50 for the dilution experiment.
Linear regression analysis of chemiluminescence signal (peak area of protein of interest)
and lysate concentration was used to pick the concentration of the protein within the lin-
ear increase. Afterwards, the antibody concentration was titrated from 1:10-1:200 in five
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steps. This was necessary to ensure that the used antibody concentration can saturate
the protein bound to the capillary in the Wes machine. Again, linear regression analysis
of chemiluminescence signal (peak area of protein of interest) to antibody dilution was
used. With increasing antibody concentration, the signal (chemiluminescence) increases
until saturation. For optimal quantification an antibody concentration near the saturation
level was chosen. The used antibodies dilutions are displayed with their corresponding
concentration of lysate in table 5.
Table 5: The table displays the used antibodies and the used lysate concentrations in western
blot
Antibody Antibody concentration Lysate concentration
anti-αβ-tubulin 1:20 0.3 µg/µl cytoplasmic
extract
anti-LaminB2 1:50 0.3-0.4 µg/µl nuclear
extract
anti-pSTAT3 1:50 0.3 µg/µl nuclear
extract
anti-pSTAT6 1:50 0.3 µg/µl nuclear
extract
Irf4 1:50 0.4 µg/µl nuclear
extract
Irf4 1:50 4 µg/µl cytoplasmic
extract
p65 1:50 0.4 µg/µl nuclear
extract
p65 1:50 4 µg/µl cytoplasmic
extract
8.6 Immunization, infection and depletion
NP-Ficoll immunization
For the T-cell independent immunization, NP-Ficoll (Biosearch Technologies) was used.
NP(33)-Ficoll was diluted to a concentration of 250 µg/ml in sterile Dulbecco’s Phosphate-
Buffered Saline (DPBS) (GIBCO). 50 µg in 200 µl DPBS were injected i.p..
NP-CGG immunization
The T-dependent antigen NP-CGG (> 40, Biosearch Technologies) was diluted to a con-
centration of 1 mg/ml in DPBS. Before each immunization experiment, the pH value of
NP-CGG was adjusted. Here, 100 µg of NP-CGG per mouse was mixed with the same
volume of 0.4 M Kal(SO4)2 in H2O. The pH value was adjusted to 6.5 with 1 N NaOH
and kept on ice for 30 min. Afterwards, the antigen was centrifuged with 5000 rpm at
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4◦C for 10 min. The supernatant was discarded and the yellow pellet was washed with
1 ml of DPBS. This step was repeated twice. Afterwards, the NP-CGG was adjusted to




The frozen virus stock was thawed and diluted in sterile PBS to obtain 5x104 pfu/30 µl.
Mice were anesthetized by i.p. injection of MMF (medetomidine 0.2 mg/kg, midazolam
1.0 mg/kg, fentanyl 0.025 mg/kg). After the mouse showed a deep anesthesia which was
confirmed by the absence of reflexes on a footpath, the mouse was held in the scruff
and 30 µl of the virus suspension was gradually released in one nostril. The mouse was
held in this position until normal breathing rhythm was achieved. Again anesthesia was
antagonized by subcutaneous injection of naloxone (1.2 mg/kg), flumazenil (0.5 mg/kg)
and atipamezole (2.5 mg/kg).
Intraperitoneal infection
The frozen virus stock was thawed and diluted in sterile PBS to obtain 25x105 pfu/ml.
200 µl of virus suspension was applied by i.p. injection.
NK cell depletion
NK cells from mice were depleted by injecting 250 µg anti-NK1.1 antibody (PK136, Bio
X cell) in 200 µl DPBS i.p.. As control, the isotype antibody IgG2a (C1.18.4, Bio X Cell)
was used. Mice were injected one day before infection and afterwards twice per week until
analysis.
8.7 Virological assays
8.7.1 Virus stock production
Virus stocks were produced in baby hamster kidney (BHK-21) cells which were cultivated
in Glasgow modified eagle medium (Pan Biotech) supplemented with 5% FCS, 2 mM L-
glutamine, 5% tryptose phosphate broth (TBP), penicillin (100 U/ml) and streptomoycin
(100 mg/ml) (BHK-21 medium). MHV-68 was added at a MOI of 0.1 to the BHK-21
cells and incubated at 37◦C until cytopathic effect (CPE) was visible in almost all cells.
The cells were frozen and thawed twice to destroy the cell membrane and release the
virus. The supernatant was cleared of cell debris by centrifuging 1300xg for 20 min at
4◦C. The virus was pelleted at 26000xg for 2 h at 4◦C. The virus was resuspended in 1 ml
of BHK-21 cell culture medium, aliquoted in 50 µl and stored at −80◦C.
8.7.2 Plaque assay
The concentration of the virus stock was determined by plaque assay on BHK-21. Cells
were plated at a concentration of 5x104 per well in a 24 well plate and incubated for
24 h. Afterwards, the virus was diluted 10-fold with BHK-21 medium from 10−1 to 10−8,
transferred onto the BHK-21 cells, and incubated for 90 min at 37◦C. The medium with
the virus was removed and each well was covered with BHK-21 medium containing 1.5%
carboxymethylcellulose (Carl Roth). After 5 d at 37◦C, cells were stained with 0.1%
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cristal violet solution (containing 1% formaldehyde in PBS (Carl Roth)) by applying
to the plate after the BHK-21 medium was removed. The cristal violet solution was
incubated for 10 min, removed with several washing steps with water, and plaques were
counted. The virus titer was calculated with following equation:
Titer (pfu/ml) = n (plaque count per well) / 0.9 * viral dilution
The viruses which were used together in one experiment were titrated in parallel.
Virus titers were as follows:




For the ex vivo plaque assay, the left lung was extracted from the infected mice and frozen
at −80◦C. The tissue was thawed and homogenized for 30 s in in a tissue homogenizer
(MP biomedicals). The cell suspension was filled up to 500 µl with BHK-21 medium and
again frozen at −80◦C. The following steps were the same as described above.
8.7.3 Generation of recombinant virus
MHV-68-NGFR
MHV-68-NGFR was constructed by inserting a SFFV-NGFR cassette between ORF 27
and 29. The SFFV-NGFR cassette was extracted with restriction enzymes from the
plasmid pCDH-SFFV-hspCas9-T2A-NGFR which was kindly provided by the group of
Prof. I. Jeremias. The map is shown in supplementary 4. First, the hspCas9-T2A was
excised by enzymatic digest with EcoRI and NsiI. Then, SFFV-NGFR was removed by
using ClaI and SalI. After generating blunt ends on both sites with the help of the Klenow
enzyme, the 1.15 kb SFFV-NGFR cassette was inserted into the PmlI site (nucleotide
position 46347 of the MHV-68 genome) of the plasmid pST76K-SR (shuttle vector for BAC
mutagenesis). This plasmid contained already a 4 kb SphI-SacI fragment of the MHV-68
genome (nucleotides 44301 to 48346). As a result, the SFFV-NGFR cassette is flanked
on both sides by homologous sequences which enables the insertion of the cassette into
the MHV-68-BAC by homologous recombination. The MHV-68-NGFR virus was then
produced by the two-step mutagenesis procedure as described earlier [Fields et al., 2007,
Wang et al., 2008].
MHV-68-LMP1wt/mut
MHV-68-LMP1wt and LMP1mut were constructed in the same way as described above.
Here, a LMP1wt and a LMP1mut cassette were inserted which were kindly provided by
Prof. A. Kieser as published in 2008 [Schneider et al., 2008]. Both genes are under the
control of the HCMV promoter. The LMP1mut cassette has mutations in both signaling
domains. CTAR1 carries an inactivating P(204)xQxT to AxAxA mutation and CTAR2
carries a deletion of 16 C-terminal amino acids. Both viruses were generated by Wei
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Zhang in the laboratory from Prof. H. Adler.
8.7.4 Ex vivo reactivation assay
For every group of infected mice, two 96 well plates were seeded with 6000 NIH3T3
cells/well in 200 µl of medium. The cells were incubated in DMEM (GIBCO) supple-
mented with 10% fetal calf serum (FCS), 2 mM L-glutamine, penicillin (100 U/ml) and
streptomoycin (100 mg/ml). Plates were incubated for 24 h at 37◦C. Spleens of infected
mice were isolated and a cell suspension was generated as described in section 8.2.1. The
splenocytes from mice, infected with the same virus, were pooled. 13.5x106 Cells were
adjusted to a concentration of 1.5x106 cells with NIH3T3 medium. 3-fold serial dilutions
with overall 7 dilutions were generated. For every dilution, 24 wells were used starting
with 5 Ö 104 splenocytes per 0.1 ml/culture well. The remaining cell suspension of every
dilution was frozen at −80◦C for the detection of virus in the lytic phase. NIH3T3 were
incubated for 14 d at 37◦C. After 7 and 14 d, the cells were analyzed with the microscope
and wells containing cells showing CPE were counted. The percentage of wells which were
positive for CPE was calculated. To detect virus in the lytic phase, the remaining spleno-
cyte suspension was frozen and thawed twice. Afterwards, cell suspension was handled as
described before. Wells positive for CPE were subtracted from the wells calculated above
to obtain the value % CPE of the virus in the latent phase.
8.7.5 Viral infection of B cells in vitro
Murine B cells were infected in a co-culture with NIH3T3 cells. 7500 NIH3T3 cells per
well of a 96 well plate were seeded and incubated for 24 h or until attached to the culturing
surface. B cells from wt mice were isolated from the spleen with the Pan B cell isolation
kit (Miltenyi). The medium of the NIH3T3 cells was removed. 5x105 B cells per well in
10% BCM was applied. 100 µl of virus suspension in 10% BCM was added to every well
resulting in a MOI of 0.5. Cells were incubated at 37◦C.
8.8 Statistics
The two-tailed Student´s t-test was performed to calculate the significance of splenic
weight values, percentages of cell populations and absolute cell numbers. In case that
three or more groups were compared the ANOVA test was used. Immunoglobulin titers
were logarithmized prior to the determination of significance. In case the respective values
showed no gaussian distribution, which was calculated with the normalization analysis
in Prism, the Mann-Whitney test was used to determine the significance. *P ≤ 0.05,
**P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001. The statistical calculations were
performed with Prism 9 (GraphPad Software).
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[Küppers, 2005] Küppers, R. (2005). Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews
Cancer, 5(4):251–262.
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Camacho, F. I., Ruiz-Marcellán, C., Adrados, M., Ortiz, N., Franco, R., Ortiz-Hidalgo, C., Suarez-
Gauthier, A., Young, K. H., and Piris, M. A. (2012). EBV-positive diffuse large B-cell lymphoma of
the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear
factor-kB activation. Modern Pathology, 25(7):968–982.
[Moon et al., 2012] Moon, H., Lee, J.-G., Shin, S. H., and Kim, T. J. (2012). LPS-Induced Migration of
Peritoneal B-1 Cells is Associated with Upregulation of CXCR4 and Increased Migratory Sensitivity
to CXCL12. Journal of Korean Medical Science, 27(1):27.
[Mora and von Andrian, 2008] Mora, J. R. and von Andrian, U. H. (2008). Differentiation and homing
of IgA-secreting cells. Mucosal Immunology 2008 1:2, 1(2):96.
REFERENCES 133
[Muramatsu et al., 2000] Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y., and
Honjo, T. (2000). Class Switch Recombination and Hypermutation Require Activation-Induced Cyti-
dine Deaminase (AID), a Potential RNA Editing Enzyme. Cell, 102(5):553–563.
[Murphy et al., 2012] Murphy, K. K. M., Travers, P., Walport, M., and Janeway, C. (2012). Janeway’s
immunobiology. New York : Garland Science, c2012., 8th ed. edition.
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S. K., Küppers, R., and Dalla-Favera, R. (2001). Hypermutation of multiple proto-oncogenes in B-cell
diffuse large-cell lymphomas. Nature, 412(6844):341–346.
[Pereira et al., 2010] Pereira, J. P., Kelly, L. M., and Cyster, J. G. (2010). Editor’s Choice: Finding the
right niche: B-cell migration in the early phases of T-dependent antibody responses. International
Immunology, 22(6):413.
[Phan et al., 2005] Phan, R. T., Saito, M., Basso, K., Niu, H., and Dalla-Favera, R. (2005). BCL6
interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and
cell cycle arrest in germinal center B cells. Nature Immunology, 6(10):1054–1060.
[Pillai and Cariappa, 2009] Pillai, S. and Cariappa, A. (2009). The follicular versus marginal zone B
lymphocyte cell fate decision. Nature Reviews Immunology, 9(11):767–777.
[PODACK et al., 2002] PODACK, E. R., STRBO, N., SOTOSEC, V., and MUTA, H. (2002). CD30-
Governor of Memory T Cells? Annals of the New York Academy of Sciences, 975(1):101–113.
[Pracht et al., 2017] Pracht, K., Meinzinger, J., Daum, P., Schulz, S. R., Reimer, D., Hauke, M., Roth,
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Figure S1: Splenic cells were sorted for single cells, lymphocytes, CD19+ cells and CD138lo
cells, and than either sorted for CD43+, CD23lo and the CD43−,CD23+ population (before),
both populations were resorted (after), and the lymphocytes were analyzed for CD19, CD23,
and CD43 surface expression.
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Figure S2: The lymphomas were detected by southern blot with a radioactive probe spanning
the region between JH4 and Eµ of the IgH locus, n ≥ 11, the lower picture shows one example
of a southern blot, the stars indicate additional band besides the germline band at 6 kB. The
right picture uses following abbreviations LC30-LMP1/CD30//Cγ1-cre, CAR-CAR//Cγ1-cre,
NP-NP-CGG, NGFR-MHV-68-NGFR
Figure S3: The histograms show an overlay of CD8+ T cells stained for KLRG1 and TIM3 of
one LMP1/CD30//Cγ1-cre and one CAR//Cγ1-cre mouse
9 SUPPLEMENT S141
Figure S4: In order to isolate the SFFV NGFR cassette from the plasmid pCDH-SFFV-hspCas9-
T2A-NGFR, hspCas9-T2A was removed with the enzymatic digest of EcoRI and NsiI. Then,
SFFV-NGFR was removed by using ClaI and SalI. The plasmid was provided by the laboratory
from Prof. I. Jeremias.
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die ausführliche Einarbeitung in alle wichtigen Experimente und Geräte, dies hat mir den
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